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Medicine is the practice of treating disease, and, consequently, the preservation and improvement of 
health (adapted from [1]). This definition, published over 100 years ago, seems to largely hold 
today. In modern medicine disease is still being treated (supplemented by, among others, pre-
vention) aimed at improving health. Health in itself is a somewhat subjective definition, but could 
be thought of as a combination of mental and physical wellbeing (e.g. expressed as quality of 
life) for an as long as possible amount of time (life expectancy). What is of interesting however 
in the old definition is the incorporation of the word consequently. Apparently it is assumed that 
treatment will always result in a preservation and improvement of health. Although this seems 
completely logical it might not per definition be the case, for instance if the (side) effects of treat-
ment on overall health are worse than the expected effects of the disease. This counterintuitive 
phenomenon is not unthinkable in the case of prostate cancer, often summarized in the terms 
‘overdiagnosis’ and ‘overtreatment’. Both terms are elaborately discussed in this thesis. In this case 
the adverse effects of the disease that would be experienced are small while the harmful side 
effects of the treatment are considered substantial. But less straightforward examples can be 
thought of resulting from the subjectiveness of the definition of health since different attributes 
compete for dominance. An example can be given in the case of life prolonging treatment in 
a person expected to suffer from his/her disease. One person might argue that this interven-
tion will extent life expectancy, albeit in suboptimal condition, and thus overall health will be 
improved. Another could state that extending the time spent while suffering from the disease 
will result in an overall decreased wellbeing for a longer time and therefore a decrease in overall 
health. These examples illustrate that the decision of detecting and treating a disease is not as 
straightforward as stated in the first mentioned definition. In modern medicine considerations 
should be made constantly on the balance between harms and benefits of medical interven-
tions. As this is subject to personal perception, medical practice is no longer a one way stream 
in which decisions are made by the physician who ‘knows’ what is best for a person’s health. 
Instead, practice is based on a shared decision making process in which the patient, with help 
from his doctor, is supposed to carefully weigh personal advantages and disadvantages of an 
intervention. It is key to have access to all relevant information for a well-informed decision. It 
is here that medical research plays an increasingly important role, after all how can one make a 
well-informed decision if there is not enough scientifically valid information to base it on? In this 
thesis an attempt is made to make a contribution in this respect to the information on prostate 
cancer screening and its challenge of minimizing harms while preserving benefits.
Starting with the latter, the most substantial evidence on the benefits of screening comes from 
the European Randomized study of Screening for Prostate Cancer (ERSPC). This study, initiated in 
the early nineties, is the largest randomized study conducted to date with inclusion of close to 
200,000 men in its core age group [2]. The rationale for this study was that detection of prostate 
cancer at an earlier stage (facilitated by the PSA test) would allow curative rather than palliative 
treatment. At that time the majority of men were diagnosed with prostate cancer already pres-
ent outside of the prostate and one third of men diagnosed with prostate cancer died of their 
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disease [3]. Taken over the entire population prostate cancer is among the top three most lethal 
cancers in men from most western countries [4, 5]. To put this in perspective, in the Netherlands 
approximately 1 in 25 to 30 men will eventually die of prostate cancer [6]. Data from the ERSPC 
show that systematic PSA screening can result in a reduction of prostate cancer specific mortality 
of 21% after 13 years of follow-up, and a reduction of metastasis of 30% [7, 8], resulting in a net 
increase of quality adjusted life years [9].
These benefits are unfortunately not without its negative side effects. First, many men need 
to be tested, most of them will experience no benefit. It is estimated that on a lifetime basis 
100 men need to be invited for screening to save the life of 1 men [9]. On top of this comes 
overdiagnosis of tumors that would not have given rise to any symptoms during a man’s life. An 
estimated 5 men are unnecessarily diagnosed by screening per 100 men invited (and thus per 1 
men saved) [9]. Overdiagnosis, besides from the effects on health of a cancer finding, would be 
less problematic if not subsequently most of these cancers are being treated (overtreatment), 
resulting in side effects with subsequent reduction of quality of life [9, 10]. A strategy developed 
to reduce overtreatment is the use of ‘active surveillance’. In active surveillance men likely to have 
an overdiagnosed cancer are not directly treated but instead monitored only to switch to active 
treatment in the case of tumor reclassification (signs of higher risk disease). But in order for active 
surveillance to be effective in reducing the harms of screening it must be able to select men 
likely to have overdiagnosed cancer at entrance, selectively filter out those with signs of more 
aggressive disease during follow-up, and do so before the tumor becomes beyond the window 
of curability (in which case the early diagnosis would be in vain). All this should be achieved 
without itself being too demanding on a patient’s health.
OBJECTIvE
This thesis will focus on two main issues. The first objective is to better understand how screening 
works and results in a reduction of mortality. This is important in order to develop methods of 
maximizing the benefits and minimizing its harms of screening. The second objective focusses 
specifically on the reduction of overtreatment with active surveillance, and emphases on how 
best to employ active surveillance to safely maximize the benefits in terms of reducing overtreat-
ment.
OUTLINE OF RESEARCH qUESTIONS ADDRESSED IN THIS THESIS
The first part will focus on screening and is divided into four chapters. These will center on the 
following research questions:
11
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- What are the mechanisms that lead to the observed reduction in prostate cancer mortality?
	 •	 	What	type	of	prostate	cancers	are	detected	and	at	what	time	during	the	screening	pro-
cess? (Chapter 1)
	 •	 	What	is	the	effect	of	correction	for	contamination	and	noncompliance?	(Chapter	2)
	 •	 	What	is	the	effect	of	treatment	on	screening	outcome?	(Chapter	3	and	4)
	 •	 	Where	does	the	benefit	originate	from?	(Chapter	1	to	4)
The second part will focus on active surveillance and is divided into five chapters addressing the 
following research questions:
- Are we able to selectively identify men with aggressive disease?
	 •	 	By	risk	based	selection	at	inclusion?	(Chapter	5)
	 •	 	By	pathology	and	biomarkers	(Chapter	8)
	 •	 	Is	 biopsy	 the	 best	 method	 to	 detect	 aggressive	 disease,	 i.e.	 what	 are	 its	 drawbacks?	
(Chapter 6 and 7)
	 •	 	Should	we	change	the	current	follow-up	protocol?	(Chapter	9)
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 Chapter 1
Positive predictive value of prostate biopsy indicated 
by PSA-based prostate cancer screening: trends over 
time in a European randomized trial.
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Fritz H. Schrödera, Monique J. Roobola.
a Erasmus University Medical Center, Department of Urology, Rotterdam, The Netherlands
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ABSTRACT
Objective:
•	 To	assess	 the	Positive	Predictive	Value	 (PPV)	of	prostate	biopsy,	 indicated	by	a	prostate-
specific antigen (PSA) cut-off of >=3.0 ng/ml, over time, in the Rotterdam section of the 
European Randomized study of Screening for Prostate Cancer (ERSPC).
Patient and methods:
•	 In	the	Rotterdam	section	of	the	ERSPC,	a	total	of	42376	participants	identified	from	popula-
tion registries (age 55-74 yr) were randomly assigned to a screening or control arm.
•	 In	the	ERSPC	men	are	screened	with	PSA	at	a	four	year	interval.	A	total	of	three	screening	
rounds were evaluated. Therefore, only men aged 55-69 yr at the first screen were eligible 
for this study.
Results:
•	 PPVs	for	men	without	previous	biopsy	remained	equal	throughout	the	three	subsequent	
screens (25.5%, 22.3% and 24.8% respectively).
•	 Conversely,	PPVs	for	men	with	previous	negative	biopsy	dropped	significantly	(12.0%	and	
15.2% at the second and third screen respectively).
•	 Additionally,	in	men	with	and	without	previous	biopsy	the	percentage	aggressive	prostate	
cancers (PCa) (clinical stage >T2b, Gleason score >=7) decreased after the first round of 
screening from 44.4% to 23.8% in the second (p<0.001) and 18.6% in the third round 
(p<0.001).
•	 Repeat	biopsies	accounted	for	24.6%	of	all	biopsies,	but	yielded	only	8.6%	of	all	aggressive	
cancers.
Conclusions:
•	 In	consecutive	screening	rounds	the	PPV	of	PSA-based	screening	remains	equal	in	previ-
ous unbiopsied men.
•	 In	 men	 with	 a	 previous	 negative	 biopsy	 the	 PPV	 drops	 considerably,	 however	 20%	 of	
cancers detected still show aggressive characteristics.
•	 Individualized	screening	algorithms	should	incorporate	previous	biopsy	status	in	the	deci-
sion to perform a repeat biopsy with the goal to further reduce unnecessary biopsies.
Trial registration: ISRCTN49127736
19
1
INTRODUCTION
Prostate-specific antigen (PSA) can be used as a biomarker for the early detection of prostate 
cancer (PCa) [1]. In the European Randomized Study of Screening for Prostate Cancer (ERSPC) 
men are screened for PCa with PSA. Results of the ERSPC have shown that PSA-based screen-
ing can reduce PCa mortality by up to 29% at eleven years of follow-up after adjustment for 
noncompliance [2].
Although screening with PSA can reduce the PCa mortality, its use has limitations as a result 
of the lack of specificity, especially in low PSA ranges [3]. Consequently, if a large group of men 
is biopsied based on a PSA cut-off, only a modest proportion of men will have PCa. In the ERSPC 
the PPv of a lateralized sextant prostate biopsy indicated by PSA is approximately 25% at initial 
screening [4, 5]. Already, multivariable risk calculators have been developed to improve the risk 
stratification and select men at high risk of PCa for conducting biopsies [6-8]. Data on cancer 
detection and PPv per screening round could further improve risk stratification.
In the ERSPC men are re-screened at a four year interval. In this paper we aim to assess the PPv 
of lateralized sextant prostate biopsy, indicated by an identical PSA cut-off value in subsequent 
screening rounds in the Rotterdam section of the ERSPC, stratified by age group and status of 
previous biopsy. We also evaluate the tumour characteristics of the diagnosed cancers. This 
knowledge may have implications for future screening strategies.
PATIENTS AND mETHODS
The study population and protocol have been described in detail previously [9]. In summary, 
men aged 55-74 yr, identified from population registries of Rotterdam, were invited for screening. 
men previously diagnosed with PCa were excluded [9]. In total, 42376 men who responded by 
returning the intake questionnaire and who provided informed consent were randomized to a 
screening (n=21210) or control arm (21166) from November 1993 until December 1999.
In the present study, three consecutive screening rounds were evaluated. men aged 55-69 yr at 
the first screening round were eligible (16600 men). Age selection was made to provide a cohort 
of men eligible for at least two consecutive screening visits. men were rescreened every four year 
until they reached the age of 75. A prostate biopsy was indicated for those with a PSA >=4.0 ng/
ml and/or abnormal digital rectal examination (DRE) and/or transrectal ultrasound (TRUS). From 
may 1997, a PSA threshold of >=3.0 ng/ml was used as the sole screening test. In screen-positive 
men, sextant biopsies were indicated; they were lateralized from June 1996, as described by 
Eskew et al [10]. An additional biopsy was taken from any suspicious area on TRUS.
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Statistical analysis
Data was stratified for age groups 55-59, 60-64 and 65-69 yr at baseline and status of previous 
biopsy (yes or no). Aggressive PCa was defined as clinical stage >T2b and/or Gleason score >=7 
as described by Roobol et al. [7].
The PPv (percentage PCa detected among all men biopsied) was calculated for each screening 
round and subgroup. The PPv and categorical clinical variables between groups were compared 
using chi-square test; for continuous variables the mann-Whitney U test was used. All statistical 
tests were two sided. A p-value < 0.05 was considered significant. SPSS v.17.0 was used for statisti-
cal analysis (SPSS Inc, Chicago, IL, USA).
RESULTS
In total 16600 men, aged 55-69 yr at baseline, were screened in the first screening round, 12120 in 
the second round and 7740 in the third round. The median age for the whole study population at 
first screen was 61.1 yr. An overview of the screening rounds is shown in the flow diagram (fig. 1).
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Figure 1. Consort trial flow diagram, screening rounds with a four year interval. PCa= prostate cancer 
 
 
Randomized into screening 
n=21210 
Screened in first round 
n=16600 
Screened in second round 
n=12120 
1225 non-attendees 
35 PCa cases excluded 
3350 age not 55-69yr 
Screened in third round 
n=7740 
1695 age >75 
2160 non-attendees: 
- 41 interval PCa cases 
- 433 deaths 
- 311 moved out of region 
- 405 health issues 
- 435 refused 
- 535 unknown 
790 PCa cases 
323 PCa cases 
525 PCa cases 
3690 non-attendees: 
- 32 interval PCa cases  
- 642 deaths 
- 694 moved out of region 
- 571 health issues 
- 605 refused 
- 1146 unknown 
Figure 1. Consort trial flow diagram, screening rounds with a four year interval. PCa= prostate cancer
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Positive predictive value
In total 7553 biopsies were performed: 3104 men were biopsied in the first round, 2789 in the 
second round and 1660 in the third round (96.3%, 92.1% and 93.5% of men with a biopsy indica-
tion). In addition, 288, 266 and 195 men refused a biopsy despite recommendation respectively. 
The numbers of cancers detected per round were 790, 525 and 323 respectively (table 1). Subse-
quently, the PPv of prostate biopsy in the first round was 25.5%. In the second round the PPvs for 
men with and without a biopsy in the first round were 22.3% and 12.0% respectively (p<0.001). 
In the third round the PPvs for men with and without previous biopsy were 24.8% and 15.2% 
respectively (p<0.001).
Table 1. Positive predictive values of prostate biopsies per screening round of the ERSPC Rotterdam
First round Second round Third round
Total Total No Biopsy 
round 1
Biopsy 
round 1
Total No Biopsy 
round 1 
or 2
Biopsy 
round 1 
and/or 2
men screened 16600 12120 10552 1568 7740 6085 1655
men biopsied (%screened) 3104 (18.7) 2789 (23) 1850 (17.5) 939 (59.9) 1660 (21.4) 743 (12.2) 917 (55.4)
PCa, No 790 525 412 113 323 184 139
% aggressivea 44.4% 23.8% 24.5%b 21.2%c 18.6% 20.7%b 15.8%c
PPv 25.5% 18.8% 22.3% 12.0%d 19.5% 24.8% 15.2%d
PCa = prostate cancer; PPv = positive predictive value; ERSPC = European Randomized Study of Screening for 
Prostate Cancer a Defined as clinical stage >T2b and/or Gleason score >=7; b p<0.001 (as to first round); c >0.05 
(as to no biopsy); d p<0.001 (as to no biopsy)
In the first round the PPv of prostate biopsy was higher in the oldest age group (28.8% in 65-69 
yr) compared to the younger age groups (23.1% in 55-59 yr, p<0.01; 23.2% in 60-64 yr, p<0.01). 
In the second and third round the differences between age groups did not reach statistical 
significance (table 2).
Tumour characteristics
Tumour characteristics per screening round are shown in table 3. The median PSA level and 
prostate volume, measured by TRUS, were significantly different in the second and third round 
of screening for men with or without previous biopsy (all p<0.001). The percentage of aggressive 
PCa (defined as clinical stage >T2b and/or Gleason >=7) was significantly higher in the first round 
compared to the second and third round (44.4%, 23.8% and 18.6% respectively; both p<0.001). 
No significant difference in percentage aggressive PCa was seen between men with or without 
previous biopsy in both the second and third screening round (21.2% vs. 24.5% in second round 
respectively, p=0.549; 15.8% vs. 20.7% in the third round respectively, p=0.337). In total 536 ag-
gressive cancers were found, of which 65.5% were found in the first screen, 25.9% in subsequent 
screens in men without previous biopsy and 8.6% in men with a previous biopsy. In the first 
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round the percentage aggressive PCa was significantly higher in the oldest age group (65-69 
yr) compared to the youngest age group (55-59 yr; 51.4% vs. 37.2% respectively, p=0.002). In all 
age groups the percentage aggressive PCa decreased after the first screening round as shown in 
table 2. In the first round 79.6% of PCa were clinically organ-confined (<=cT2). In the second and 
third round this number increased to 96.2% and 98.4% respectively. No statistically significant 
difference was seen between men with or without previous biopsy.
Table 4 outlines the characteristics at the time of the preceding round of men without previous 
biopsy, who were diagnosed in later screens. In the second round 46.6% of these men had a PSA 
of 2.0-2.9 ng/ml in the first round. In the third round a similar amount (48.4%) had a PSA of 2.0-2.9 
ng/ml in the second round.
Table 2. Positive predictive value per age group at baseline and round of screening
First round Second round Third round
Total Total No Biopsy 
round 1
Biopsy 
round 1
Total No Biopsy 
round 1 or 2
Biopsy round 
1 and/or 2
55 – 59 yr
men screened 6498 5061 4630 431 4004 3280 724
men biopsied 792 937 703 234 747 360 387
PCa, No 183 168 142 26 154 91 63
% aggressivea 37.2% 23.2% 23.9% 19.2% 17.5% 13.2% 23.8%
PPv 23.1% 17.9% 20.2% 11.1% 20.6% 25.3% 16.3%
60 – 64 yr
men screened 5336 3946 3373 573 2873 2184 689
men biopsied 1032 958 612 346 667 289 378
PCa, No 239 186 145 41 135 76 59
% aggressivea 39.3% 24.7% 24.1% 26.8% 20.0% 27.6% 10.2%
PPv 23.2% 19.4% 23.7% 11.8% 20.2% 26.3% 15.6%
65 – 69 yr
men screened 4766 3113 2549 564 863 621 242
men biopsied 1280 894 535 359 246 94 152
PCa, No 368 171 125 46 34 17 17
% aggressivea 51.4%b 23.4% 25.6%c 17.4% 17.6% 29.4%c 5.9%
PPv 28.8%b 19.1% 23.4%c 12.8% 13.8% 18.1%c 11.2%
PCa = prostate cancer; PPv = positive predictive value; a Defined as clinical stage >T2b and/or Gleason score 
>=7; b p<0,01 (as to 55-59 yr); ^ p>0,05 (as to 55-59 yr)
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DISCUSSION
Although results of the ERSPC have shown to reduce PCa mortality [2], the US preventive Ser-
vices Task Force recently released an updated recommendation against PSA screening, as the 
authors concluded that the harms outweigh the benefits [11, 12]. moreover, a meta-analysis by 
Djulbegovic et al. [13] concluded that the existing evidence does not support the routine use of 
screening for prostate cancer. In addition to overdiagnosis, unnecessary biopsies triggered by 
false-positive screening results could be considered as one of the most important harms, leading 
to infections and hospital admissions [14].
In this study we assessed the PPv of a PSA indicated prostate biopsy throughout subsequent 
screening rounds of the ERSPC, section Rotterdam. This gives insight in the screening efficacy of 
the current algorithm and may be valuable in the development of future screening strategies. 
Our results demonstrate that during screening rounds the PPv of men without a previous biopsy 
remained equal (25.5%, 22.3% and 24.8% in first, second and third round respectively). The PPv of 
prostate biopsy indicated by a PSA cut-off dropped considerably to 12.0%-15.2% in men with a 
previous biopsy; 20% of cancers detected however still show aggressive characteristics.
Because the PPv depends on the underlying prevalence and the first screening round was 
performed in a relatively unscreened population, one would expect a decline in PPv after the first 
Table 3. Tumour characteristics per round of screening
First round Second round Third round
Total Total No Biopsy 
round 1
Biopsy 
round 1
Total No Biopsy 
round 1 or 2
Biopsy round 
1 and/or 2
PCa, No 790 525 412 113 323 184 139
Age, median 64.6 66.7 66.4 68.2 68.6 68.4 69.3
PSA (ng/ml), median 5.6 3.9 3.6 5.7d 4.2 3.7 5.3d
Prostate volume (cc), 
median
35.9 38 36 50.5d 42.5 37.2 50.9d
Aggressivea (%) 351 (44.4) 125 (23.8) 101 (24.5)b 24 (21.2)c 60 (18.6) 38 (20.7)b 22 (15.8)c
Clinical stage
T1 (%) 325 (41.1) 356 (67.8) 290 (70.4) 66 (58.4) 229 (70.9) 127 (69) 102 (73.4)
T2 (%) 304 (38.5) 149 (28.4) 107 (26) 42 (37.2) 88 (27.2) 54 (29.3) 34 (24.5)
T3 (%) 155 (19.6) 20 (3.8) 15 (3.6) 5 (4.4) 6 (1.9) 3 (1.6) 3 (2.2)
T4 (%) 6 (0.8) - - - - - -
Gleason
<=6 (%) 531 (67.2) 417 (79.4) 324 (78.6) 93 (82.3) 268 (83) 148 (80.4) 120 (86.3)
7 (%) 202 (25.6) 93 (17.7) 78 (18.9) 15 (13.3) 39 (12.1) 26 (14.1) 13 (9.4)
>=8 (%) 50 (6.3) 15 (2.9) 10 (2.4) 5 (4.4) 14 (4.3) 9 (4.9) 5 (3.6)
PSA = prostate-specific antigen; PCa = prostate cancer; a Defined as clinical stage >T2b and/or Gleason score 
>=7; b p<0.001 (as to first round); c p>0.05 (as to no biopsy); d p>0.001 (as to no biopsy)
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round considering the slow natural course of PCa [15, 16]. However, data from the PCPT trial has 
shown that 23.9% of men with a PSA 2.1-3.0 ng/ml harbor PCa [17]. In the current analysis, almost 
half of the cancers detected in men without previous biopsy originated from the 2.0-2.9 ng/ml 
PSA group as shown in table 4. The PSA in these men increased and subsequently surpassed the 
biopsy threshold during the four year screening interval, resulting in equal PPvs of approximately 
Table 4. Characteristics of men at the time of the preceding round and of prostate cancers which were eventu-
ally diagnosed
Biopsy PCa, No (%) % PCa / 
Biopsies
Aggressivea, 
No (%)
% Aggressivea 
/PCa
Second round, no biopsy first round
Total 1850 412 (100) 22.3 101 (100) 24.5
Age at baseline
55-59 yr 703 142 (34.5) 20.2 34 (33.7) 23.9
60-64 yr 612 145 (35.2) 23.7 35 (34.7) 24.1
65-69 yr 535 125 (30.3) 23.4 32 (31.7) 25.6
PSA first round (ng/ml)
<1.0 ng/ml. 212 29 (7) 13.7 11 (10.9) 37.9
1.0-1.9 ng/ml. 660 133 (32.3) 20.2 27 (26.7) 20.3
2.0-2.9 ng/ml. 755 192 (46.6) 25.4 42 (41.6) 21.9
>=3.0 ng/ml 223 58 (14) 26.0 21 (20.8) 36.2
Reason no biopsy first round
medication 9 2 (0.5) - - -
Refused biopsy 11 5 (1.2) - 3 (3) -
DRE and TRUS normal 203 51 (12.4) 25.1 18 (17.8) 35.3
Third round, no previous biopsy
Total 743 184 (100) 24.8 38 (100) 20.7
Age at baseline
55-59 yr 360 91 (49.5) 25.3 12 (31.6) 13.2
60-64 yr 289 76 (41.3) 26.3 21 (55.3) 27.6
65-69 yr 94 17 (9.2) 18.1 5 (13.2) 29.4
PSA second round (ng/ml)
<1.0 ng/ml. 153 22 (12) 14.4 4 (10.5) 18.2
1.0-1.9 ng/ml. 269 67 (36.4) 24.9 10 (26.3) 14.9
2.0-2.9 ng/ml. 300 89 (48.4) 29.7 24 (63.2) 27.0
>=3.0ng/ml 21 6 (3.3) 28.6 - -
Reason no previous biopsy
medication 4 1 (0.5) - - -
Refused biopsy 17 5 (2.7) - - -
PSA = prostate-specific antigen; PCa = prostate cancer; DRE = digital rectal examination; TRUS = transrectal 
ultrasound; a Defined as clinical stage >T2b and/or Gleason score >=7;
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25%. If we would assume that these cancers were already detectable at the previous screening 
round, these men may have been diagnosed when the biopsy threshold was set at a PSA of 2.0 
ng/ml. However, a lower cut-off would also increase the number of overdiagnosed cancers and 
unnecessary biopsies [17, 18]. Lowering the biopsy threshold to a PSA of 2.0 ng/ml would have 
increased the number of biopsies with 64%-72% in the current study (data not shown). Applying 
a shorter screening interval in men with a PSA of 2.0-2.9 ng/ml may be another option. Future re-
search should further address this problem and study the origin of cancers detected in previously 
screened but unbiopsied men, with the goal to reduce unnecessary biopsies, overdiagnosis and 
mortality.
Even more important than the actual number of PCa detected, are the characteristics of the 
cancers. In the first round of screening, we found almost half of the cancers to be aggressive 
(Gleason score >=7 and/or clinical stage >T2b). Even though the PPv in the second and third 
round remained equal in men without previous biopsy, the proportion of aggressive PCa de-
creased to 20.7%-24.5%. Almost all cancers in the second and third round were clinically organ-
confined (96.4%-98.4%). If these cancers were detectable in the first screening round, they did 
not progress to a stage where they became incurable. The low number of cancers detected in the 
interval period, as described previously [19, 20], supports this assumption.
Still, overdiagnosis is one of the major drawbacks of PCa screening. A simple solution to reduce 
the number of low risk PCa, which could be considered overdiagnosed, is to raise the PSA cut-
off for a biopsy indication [21]. Indeed, if only men with a PSA >=4.0 ng/ml were biopsied, the 
described PPvs in men without a previous biopsy in the first, second and third round would 
increase to 26.5%, 28.6% and 34.1% respectively (data not shown). Additionally 32.3%, 66.9% and 
64.4% off the non-aggressive PCa would not have been detected, possibly sparing these men 
the burden of PCa and its treatments. However, and this is undesirable, with this strategy 19.1%, 
38.6% and 47.4% of all aggressive cancers would also have been missed in the first, second and 
third round respectively. The drawbacks of a single PSA cut-off emphasize the need for better 
risk stratification tools. Already different multivariable risk calculators have been developed to 
improve risk stratification [22]. An external evaluation of the ERSPC risk calculator step 3 (www. 
prostatecancer-riskcalculator.com) showed both an improvement of PPv to 64% and an improved 
selection of aggressive PCa (personal communication with H.A. van vugt, Erasmus University 
medical Center, manuscript in preparation). Risk calculators will play an important role until bet-
ter biomarkers and imaging techniques are validated. Several studies have already demonstrated 
the additional value of mRI in the diagnosis of PCa [23, 24].
In men with a previous biopsy a drop in PPv was seen at repeat screening. However, there are 
still cancers detected. Two explanations can be given. First, it is known that a sextant prostate 
biopsy does not detect all cancers. In a literature review by Schröder et al. [25], the average 
proportion of cancers missed with a lateralized prostate biopsy was 19%. Possibly a group of PCa 
was missed in the first screening round and emerged at repeat biopsy. Although some might 
suggest a more extended biopsy scheme, only a limited reduction in disease-specific mortality 
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can be expected [25]. Second, some of the cancers that were detected at repeat screening may 
have developed during the screening interval. This would lower the number of cancers that 
potentially could have been detected earlier on.
Furthermore, we found that the prostate volume of men with a previous biopsy was signifi-
cantly higher than men without a previous biopsy. Because a larger prostate is associated with 
a higher PSA value, these men were more likely to be biopsied. Previous studies have shown a 
negative association between prostate volume and the risk of PCa [26, 27]. This could attribute to 
the relatively lower PPv in men with a previous biopsy. On the other hand, there are still cancers 
detected and although the PPv is lower, the percentage aggressive PCa is comparable to men 
without a previous biopsy. The number of aggressive PCa detected in men with a previous biopsy 
only accounted for 8.6% of the total number of aggressive PCa found, whereas the number of 
biopsies in previously biopsied men accounted for 24.6% of the total biopsies. This emphasizes 
the need for a more individualized screening approach, in which a previous negative biopsy 
should be taken into account. Already, previous biopsy status is incorporated in step 4 of the 
ERSPC risk calculator (www. prostatecancer-riskcalculator.com). External validation of this risk 
calculator in a Canadian and European cohort showed previous biopsy status to be a significant 
predictor of PCa in multivariable analysis [28, 29].
In the first round of screening, tumours detected in the oldest age group were of a higher 
grade than in the younger age groups. This poorer differentiation in older men was reported 
before [30, 31]. After the first round this difference is less obvious. Because in the first round the 
tumours in older men had a longer time to develop, this could be expected. This concurs with a 
previous study by Boevee et al. [32] and could be seen as an effect of screening.
Some limitations should be mentioned. First, the PPvs provided in this study are calculated 
for only those who actually underwent biopsy; men with a positive screening test who did not 
have a biopsy were not included in the analysis. However, in our cohort the compliance to a 
biopsy indication was > 90%, and there is no reason to assume the PPv in men who had an 
indication but did not undergo biopsy would be significantly different from those who actually 
had a biopsy. Second, sextant prostate biopsy, either classical or lateralized, will miss 23% or 19% 
of biopsy-detectable PCa [25]. Therefore, the PPv in this study may be underestimated. However, 
because the number of biopsies remained equal throughout screening rounds a comparison 
between screens was possible and was not affected by a change in protocol. Last, the biopsy 
indication has been modified over time: in the first screening round men were initially biopsied 
based on the results of a PSA test, DRE and TRUS; half way the first round the use of DRE and TRUS 
as a biopsy indication was omitted, because of limited additional value [33, 34]; in the second and 
third round some men were screened in side studies with different biopsy indications. Even so, a 
subanalysis in men who were biopsied with PSA >=3 ng/ml as the sole biopsy indication showed 
only a negligible change in PPvs. Therefore all side studies were included in the current analysis.
In conclusion, the results of this study show that the PPv of PSA-based PCa screening remains 
equal in previous unbiopsied men. In men with a previous biopsy the PPv drops considerably, 
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however 20% of cancers detected still show aggressive characteristics. In both groups a decline 
in aggressive PCa is seen after the first screening round. This study indicates that previous biopsy 
status should definitively be considered in the decision to perform a repeat biopsy. Also, in men 
without an initial biopsy and a PSA value of 2.0-2.9 ng/ml earlier repeat screening could be con-
sidered. Furthermore, future research should study the origin of PCa in men without a previous 
biopsy. Knowing the origin of these cancers could change the way men are screened, further 
reducing the PCa mortality and overdiagnosis.
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ABSTRACT
Background: Large randomized screening trials provide an estimation of the effect of screen-
ing on a population based level. The effect of screening for individuals is however diluted by 
nonattendance and contamination in the trial arms.
Objective: To determine the prostate cancer (PCa) mortality reduction from screening after 
adjustment for nonattendance and contamination.
Design, setting, and participants: A total of 34833 men in the core age group of 55-69 years 
were randomized to a screening or control arm in the Rotterdam section of the ERSPC. PSA 
testing was offered to all men in the screening arm at a four year interval. A prostate biopsy 
was offered to men with an elevated PSA. The primary end-point was PCa specific mortality.
Outcome measurements and statistical analysis: Nonattendance was defined as non-
participation in the screening arm. Contamination in the control arm was defined as receiving 
asymptomatic PSA testing or a prostate biopsy in the absence of symptoms. Relative risks (RR) 
were calculated with an intention to screen (ITS) analysis and after correction for nonattendance 
and contamination using a method which preserves the benefits obtained by randomization.
Results and limitation: The ITS analysis resulted in a RR of 0.68 (95% confidence interval (CI) 
0.53-0.89) in favour of screening at a median follow-up of 13 years. Correction for both nonat-
tendance and contamination resulted in a RR of 0.49 (95% CI 0.27-0.87) in favour of screening.
Conclusion: PCa screening as conducted in the Rotterdam section of the ERSPC can reduce 
the risk of dying from PCa with up to 51% for an individual man choosing to be screened 
repeatedly as compared to a man that was not screened. These benefits of screening should 
be balanced against the harms of overdiagnosis and subsequent overtreatment.
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INTRODUCTION
Recently, the 13 year follow-up results of the Dutch centre of the European Randomized study 
of Screening for Prostate Cancer (ERSPC) were published, showing a prostate cancer (PCa) spe-
cific mortality reduction of 32% in favour of screening with prostate-specific antigen (PSA) [1]. 
Although the conventional intention to screen (ITS) analysis provides the best estimation of the 
PCa specific mortality reduction on a population based level, the potential effect of screening for 
an individual choosing to be screened needs to be corrected for nonattendance in the interven-
tion arm and contamination (e.g. PSA testing/prostate biopsy) in the control arm. This adjustment 
should however not influence the benefits obtained by randomization (namely, the same baseline 
risk of PCa mortality in both arms). A simple comparison of men who actually receive screening 
(attenders), against those who do not (non-attenders), could be biased since the baseline risk of 
having PCa for attenders and non-attenders may be different. In order to correct for nonattendance 
and contamination without creating a difference in baseline risk in the two compared groups a 
method developed by Cuzick et al.[2] was used. This method was previously applied to correct for 
nonattendance and contamination at the 9 year follow-up results of the whole ERSPC [3].
The aim of this paper is to determine the PCa specific mortality reduction from PSA-based PCa 
screening, adjusted for nonattendance and contamination in the ERSPC, section Rotterdam, with 
a median follow-up of 13 years and to give detailed data on PSA and biopsy use in the control 
arm. Results will provide a more accurate estimation of PCa specific mortality reduction for those 
men who choose to be screened as compared to an ITS analysis.
mATERIALS AND mETHODS
The study population and protocol have been described in detail previously [4, 5]. In summary, 
in the Rotterdam section of the ERSPC 17,443 men were randomized to the screening arm and 
17,390 to the control arm in the core age group of 55-69 year (at time of randomization). 
Randomization for this study started in 1993. men in the Rotterdam section of the ERSPC were 
randomized after providing written informed consent. In the screening arm men were offered 
PSA testing with a 4 year interval until the age of 75. Initially, a prostate biopsy was offered in 
men with a PSA level >= 4.0 ng/ml and/or an abnormal digital rectal examination (DRE). From 
may 1997 onwards, a PSA level >=3.0 ng/ml was the only indication for sextant prostate biopsy. 
The primary endpoint of the ERSPC is PCa specific mortality.
Data on PCa of all men diagnosed outside the screening protocol (both in the screening and 
the control arm) were collected through linkage with the national cancer registry and subse-
quent patient chart review of all men with PCa. Cause of death of all men with PCa was assessed 
by an independent monitoring committee according to a predefined algorithm and blinded for 
study arm [6].
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Follow-up for the current analysis ended December 31, 2010. The study was approved by the 
medical ethical committee (trial registration: ISRCTN49127736).
Nonattendance in the screening arm
In the screening arm two groups were defined: non-attenders, men refusing PSA testing at the 
first screening round (men refusing participation were no longer invited for subsequent screen-
ing rounds), and attenders, men attending at least the first screening round.
Contamination in the control arm
Two definitions were used for contamination in the control arm. First, contamination in the con-
trol arm was defined as having at least one PSA test in the absence of symptoms (opportunistic 
screening). Through linkage of the ERSPC Rotterdam database to the central laboratory of the 
Rotterdam region, the Netherlands, PSA testing of men in the control arm could be retrieved. The 
central laboratory covered 77.7% of all Dutch participants [7, 8]. Data was therefore extrapolated 
to the entire cohort. An analysis based on self-reported PSA testing of men in the screening arm, 
showed the 23.3% of GPs not covered by the laboratory were not biased for demanding PSA tests 
(data not shown). To determine which men received PSA testing for clinical reasons (symptom-
atic testing) and which men received PSA testing for screening purposes (true contamination), 
a survey was conducted among general practitioners (GPs) of a random sample of men without 
PCa. Furthermore, the reason to be referred to the urologist for all men with PSA testing and 
PCa was known through medical records. These data could then be used to determine the true 
contamination rate for all Dutch participants in the control arm.
As a screening test can only be seen as such if an abnormal test leads to an additional test to 
confirm the diagnosis (in the case of PCa screening a prostate biopsy) the second definition of 
contamination was defined as: having a prostate biopsy at least once in the absence of symptoms 
(and thus only because of an elevated PSA test). Through linkage with the nationwide network 
and registry of histo- and cytopathology in the Netherlands (PALGA), data on prostate biopsy of 
men in the control arm could be retrieved [8, 9]. The PALGA database covers all pathology reports 
in the Netherlands since 1991 and correct linkage is achieved in up to 98% of cases [10]. True 
contamination was then defined in the same way as with PSA testing, using reason for referral to 
the urologist for all men with PCa and the reason to be tested by the GP for all men without PCa.
Both data on PSA testing and prostate biopsy were available until the end of follow-up.
Contamination was however defined as a PSA test or biopsy more than two years before the 
end of follow-up (before the end of 2008).
Statistical analysis
The effect of screening on the PCa specific mortality for the ITS analysis and adjusted analysis 
was calculated as relative risk (RR). For the adjustment of nonattendance and contamination 
the method of Cuzick et al. [2] was applied (figure 1). Three methods for adjustment have been 
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likely to be more regular than screening as done in the contaminators. Furthermore, men in 
the screening arm not attending all screening visits (partial compliers) are still classified as 
‘full’ attenders. The correction for contamination and non-attendance could therefore be 
both under- and overestimated. 
 
Figure 1. Example of the Cuzick method for the correction of nonattendance and contamination (numbers 
are fictitious): On the left side the intention to screen (ITS) analysis is shown, with in red the proportion of the 
endpoint, i.e. prostate cancer mortality. In this example there would be a 25% lower risk of the endpoint in the 
screening arm versus the control arm (30% versus 40%).
Correction: Step 1: The proportion of non-attenders (10% of participants) with the corresponding endpoint 
(40% of non-attenders), i.e. prostate cancer mortality, is determined and subtracted from the screening arm. 
Step 2: Due to the randomization process we can assume that equal numbers of individual per arm are prone to 
non-attendance and that these individuals as a group have the same baseline risk of dying from prostate cancer. 
Therefore a similar proportion of participants (10%) in the control arm, with the same rate in endpoints reached 
(40%), are assumed to would have been noncompliant if not randomized to the control arm. These so called 
‘potential’ non-attenders are therefore subtracted from the control arm. Step 3: The proportion of contaminators 
in the control arm is determined (40% of which 40% reached the endpoint). Step 4: Due to the randomization it 
can again be assumed that equal numbers of individual are prone to contamination. Therefore a similar group 
of participants (40%) with the same rate of endpoints reached (40%) should be subtracted from the control arm 
(these are the ‘potential’ contaminators, that would have opted for screening if not randomized to the screening 
arm). The two remaining groups are the participants adhering to the allocated protocol. Furthermore, due to 
the randomization and the correction with the method described above, they still have the same baseline risk of 
dying from prostate cancer. Comparing these groups gives an estimate of the difference in endpoints between 
the screening and the control arm if nonattendance and contamination would not have occurred. After correc-
tion there would be a 50% lower risk of the endpoint in the screening arm versus the control arm (20% versus 
40%) in this example. This correction necessitates the assumption that the ‘treatment’ given has the same effect 
in all groups. This assumptions might not hold as the screening offered in the screening arm is likely to be more 
regular than screening as done in the contaminators. Furthermore, men in the screening arm not attending all 
screening visits (partial compliers) are still classified as ‘full’ attenders. The correction for contamination and non-
attendance could therefore be both under- and overestimated.
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described previously: a binary analysis; a Poisson analysis, taking into account time to PCa death, 
nonattendance and contamination; and a semiparametric Cox proportional hazard analysis, as-
suming nonattendance and contamination occurred at randomization. Here, the binary analysis 
was used because all models gave very similar results, as described by Kerkhof et al [11].
Although the ERSPC section Rotterdam was not designed as a stand-alone trial, a separate 
power calculation was done as described previously [1].
RESULTS
The total number of men in the core age group was 34,833. At a median follow-up of 13.0 year 
2,226 men were diagnosed with PCa in the screening arm (cumulative incidence, 12.8%) and 96 
men died of their disease. In the control arm 1,152 men were diagnoses with PCa (cumulative 
incidence, 6.6%) and 140 died of their disease at a median follow-up of 13.0 year. A detailed 
description of the PCas found is given in [1] and in table 1 and 2. Using a binary ITS analysis 
(no correction for attendance and contamination) the PCa specific mortality reduction in the 
screening arm compared to the control arm was 0.68 (95% confidence interval (CI), 0.53-0.89) at 
the end of follow-up.
Table 1. Clinical characteristics of prostate cancer cases in the screening arm for non-attenders and attenders
Non-attenders (%) Attenders (%) Total (%)
Age at baseline, median 60.9 62.4 62.4
PSA, median 11.9 4.9 4.9
T-stage
1 18 (38.3) 1257 (57.7) 1275 (57.3)
2 12 (25.5) 659 (30.2) 671 (30.1)
3 12 (25.5) 222 (10.2) 234 (10.5)
4 2 (4.3) 16 (0.7) 18 (0.8)
missing 3 (6.4) 25 (1.1) 28 (1.3)
Gleason score
<=6 22 (46.8) 1586 (72.8) 1608 (72.2)
7 15 (31.9) 445 (20.4) 460 (20.7)
>=8 6 (12.8) 141 (6.5) 147 (6.6)
missing 4 (8.5) 7 (0.3) 11 (0.5)
m+
0/X 41 (87.2) 2143 (98.3) 2184 (98.1)
1 6 (12.8) 36 (1.7) 42 (1.9)
Total 47 (100) 2179 (100) 2226 (100)
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Nonattendance in the screening arm
In total 16,502 men (94.6%) attended at least one screening round. The numbers of men per 
group and the numbers of (PCa) deaths are given in Table 3. Overall mortality was higher in 
non-attenders (37.6%) versus attenders (24.4%).
PSA contamination in the control arm
Of the 17,443 men in the Dutch control arm of the ERSPC, 6,880 (39.5%) had at least one PSA test 
before December 31, 2008 (extrapolated from a 77.7% coverage, according to Roemeling et al. 
[7]). Of these men, 660 were diagnosed with PCa (9.6%) and 81 men (12.3%) died of their disease 
at the end of follow-up (December 31, 2010) (table 4). Subsequently, a survey was conducted 
among GPs of a random sample of 671 men without PCa (10% of men with PSA testing). A 
total of 585 questionnaires (87.2%) were returned. Reason for PSA testing was unknown in 117 
cases, of the remaining 468 cases reason for PSA testing was diagnostic (voiding problems, other 
relevant problems or suspicious digital rectal examination) in 50.2% and for screening purposes 
(patient requested testing or test was part of general blood exam) in 49.8%. So, of men without 
PCa but with PSA testing, 49.8% were defined as contaminators. After careful investigation of 
reason for referral of all men with PCa and PSA testing, 275 of 660 men (41.7%) were classified as 
contaminators (no symptoms or suspicious DRE). A total of 27 out of 81 PCa deaths (33.9%) were 
attributed to these true contaminators. The number of total true contaminators hence was 3,372 
Table 2. Clinical characteristics of prostate cancer cases in the control arm for true biopsy contaminators and 
non- true biopsy contaminators
True biopsy contaminators Non- true biopsy contaminators Total (%)
Age, median 62.8 63.2 63.1
PSA, median 10.7 11.0 11.0
T-stage
1 220 (52.4) 352 (48.1) 572 (49.7)
2 104 (24.8) 180 (24.6) 284 (24.7)
3 72 (17.1) 145 (19.8) 217 (18.8)
4 15 (3.6) 38 (5.2) 53 (4.6)
missing 9 (2.1) 17 (2.3) 26 (2.3)
Gleason score
<=6 225 (53.6) 354 (48.4) 579 (50.3)
7 133 (31.7) 203 (27.7) 336 (29.2)
>=8 59 (14.0) 163 (22.3) 222 (19.3)
missing 4 (1.0) 11 (1.5) 15 (1.3)
m+
0/X 387 (92.1) 629 (85.9) 1016 (88.2)
1 33 (7.9) 103 (14.1) 136 (11.8)
Total 420 (100) 732 (100) 1152 (100)
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((49.8% of men without PCa = 3,097) + (41.7% of men with PCa=275)). The PSA contamination 
rate in the control arm was therefore 19.4% (3,372/17,390) (table 4).
Biopsy contamination in the control arm
A total of 2,422 men in the control arm received at least one prostate biopsy before the end of 
2008 (13.9% of all men in the control arm). A total of 923 (38.1%) of these men were diagnosed 
with prostate cancer. In total 46 PCa deaths and 420 PCa cases in the control arm were classified 
as true contaminators (table 4).
Of the 896 men diagnosed with prostate cancer in the control arm until the end of 2008, 74 
were not detected trough linkage with the PALGA database (896-822=74). Chart review showed 
15 were diagnosed by prostate biopsy (and were thus missed with the PALGA linkage) and 59 
were diagnosed in another way (TURP, cystoprostatectomy, other) (These were not detected 
because linkage was only done for biopsies). The correct detection of the linkage with the PALGA 
database for men with PCa was 98.2% (822/(896-59)).
Table 3. Nonattendance in the screening arm of the European Randomized study of Screening for Prostate 
Cancer (ERSPC) section Rotterdam
mortality follow-up until the end of 2010
Non-attenders Attenders Total
n (% of Total) 941 (5.4) 16502 (94.6) 17443 (100)
PCa diagnosis (% of n) 47 (5.0) 2179 (13.2) 2226 (12.8)
Death overall (% of n) 354 (37.6) 4021 (24.4) 4375 (25.1)
PCa death (% of n) 7 (0.74) 89 (0.54) 96 (0.55)
PCa = prostate cancer
Table 4. Contamination in the control arm of the European Randomized study of Screening for Prostate Cancer 
(ERSPC) section Rotterdam using two definitions: a PSA test before the end of 2008 and a prostate biopsy before 
the end of 2008
mortality follow-up until the end of 2010
PSA test Biopsy Total
n (% of Total) 6880 (39.6) 2422 (13.9) 17390 (100)
PCa diagnosis (% of n) 660 (9.6) 923 (38.1) 1152 (6.6)
Death overall (% of n) 1440 (20.9) 603 (24.9) 4355 (25.0)
PCa death (% of n) 81 (1.18) 126 (5.20) 140 (0.81)
True contaminators* (% of total) 3372 (19.4) 1071 (6.2) 17390 (100)
PCa diagnosis (% of true) 275 (8.2) 420 (39.2)
PCa death (% of true) 27 (0.81) 46 (4.33)
PCa = prostate cancer; * PSA testing/biopsy in the absence of symptoms (opportunistic screening)
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Disease specific mortality adjusted for nonattendance and contamination
Adjustment for nonattendance and biopsy contamination using the method of Cuzick et al. [2] 
is shown in figure 2. The correction for nonattendance and biopsy contamination resulted in a 
reduction of the PCa specific mortality of 51% in favour of screening (RR 0.49, 95% CI 0.27-0.87). 
Correction for non-attendance alone had a small effect (RR 0.68 versus RR 0.67)(table 5).
In figure 3 the absolute risk of dying from PCa per arm is given for different years of ending 
follow-up, with or without correction for non-attendance and PSA contamination. At the end of 
follow-up (2010), 5.5 PCa deaths/ 1000 men occurred in the screening arm versus 8.1/ 1000 in the 
control arm (ITS analysis). After correction for nonattendance and PSA contamination there were 
4.7 PCa deaths/1000 men in the screening arm versus 8.1/1000 in the control arm, a difference 
of 3.4/1000.
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Figure 2. Correction for nonattendance and biopsy contamination in the Rotterdam section 
of the ERSPC using the method of Cuzick et al. [2]. Mortality follow-up until the end of 2010 
 Figure 2. Correction for nonattendance and biopsy contamination in the Rotterdam section of the ERSPC using 
the method of Cuzick et al. [2]. mortality follow-up until the end of 2010
DISCUSSION
PSA based PCa screening as conducted in the Dutch centre of the ERSPC (4 year interval, PSA 
cut-off >= 3.0 ng/ml and lateralised sextant biopsy) resulted in a reduction of PCa mortality of 
32% using an ITS analysis after a median of 13 years of follow-up. This can be regarded as the 
effect of screening on a population based level. However, for an individual man who attended 
screening as mentioned above the current study shows that the risk of dying from PCa can be 
reduced with up to 51% as compared to a man not screened at all. This information might serve 
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men who face the dilemma of PCa screening to make a more balanced judgement between the 
harms and benefits.
The amount of men that attended at least one screening round was high (95%) in the current 
study. Therefore the effect of correction for only non-attenders was minimal. The PCa mortality 
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Figure 3. Absolute risk of dying from prostate cancer per arm for the intention to screen (ITS) 
analysis and after correction for non-attendence and PSA contamination. Results are given 
for different years of ending follow-up. 
 
Figure 3. Absolute risk of dying from prostate cancer per arm for the intention to screen (ITS) analysis and after 
correction for non-attendence and PSA contamination. Results are given for different years of ending follow-up.
Table 5. Reduction of prostate cancer (PCa) specific mortality from screening (relative risk (RR)) for the intention 
to screen (ITS) analysis, correction for nonattendance and correction for contamination.
mortality follow-up until the end of 2010
RR 95% CI p-value
ITS 0.68 (0.53-0.89) 0.004
Correction for nonattendance
Adjustment for non-attenders 0.67 (0.51-0.88) 0.004
Correction for contamination
PSA contamination 0.61 (0.42-0.88) 0.008
Biopsy contamination 0.53 (0.32-0.88) 0.014
Correction for nonattendance and 
contamination
Non-attenders + PSA 0.58 (0.39-0.86) 0.007
Non-attenders + Biopsy 0.49 (0.27-0.87) 0.015
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rate of the non-attenders was higher than the PCa mortality rate of the entire screening arm. It 
was however lower than the PCa mortality rate of the control arm. This could be explained by the 
higher overall mortality rate in the non-attenders, which was seen in other ERSPC centres as well 
[12]. It seems these men had a worse overall health status at the beginning of the trial and this 
could have been the reason for not complying with the screening protocol. It also shows that 
there is a baseline difference between the different groups. A simple subtraction of these men 
without using the method of Cuzick et al.[2] could therefore have misinterpreted the risk of PCa 
death for the men that did comply with the screening protocol [13].
During follow-up 19.4% of men in the control arm had asymptomatic PSA testing at least once 
until the end of 2008. Correction for this so-called PSA contamination had a relatively small effect 
on the mortality reduction as compared to the biopsy contamination. The PCa mortality rate in 
men having PSA testing in the control arm was lower than the total PCa mortality rate of the con-
trol arm. It is however still higher than in the screening arm. Although groups could be dissimilar 
in baseline risk, results suggest unorganized screening is not as effective as organized screening 
(as conducted in the ERSPC) in reducing the prostate cancer mortality. This is in contrast with 
the results published from the PLCO trial [14]. Reason for this difference in effect of screening 
could be that men in the screening arm of the ERSPC were advised to undergo prostate biopsy if 
PSA was >= 3.0 ng/ml. more than 90% of men complied with this biopsy recommendation [15]. 
Outside the study protocol it is not common practice to perform a biopsy if PSA is >=3.0 ng/ml. 
In a study by Otto et al. [8] it was shown that only 7.7% of men with a PSA >=3.0 ng/ml in the 
control arm got a subsequent prostate biopsy within 6 months. In the PLCO trial the decision to 
perform a prostate biopsy was not protocol based, but was left over to the participant and his 
health-care provider [14].
Furthermore, only 60% of all cancers detected in the control arm until 2008 (546/896) were 
detected in men with a PSA test ordered by the GP. The remaining men were presumably di-
agnosed after direct referral to the urologist. In the current analysis PSA testing at the urologist 
was not assessed. The PSA contamination as assessed in the current study is therefore likely to 
underestimate the true PSA contamination rate in the control arm.
With the biopsy contamination 98% of all men with PCa were detected. Therefore a more com-
plete assessment could be made which men were true contaminators (biopsied only because 
of an elevated PSA) and which men were biopsied for diagnostic purposes. Of all biopsies in 
the control arm 44% were done in the absence of symptoms and thus for screening purposes. 
Correction for biopsy contamination hence resulted in the largest increase in RR (RR 0.53 versus 
RR 0.68 for the ITS analysis). The PCa detection rate of 39.2% in the true biopsy contaminators 
might seem relatively high for asymptomatic men. True contaminators were defined as having 
an asymptomatic biopsy at least once. However, more than 30% of these men (data not shown) 
had more than one biopsy, which resulted in the relatively high detection rate.
The absolute difference in PCa deaths between the arms after correction for nonattendance 
and PSA contamination was 3.4/1000 men with a median follow-up of 13 years. This number is 
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however highly dependent on the percentage of men in both arms that died [16] and therefore 
changes over time. Until the end of follow-up (2010) only 25% of participating men had died. The 
real absolute difference can therefore only be given if all participants have died.
In the contamination group, especially in the PSA contaminators, the overall mortality rate 
was lower than in the rest of the control arm (20.9%). This could indicate that men in the control 
arm who chose to undergo a PSA test have a better life expectancy. As death from PCa may 
increase even after 15 years, especially in men with a longer life expectancy, longer follow-up 
could further increase the effect of the correction [17].
The diluting effect of contamination and nonattendance is not exclusively limited to the ef-
fect of screening on PCa mortality. The downside of screening, overdiagnosis (with subsequent 
overtreatment), is watered down as well. It should therefore be recognized that although the 
effect of screening as conducted in this study has a major effect on PCa mortality of an individual 
men, PSA based screening is still far from ideal. If screening is still asked for, already available tools, 
such as risk calculators, should be used to reduce the overtesting and overdiagnosis [18-22]. 
Furthermore, a man demanding a PSA test for screening purposes should be informed about 
the large risk of detecting low-risk prostate cancer with screening beforehand and treatment 
options like active surveillance to reduce the side effects of radical treatment without effecting 
oncological outcome [23-25].
The current analysis is limited by the extrapolation of the PSA contamination data and by the 
assessment of the reason for a PSA test using a questionnaire of a random part of men without 
PCa. Furthermore, the correction for biopsy contamination is most dependent on the determina-
tion of the amount of PCa deaths that are classified as true contaminators. For follow-up until 
the end of 2010, 36.8% of all men in the control arm with a biopsy and who died of prostate 
cancer were classified as contaminators (this translates into 46 men or 4.33% of contaminators). 
If this 36.8% was overclassified with 5% points the chance of dying from prostate cancer in the 
screening arm would be 48% lower after correction instead of 51%.
The current analysis is only done in a single centre of the ERSPC, in a single country, limiting 
the possibility to extrapolate the results. In the Rotterdam section of the ERSPC, data on reason 
for referral of men with PCa was however complete making the determination of the true con-
tamination rate in these men very precise. Last, the current analysis was limited to the predefined 
core age group of the ERSPC [26]. A sub-analysis in men outside the core age group (70-74 years) 
showed no significant benefit of screening in this subgroup (RR 1.23, 95% CI 0.70-2.16)(data not 
shown).
CONCLUSION
The effect of screening for an individual man choosing to be screened repeatedly with PSA tests 
is higher than the effect provided by large randomised trials, which provide an estimation of the 
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effect on a population based level. Screening as conducted in the Dutch centre of the ERSPC 
can reduce the risk of PCa death with up to 51% in men who undergo organized screening. This 
information can be helpful in informed decision making on PSA based screening for prostate 
cancer.
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ABSTRACT
Screening for prostate cancer (PCa) results in a favorable stage shift. However even if screening 
did not result in a clinically apparent lower stage or grade, it might still result in less disease 
recurrence after treatment with curative intent (radical prostatectomy (RP) and radiation 
therapy (RT)), because the tumor had less time to develop outside the prostate.In addition, the 
outcome after treatment could differ because of differences in treatment quality (e.g. radiation 
dosage/adjuvant hormonal therapy). To test these hypothesis we compare differences in treat-
ment quality of the screening and control arm of the European Randomized study of Screening 
for Prostate Cancer (ERSPC) Rotterdam and disease free survival after curative treatment in PCa 
patients with similar stage and grade.In total 2595 men were initially treated with RP or RT.In 
the control arm,RT was more often combined with hormonal therapy andtreatment dosage 
was more often >=69Gy. This resulted most likely from changes over time in treatment which 
coincided with the later detection in the control arm. Disease free survival was higher in the 
screening arm in all risk-groups. After correction for lead-time these differences were however 
minimal.We concluded that treatment quality differed between the screening and control arm 
of the ERSPC, Rotterdam. Especially radiotherapy quality was superior in the control arm with 
higher dosages and more often radiotherapy in combination with hormonal therapy. Despite 
these differences, favoring the control arm, disease free survival differences were minimal.
Trial registration: ISRCTN49127736.
Patient summary: In this report we looked at differences in prostate cancer treatment and 
outcome after prostate cancer treatment in men diagnosed after screening and men diag-
nosed after normal clinical practice. Treatment differed with superior treatment given in men 
diagnosed in normal clinical practice. In this paper we have proposed a likely explanation for 
this, at first sight, counter intuitive finding (progressive insight combined with an, on average, 
later detection of tumors in unscreened men). Despite the fact that unscreened men received 
better treatment this advantage seemed to be outweighed by the advantage associated with 
the, on average, earlier detection of the tumor in screened men.
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Screening as done in the Rotterdam section of the European Randomized study of Screening 
for Prostate Cancer (ERSPC) has shown to reduce prostate cancer (PCa) specific mortality with 
32% after 13 years of follow-up, and with up to 51% after correction for nonattendance and 
contamination [1, 2].
PCa screening may achieve this positive effect in multiple ways. most likely as a result of 
the favorable stage shift in the screening arm, resulting e.g. in less men with advanced and 
metastatic disease and thus more curative rather than palliative treatment [1, 3]. But, even if 
screening did not result in a clinically noticeable lower stage or grade for an individual patient, 
earlier detection with its associated earlier treatment could still have prevented micro-metastatic 
tumor development outside the prostate, resulting in higher curation rates after treatment in 
men with screen detected PCa compared to men with clinically detected cancer with a similar 
clinical stage and grade. This principle is visualized in figure 1. In addition, treatment between 
arms could differ, this includes differences in treatment modality (e.g. radical prostatectomy 
(RP) versus radiation therapy (RT)), but also differences in treatment quality of similar treatment 
modalities (e.g. radiation dosage/adjuvant hormonal therapy in men receiving RT). We therefore 
aimed to compare differences in treatment quality between the screening and control arm of 
the ERSPC Rotterdam and to compare the outcome of curative treatment in PCa patients within 
similar prognostic groups, based on stage and grade at time of diagnosis, to test the hypothesis 
that screen detected and clinically detected men with similar characteristics might still have a 
different prognosis.
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Figure 1. Model on how screening could result in better outcome 
 
1: Screening could result in a stage shift, resulting in better prognosis. 
2: If screening did not result in a clinical apparent stage shift, earlier diagnosis and treatment in 
time could still have resulted in a better prognosis, for instance because of less time for the 
tumor to develop outside the prostate.  
Figure 1. model on how screening could result in better outcome
1: Screening could result in a stage shift, resulting in better prognosis.
2:  If screening did not result in a clinical apparent stage shift, earlier diagnosis and treatment in time could still 
have resulted in a better prognosis, for instance because of less time for the tumor to develop outside the 
prostate.
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The screening protocol and study population of the ERSPC Rotterdam have previously been 
described in detail [4, 5]. For this analysis all men receiving RP or RT as initial treatment were 
compared. Characteristics of treatment quality were studied. For comparison, men were divided 
by clinical characteristics into four risk groups: low-, intermediate- and high-risk PCa, based on 
the criteria of D’Amico et al.[6], and a separate group for men with metastatic PCa (m1 and/or 
PSA >=100 ng/ml). The last group was not further assessed in the current analysis as treatment 
was not with curative intent. Furthermore, disease free survival (DFS) defined as no biochemical 
recurrence (BCR), i.e. a PSA value 2 times > 0.2ng/ml after RP, or a PSA value >= 2.0ng/ml above 
the PSA nadir after RT, no local progression, no distant metastasis, no PCa death and no additional 
treatment during follow-up was compared between the arms using the Kaplan-meier method. 
The between arm survival curve comparisons were done for equal clinical parameters and most 
important treatment quality characteristics, as these could affect results. The comparison was 
certainly affected by lead-time in the screening arm (notably for low and intermediate risk dis-
ease). For PCa, this lead-time was estimated to range from 12.2 to 2.9 years depending on tumor 
characteristics [7]. Therefore, a method described by Duffy et al.[8] was used to correct survival 
times in the screening arm for tumor characteristic specific lead-times.
Of all PCa cases in the ERSPC Rotterdam, 2595 (62.6%) were initially treated with RP or RT (supple-
mental table 1). Within the pre-defined groups, tumor characteristics at RP, as extra capsular 
extension, were less favorable in the control arm (supplemental table 2a). Furthermore, surgical 
margins were more often positive in the control arm in the low- and intermediate-risk group. 
These differences indicate that even within similar risk groups tumors were more advanced in the 
control arm. most likely due to the later detection in time.
TREATmENT COmPARISON
If looked at treatment itself, especially in men receiving RT, treatment was superior in the control 
arm. In the high-risk group of the control arm more men received hormonal therapy (HT) in ad-
dition to RT (50.4% versus 12.0%)(supplemental table 2b). The addition of HT to RT for men with 
higher risk tumors was proven to increase overall survival in a randomized trial first published 
in 2002 [9]. The majority of men in the screening arm were diagnosed and treated before the 
first publication of this trial, resulting in very low rates of men receiving HT in addition to RT in 
the screening arm. In the control arm diagnosis was more often after 2002, meaning these men 
could benefit from the improved treatment (RT + HT). In addition to the combination of HT and 
RT, radiation dosages given in the control arm were significantly higher than in the screening 
arm (supplemental table 2b). This again is most likely a result of the later diagnosis in time of 
men in the control arm as treatment dosages gradually increased during the course of the trial. 
The superior RT in the control arm could have improved PCa-specific survival in the control arm.
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In the RP group, surgical technique (e.g. open or laparoscopic) and individual surgeons case 
load/hospital volume could have differed between the screening and control arm, but both were 
not available for analysis. In could be expected that surgical technique might have changed 
over time in favor of the control arm, as with RT. Individual surgeon case load/hospital volume 
could have effected surgical margin status. In the Netherlands, differences between hospitals 
are however smaller than in some other counties, with the largest hospital performing 240 RP in 
2010 [10], it might therefore be expected that its effect is small.
DISEASE FREE SURvIvAL COmPARISON
Without correction for lead-time DFS rates were higher in the screening arm in both men receiv-
ing RP and RT. After correcting the screening arm for lead-time, differences were however less 
apparent (figure 2 and supplemental figure 3). Correction (based on an assumed exponential 
model [8]) seems not perfect as it resulted in lower DFS rates in the screening arm directly after 
diagnosis. At the end of the survival curves DFS in the screening arm (corrected for lead-time) 
was higher than in the control arm. Point estimate comparison (Z-test) at the end of the survival 
curves only resulted in significant differences in the Gleason score 7 group in men receiving RP 
with positive surgical margins (DFS 38% in the screening arm versus 13% in the control arm at 9.8 
years (p=0.046)) and in men receiving RT with a dosage <69 Gy (DFS 47% in the screening arm 
versus 9% in the control arm at 7.9 years (p<0.001)). This corroborates the hypothesis that early 
detection and treatment reduces PCa development outside the prostate and therefore increases 
DFS. more detailed data on outcome after treatment and additional treatment given can be 
found in supplemental table 3.
The current analysis was further limited by overdiagnosis [11]. Overdiagnosed cancers could 
have resulted in more favorable outcomes in the screening arm, especially in the group of low-
risk PCa. This makes interpretation of the difference between the screening and control arm in 
especially the low-risk PCa group difficult.
CONCLUSION
The fact that the ERSPC is a randomized study does not imply that treatments in both study 
arms are comparable. Therefore this study aimed to compare differences in treatment quality in 
men receiving treatment with curative intent in the screening and control arm of the ERSPC Rot-
terdam, as well as comparing the outcome of men with clinically similar tumor characteristics. We 
found difference in the quality of similar treatments between the screening and control arm of 
the ERSPC, Rotterdam. Especially RT quality was superior in the control arm with higher dosages 
and more often RT in combination with HT. We provided a reasonable explanation(progressive 
52
insight combined with later detection in control arm). Despite these quality differences in treat-
ment that favored the control arm, disease free survival in men with similar treatment and tumor 
characteristics was marginally better in the screening arm.
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Figure 2. Disease free survival after radical prostatectomy for men with T1-T2 disease, stratified 
by pGleason score ( <=6, 7, >=8), surg cal margin (SM)(positive (+)/negative(-)), and arm, after 
correction for l ad-time in the screening arm. Time in the screening arm was corrected for lead 
time u ing a method previously described [8].  
 
  
Figure 2. Disease free survival after radical prostatectomy for men with T1-T2 disease, stratified by pGleason 
score ( <=6, 7, >=8), surgical margin (Sm)(positive (+)/negative(-)), and arm, after correction for lead-time in the 
screening arm. Time in the screening arm was corrected for lead time using a method previously described [8].
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APPENDIX.
Table 1. Baseline characteristics.
Control n=791
(% of column total)
Screening n=1804
(% of column total)
Total n=2595 
(% of column total)
Age at randomization (years), median 63.2 63.7 63.5
Age at diagnosis (years), median 70.1 67.4 68.2
PSA at diagnosis (ng/ml), median 10.3 5.6 6.8
Time randomization-diagnosis, median 6.6 0.6 4.2
Follow-up time after diagnosis, median 5.2 8.7 7.6
Charlson comorbidity score at diagnosis
0 336 (42.5) 802 (44.5) 1138 (43.9)
1-2 360 (45.5) 666 (36.9) 1026 (39.5)
3-4 92 (11.6) 331 (18.3) 423 (16.3)
>=5 3 (0.4) 5 (0.3) 8 (0.3)
cT-stage at diagnosis
1 379 (47.9) 878 (48.7) 1257 (48.4)
2 238 (30.1) 648 (35.9) 886 (34.1)
3 161 (20.4) 263 (14.6) 424 (16.3)
4 8 (1) 8 (0.4) 16 (0.6)
missing 5 (0.6) 7 (0.4) 12 (0.5)
Gleason score at diagnosis*
<=6 393 (49.7) 1169 (64.8) 1562 (60.2)
7 262 (33.1) 486 (26.9) 748 (28.8)
>=8 136 (17.2) 147 (8.1) 283 (10.9)
missing 0 (0) 2 (0.1) 2 (0.1)
Risk-group at diagnosis
Low 182 (23) 799 (44.3) 981 (37.8)
Intermediate 258 (32.6) 455 (25.2) 713 (27.5)
High 336 (42.5) 532 (29.5) 868 (33.4)
meta 8 (1) 4 (0.2) 12 (0.5)
missing 7 (0.9) 14 (0.8) 21 (0.8)
Total 791 (100) 1804 (100) 2595 (100)
*In 84 men (3% of total) Gleason scores at diagnosis were missing. Instead tumor grade was recoded as Gleason 
score group (Grade 1 = Gleason <=6, Grade 2 = Gleason 7, Grade 3 = Gleason >=8)
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Supplemental figure 3. Disease free survival after radiotherapy (no hormonal treatment, no 
brachytherapy) for men with T1-T2 disease, stratified by Gleason  score ( <=6, 7, >=8), dosage 
(<69 Gy, >=69 Gy), and arm, after correction for lead-time in the screening arm. Time in the 
screening arm was corrected for lead time using a method previously described[8]. 
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ABSTRACT
Purpose: To assess differences in treatment between the screening and control arm of Euro-
pean Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam and to study if 
possible treatment differences explained the positive study outcome.
Materials and Methods: In ERSPC Rotterdam, men aged 55-74 were randomized between 
a screening (n=21210) and a control arm (n=21166). Treatment after diagnosis was left to the 
care provider of the patients choice. Initial treatment was compared within four risk groups.
The relation between prostate cancer incidence and prostate cancer mortality was assessed 
per risk group by correlating the relative risk (RR) of prostate cancer incidence and the RR of 
prostate cancer mortality. A direct relation would support a stage shift as the main cause of 
changes in prostate cancer mortality.
Results: Initial treatment differed between the arms in the low-, intermediate-, and high-risk 
groups, but not in the metastatic group. RR of prostate cancer incidence and prostate cancer 
mortality per risk group were 1:1 related (slope of regression line 1.00, 95% confidence interval 
(CI); 0.30-1.74) and 94% of the changes in prostate cancer mortality could be explained by 
changes in prostate cancer incidence. This makes differences in treatment unlikely as the 
reason for the observed prostate cancer mortality reduction.
Conclusion: Differences in treatment between the screening and control arm of ERSPC Rot-
terdam were unlikely to explain the differences in prostate cancer mortality. Instead results 
are consistent with a reduction in prostate cancer mortality as a result of a favourable stage 
through screening.
Trial registration: ISRCTN49127736.
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INTRODUCTION
A 32% prostate cancer specific mortality reduction was seen in the screening arm of the Euro-
pean Randomized study of Screening for Prostate Cancer (ERSPC) section Rotterdam in the age 
group 55-69 years, and a 20% reduction for ages 55-75 years at a follow-up time of 13 years.
[1] In a secondary analysis, correction for nonattendance in the screening arm and contamina-
tion (opportunistic PSA testing resulting into biopsy) in the control arm, the benefit for a man 
choosing to be screened versus a man choosing not to be screened was estimated at 51%.[2] A 
large reduction in metastatic disease at diagnosis was also shown using a similar correction.[3] 
These reductions in mortality and metastatic disease resulted from a screening strategy with PSA 
testing every 4 years until the age of 75 and a subsequent biopsy if PSA was abnormal.
After prostate cancer was detected, treatment was left to the care provider of the patients 
choice in both the screening and control arm. Because treatment was not standardized in the 
screening protocol, differences in treatment might have arisen between the screening and 
control arm. Possible differences in treatment could potentially have affected the main outcome 
of the trial (i.e. prostate cancer specific mortality).
The aim of the current analysis is to assess differences in treatment between the screening 
and control arm of the ERSPC Rotterdam and to study whether possible treatment differences 
explained the positive study outcome.
mATERIALS AND mETHODS
Between 1993 and 1999, 42376 men aged 55-74 year were randomized between a screening and 
control arm after providing written informed consent. In the screening arm, men were invited for 
PSA testing every 4 years until the age of 75. In the first half of the first screening round, men were 
offered a prostate biopsy if PSA was >=4 ng/ml or if DRE was abnormal. Apart from this first half of 
the first screening round a PSA value >=3ng/ml was the only indication for prostate biopsy in all 
subsequent screening rounds.[4] After detection of prostate cancer, both men in the screening 
and the control arm received further diagnostics and treatment from their local care provider of 
choice. Data on all men with prostate cancer (in both screening and control arm) were collected 
through linkage with the national cancer registry and chart review every 6 months. Cause of 
death for all men with prostate cancer in the screening and control arm was determined by 
the cause of death committee (CODC) using medical records based on a pre-defined algorithm 
and blinded for study arm.[5] The protocol of the ERSPC Rotterdam has been described in detail 
previously.[4, 6] Analyses of the main outcome (prostate cancer specific mortality) were done 
on the entire cohort and on the pre-defined core age group (55-69 year).[1] Follow-up for the 
current analysis ended December 31, 2010.
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Initial treatment was coded as radical prostatectomy (RP), radiotherapy (RT), radiotherapy 
combined with hormonal therapy (RT+HT), hormonal therapy (HT), and a combined group for 
watchful waiting and active surveillance (WW/AS) as both treatment modalities were not well 
distinguishable in our database.
Because treatment choice is highly dependent on tumour characteristics, comparison of treat-
ment between the screening and control arm was done within 4 risk groups. Risk groups were 
defined as: low-risk (clinical stage <=T2a, and Gleason score (GS)<=6, and PSA <=10 ng/ml), 
intermediate-risk (clinical stage T2b, and/or GS =7, and/or PSA >10 and<=20 ng/ml) and high-risk 
prostate cancer (clinical stage >=T2c, or GS >=8, or PSA >20 ng/ml), based on the criteria of 
D’Amico et al.[7] (with the addition of clinical stage T3 and T4 to the high-risk group), and a 
separate group for men with metastatic prostate cancer (m1 or PSA >=100 ng/ml).
STATISTICAL ANALYSIS
Descriptive statistics and the chi-square tests were used to compare initial treatment between 
the screening and control arm within the risk groups. To assess if possible differences in treat-
ment within risk groups could have an impact on total prostate cancer mortality, all mortality 
rates were scaled on the total prostate cancer mortality rate in the control arm (i.e. total prostate 
cancer mortality in the control arm is set at 100). We then adopted a method that was previously 
applied in breast cancer screening studies to assess the relationship between prostate cancer 
incidence and prostate cancer mortality within the risk groups.[8] A direct relation would support 
a stage shift as the main cause of changes in prostate cancer mortality, making a large effect of 
differences in treatment unlikely.
We regressed the natural logarithm (ln) of the relative risk (RR) of prostate cancer incidence per 
risk group on the ln(RR) of prostate cancer mortality per risk group. The inverse of the variance 
of the ln(RR) of prostate cancer mortality was used to weight each risk group. The regression line 
was forced through zero. By doing so it is assumed that if the RR of prostate cancer incidence 
is equal to the RR of prostate cancer mortality, treatment did not affect prostate cancer mortal-
ity, but changes in prostate cancer incidence (caused by screening) did. This concept is further 
explained in figure 1.
Because of overdiagnosis in the screening arm, the effect of prostate cancer incidence on 
prostate cancer mortality using this method could be misinterpreted. As overdiagnosis is most 
common in the low-risk tumour group, this group was not used in the initial analysis, but added 
in a sensitivity analysis. In addition, the effect of excluding different age groups at randomization 
and division of the high-risk group based on extra-prostatic extension (cT3-cT4) was evaluated, as 
choice of treatment might be particularly dependent on these characteristics.
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RESULTS
During a median follow-up period of 12.8 years 1444 prostate cancers were diagnosed in the 
control arm and 2699 in the screening arm, resulting in a cumulative incidence during this period 
of 6.8% and 12.7% respectively. Prognostic features of prostate cancers found in the screening 
arm were more favourable (table 1).
In the low-risk group RP was more often given in the screening arm than in the control arm (29.9% 
versus 21.4%, Fig 2). In the intermediate-risk group RP was again more often used in the screen-
ing arm (35.1% versus 24.1%) instead of WW/AS (13.9% versus 24.9%). In the high risk group, RT 
was more often combined with HT in the control arm (27.3% versus 6.8% for the screening arm) 
102 
 
102 
 
 
Figure 1. Relationship of prostate cancer incidence and prostate cancer mortality to determine the effect of 
treatment on outcome.
At randomization men in both arms have the same risk of prostate cancer death. During follow-up men can be 
diagnosed in one of four pre-defined risk groups (1: (incidence)). After diagnosis in one of the risk groups men 
could die of prostate cancer (2: (mortality)). Differences in incidence and mortality per risk group between the 
arm can be expressed as a relative risk (RR). During follow-up screening can affect the prostate cancer mortality 
either because of a stage shift affecting tumour characteristics at diagnosis (which affects incidence)(3), or by 
earlier detection (without effecting the risk group at diagnosis) and therefore earlier treatment (4). Differences 
in treatment between arms can only affect the risk of death after diagnosis (which does not affect incidence)(4).
If changes in mortality within a risk group are directly related to changes in incidence in that risk group (e.g. both 
are reduced by 50%), it can be assumed that this is a direct result of a stage shift caused by screening, therefore 
excluding differences in treatment between the arms as likely cause of the mortality reduction.
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as compared to the screening arm in which RT alone was more common (49.9% versus 27.0% for 
the control arm). In the metastatic risk group treatment differences between the arms were small 
with most men receiving HT (90.7% and 87.7%).
Table 1. Clinical characteristics per arm.
Control, n=1444 (% of column 
total)
Screening, n=2699 (% of 
column total)
Age at diagnosis, median [25-75] 72.1 [67.5-75.8] 68.7 [64.8-72.5]
PSA ng/ml at diagnosis, median [25-75] 11.8 [7.2-27.5] 5.2 [3.5-9.1]
cT-stage at diagnosis
 1 700 (48.5) 1504 (55.7)
 2 379 (26.2) 819 (30.3)
 3 272 (18.8) 319 (11.8)
 4 65 (4.5) 28 (1)
 missing 28 (1.9) 29 (1.1)
Gleason score at diagnosis*
 <=6 701 (48.5) 1863 (69)
 7 426 (29.5) 592 (21.9)
 >=8 292 (20.2) 223 (8.3)
 missing 25 (1.7) 21 (0.8)
M-stage at diagnosis
 0/X 1312 (90.9) 2643 (97.9)
 1 132 (9.1) 56 (2.1)
Risk group at diagnosis
 Low 350 (24.2) 1386 (51.4)
 Intermediate 371 (25.7) 553 (20.5)
 High 512 (35.5) 647 (24)
 metastatic 182 (12.6) 73 (2.7)
 missing 29 (2) 40 (1.5)
Charlson comorbidity at diagnosis
 0 561 (38.9) 1146 (42.5)
 1-2 650 (45) 1051 (38.9)
 3-4 217 (15) 489 (18.1)
 >=5 16 (1.1) 13 (0.5)
Deaths (from all causes) 490 (33.9) 781 (28.9)
 Prostate cancer deaths 188 (13) 151 (5.6)
total 1444 (100) 2699 (100)
* In 163 men (141 screening arm and 22 control arm) with missing Gleason scores (3.9% of total men with pros-
tate cancer) tumour grades 1, 2, and 3 were re-coded into Gleason score groups <=6, 7, and >= 8 respectively 
to allow more complete analysis. 46 men had missing Gleason scores and tumour grades.
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Figure 2. Initial treatment per arm, divided per risk group. 
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Figure 2. Initial treatment per arm, divided per risk group.
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The prostate cancer mortality in the screening arm relative to the control arm was substantially 
reduced in the metastatic risk group (Fig 3a). In the low, intermediate and high-risk groups pros-
tate cancer mortality was higher the screening arm relative to the control arm (Fig 3a). Prostate 
cancer incidence was increased in all risk groups in the screening arm except for the metastatic 
risk group (Fig 3b).
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Figure 3. Prostate cancer mortality and incidence relative to the overall risk in the control arm (scaled as 100) by risk group. For comparison 
data were indexed on the total prostate cancer mortality and incidence in the control arm: 3A: Distribution of prostate cancer mortality in the 
screening and control arm per risk group. 3B: Prostate cancer incidence in the screening and control arm per risk group.  
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Figure 3. Prostate cancer mortality and incidence relative to the overall risk in the control arm (scaled as 100) 
by risk group. For comparison data were indexed on the total prostate cancer mortality and incidence in the 
control arm: 3A: Distribution of prostate cancer mortality in the screening and control arm per risk group. 3B: 
Prostate cancer incidence in the screening and control arm per risk group.
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Within the risk groups, none of the RRs of prostate cancer incidence diff ered signifi cantly from 
the RRs of prostate cancer mortality (Table 2). The slope of the regression line of ln(RR) prostate 
cancer incidence on ln(RR) prostate cancer mortality of the intermediate, high and metastatic 
risk group was 1.00 (95% confi dence interval (CI); 0.30-1.74), with a R2 of 0.94 (fi gure 4). This 
means that prostate cancer incidence and prostate cancer mortality were 1:1 related in these 
groups and 94% of the changes in prostate cancer mortality could be explained by diff erences in 
prostate cancer incidence. Addition of the low-risk group did not change the results (slope 1.06, 
95% CI 0.44-1.68, R2 0.91). Results for the core age group (55-69 years) were similar (slope 1.12, 
95% CI -0.20-2.43, R2 0.87), as were result if the high-risk group was split based on extra-capsular 
extension (slope 0.99, 95% CI 0.49-1.49, R2 0.93).
Table 2. Prostate cancer (PCa) incidence and mortality in the screening and control arm, divided per risk group. 
(RR=relative risk)
Absolute PCa incidence PCa 
Incidence
PCa 
mortality
Absolute PCa mortality p-value
Control 
(% of 
total men 
control 
arm)
Screening 
(% of 
total men 
screening 
arm)
RR 
(screening 
arm versus 
control 
arm)
RR
(screening 
arm versus 
control 
arm)
Control 
(% of 
total men 
control 
arm)
Screening 
(% of 
total men 
screening 
arm)
(RR PCa 
incidence 
versus RR PCa 
mortality)
missing 29 (0.1) 40 (0.2) 1.38 - 1 (0.005) 0 (0) -
Low 350 (1.7) 1386 (6.5) 3.95 14.97 1 (0.005) 15 (0.07) 0.198
Intermediate 371 (1.8) 553 (2.6) 1.49 1.40 10 (0.05) 14 (0.07) 0.881
High 512 (2.4) 647 (3.1) 1.26 1.06 82 (0.39) 87 (0.41) 0.287
metastatic 182 (0.9) 73 (0.3) 0.40 0.37 94 (0.44) 35 (0.17) 0.758
Total 1444 (6.8) 2699 (12.7) 1.87 0.80 188 (0.89) 151 (0.71) <0.001
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Figure 4. Relationship b tw en the prostate cancer incidence and prost te cancer mortality in the intermediate, high, and metastatic risk 
groups.  
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Figure 4. Relationship between the prostate cancer incidence and prostate cancer mortality in the intermedi-
ate, high, and metastatic risk groups.
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DISCUSSION
In the current analysis we found differences in initial treatment between the screening and 
control arm of ERSPC Rotterdam. In addition, a favourable stage shift resulting in, among others, 
a large reduction of metastatic disease at diagnosis in the screening arm was seen. Comparison 
of the changes in prostate cancer incidence and mortality by risk group showed that changes 
in prostate cancer mortality were consistent with the changes in prostate cancer incidence. This 
observation supports stage shift through screening as the main reason for reduced prostate 
cancer mortality in the screening arm of the ERSPC Rotterdam, and thus makes treatment dif-
ferences unlikely to have played a large contributing role. This observation confirms the earlier 
report of Wolters et al. where trial arm had only a minor role in treatment choice compared to 
other variables.[9]
Initial treatment differed between the screening and control arm within the low, intermedi-
ate, and high risk groups. Because 93.6% of all prostate cancer deaths in the control arm and 
80.8% of all prostate cancer deaths in the screening arm occurred in the metastatic or high-risk 
group, differences in treatment in these groups can be seen as most relevant. Starting with the 
high-risk group two main differences were seen. In the control arm 53% of men receiving RT 
got HT in addition to their RT, compared to only 12% in the screening arm. This difference in 
treatment will benefit the control arm as RT in combination with HT was shown to improve sur-
vival.[10-12] In addition, a previous report showed that men with RT in the control arm received 
higher dosages which again improved survival.[13] Both are most likely explained by the fact that 
overall diagnosis of prostate cancer occurred later in time in the control arm at the moment that 
adjuvant endocrine therapy for high risk disease and higher radiation dosages were included in 
international guidelines for treatment.[13] The second difference in the high-risk group was that 
approximately 15% more men received RP in the screening arm, while in the control arm these 
men received HT. This difference remained after division of the high-risk group based on extra 
capsular extension (data not shown). Differences in treatment could also be based on patient 
characteristics such as comorbidity status and personal preference. The latter is also applicable to 
the physician who is in general heavily involved in treatment decisions. On multivariate logistic 
regression analysis men with higher PSA, age, and Charlson comorbidity score at diagnosis were 
more likely to receive HT. After correction for these variables, the study arm to which the men 
were randomized (screening arm versus control arm) was not a significant predictor of HT. This 
means that the difference in treatment between the arms in the high risk group was caused by 
differences in clinical characteristics, rather than by a difference in treatment preference in one of 
the two study arms (data not shown). In the metastatic risk group there were no large differences 
in treatment between the two arms, almost all men received HT as initial treatment.
Interestingly, we noted a relative increase in mortality in the screening arm as compared to the 
control arm in all risk groups except for the metastatic risk group. This indicates that the prostate 
cancer mortality reduction seen in the entire screening arm can largely be attributed to a reduc-
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tion in prostate cancer mortality from men with metastatic disease at diagnosis. This last group 
was the only group where treatment did not differ between the screening and control arm. The 
only remaining and most plausible explanation for the reduction in prostate cancer mortality is 
a simple decrease in prostate cancers being diagnosed with metastasis as a result of a stage shift 
to more favourable tumour characteristics at diagnosis. This seems to be confirmed by the almost 
identical relative reduction in the screening arm of prostate cancer incidence (60%) and prostate 
cancer mortality (63%) in the metastatic risk group. Including all risk and age groups, changes 
in prostate cancer incidence (stage shift) could explain 90% of the changes in prostate cancer 
mortality. This support stage shift as main cause of the observed prostate cancer mortality reduc-
tions and makes a large effects of the observed differences in treatment between arms unlikely.
A stage shift is most likely also the reasons why the mortality in the screening arm was higher 
in especially the intermediate and low-risk groups as compared to the control arm. Screening 
reduced the amount of men diagnosed with metastatic prostate cancer at diagnosis by 60%. It is 
likely that a (substantial) part of these men will still develop metastatic disease and die. It is often 
assumed that men not diagnosed with metastatic disease because of screening will “stage shift” 
to the high-risk group. It could, however, well be that these men were not diagnosed in the high-
risk group but in the intermediate or even the low-risk group. If so, the risk of prostate cancer 
death in these groups will increase due to the enrichment by higher risk men compared to the 
control arm. So, although screening led to an earlier diagnosis, cancer was still detected too late 
in these men. Besides screening algorithm related causes (e.g. inadequate screening tests, too 
long screening intervals, nonattending),[14] age at which screening was started might affect its 
result.[13] Simply intensifying the screening protocol or starting screening at an earlier age for 
all men will however also increase overdiagnosis. Individual risk adapted screening strategies, for 
instance based on nomogram predictions, could help to overcome this problem.[15]
Other explanations for the relative increase in mortality in the screening arm in the low and 
intermediate risk groups could be due to changes in the grading and staging of prostate cancer. 
The Gleason scoring system was changed during the course of the trial resulting in a shift to 
higher Gleason scores.[16] moreover, the number of biopsy cores taken as standard, gradually 
increased in common practice (control arm) while in the screening arm the number of biopsy 
cores taken remained 6. As men in the control arm were diagnosed later in time, these changes 
in staging could have resulted in a shift towards higher risk groups in the control arm, which, as 
compared to the screening arm, would have a lower risk of mortality (Will Rogers phenomenon).
Last, more men were diagnosed with prostate cancer in the screening arm. This means that 
potentially more men could have died of prostate cancer. Attribution of cause of death was done 
by an independent committee according to a predefined algorithm blinded for study arm.[5] 
The committee reviewed, however, only men diagnosed with prostate cancer. This could have 
resulted in an underreporting of prostate cancer deaths in the control arm as less men were 
diagnosed with prostate cancer. Analysis using an excess mortality approach, which circumvents 
this problem, however showed similar results concluding this was not a large issue.[17, 18]
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Some limitations should be mentioned. The regression method used to assess the relation 
between prostate cancer incidence and prostate cancer mortality does not take into account 
overdiagnosis. Overdiagnosis causes men to be diagnosed, who would not have been diagnosed 
if not screened. Overdiagnosis causes higher incidence rates in the screening arm, but overdiag-
nosed men will by definition never develop metastatic disease or die of prostate cancer. It can 
therefore be expected that the increase in incidence in the low, intermediate and even high-risk 
group is higher than the increase in mortality. Last, because the regression analysis was based on 
only few risk groups, its stability may be low.
CONCLUSION
A favourable stage shift, with less metastatic disease at diagnosis, was seen in the ERSPC Rot-
terdam. The changes in mortality observed within the ERSPC Rotterdam were consistent with the 
changes in prostate cancer incidence per risk group initiated through screening. This observation 
supports a stage shift with subsequent earlier treatment as the main reason for lower prostate 
cancer mortality in the screening arm of the ERSPC Rotterdam, excluding a large effect of the 
observed differences in treatment between arms on the primary outcome.
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ABSTRACT
Since the introduction of PSA for the early detection of prostate cancer, overdiagnosis and 
subsequent overtreatment have become more and more apparent. Conservative treatment 
options, specifically active surveillance, are therefore becoming increasingly used in an at-
tempt to reduce the morbidity of radical treatment. Several clinical prediction models were 
developed to assess an individual’s risk of having indolent prostate cancer. Those with high 
probabilities of indolent cancer are best suited for conservative management. Prediction 
models readily provide detailed risk estimates when presented as nomograms, which is prefer-
able over simpler presentations as rules. Incorporation of prediction models into decision aids 
is a good way of providing the best of care for men facing a treatment decision of low-risk 
prostate cancer with improved patient knowledge and more conscious treatment choices. 
In this chapter different currently available nomograms are discussed, with considerations to 
select the most appropriate nomogram for an individual patient.
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INTRODUCTION
Over the past decades, increasing numbers of men are faced with the diagnosis of prostate 
cancer.[1, 2] Conversely, prostate cancer mortality rates have decreased.[3] In addition, men are 
more often diagnosed at an earlier stage of the disease. The obvious reason for these profound 
changes is the introduction of the prostate-specific antigen (PSA) test for the early detection of 
prostate cancer. Early detection of prostate cancer at an more favorable stage, allows the cancer 
to be treated with curative, rather than palliative, intend. Screening for prostate cancer using PSA 
was indeed shown to reduce the prostate cancer specific mortality rate by 21% after 13 years of 
follow-up in the largest randomized prostate cancer screening trial.[4] A major disadvantage is 
the detection of many additional prostate cancers, with an increase in prostate cancer incidence 
by over 50%.[4] many of these additionally identified cancers are likely not to result in any symp-
toms of death during a man’s lifetime. In fact, it is estimated that 50% of men diagnosed through 
screening have these so-called “overdiagnosed” prostate cancer.[5] The presence of many non-
aggressive tumors has already been observed in autopsy studies which showed that prostate 
cancer was present in a large percentage (10-30% depending on age) of men who died of other 
causes.[6] Because of the introduction of the PSA test resulting in subsequent prostate biopsies, 
this large reservoir of prostate cancers is now detected. Hence, radical treatment of PSA detected 
tumors will for most men not result in any survival benefit.[7] It may however lead to side-effects 
such as impotency or incontinence, decreasing quality of life in a substantial number of men.[8] A 
way of avoiding the side-effects of radical treatment is to offer these patients active surveillance. 
This treatment option aims to avoid or delay treatment for most, while by monitoring tumor 
progression be able to offer radical treatment for those who benefit. men diagnosed today with 
early detected prostate cancer are thus facing the difficult choice of radical treatment with its 
likely low benefit, but substantial risks of side-effects, versus conservative treatment, which might 
risk losing the benefit obtained by early detection. In this chapter we will discuss some of the 
tools that are available to help men to choose between active treatment of their prostate cancer 
or to opt for the more conservative approach of active surveillance.
DEFINING INDOLENT PROSTATE CANCER
Indolent prostate cancer is defined as a tumor that will not result in symptoms or death dur-
ing a man’s lifetime if left untreated. The dynamic aspect of this definition makes it difficult to 
operationalize. A tumor that might be moderately progressive over time could be no threat for 
a man with a short life expectancy, but might become problematic (e.g. metastasize or cause 
symptoms) for a man with a longer life. Furthermore, no single parameter yet will provide defini-
tive information on future tumor development. Last, as tumor progression in a low risk prostate 
cancer group is relatively rare and takes usually at least a decade to develop, statistical evaluation 
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of this end-point is difficult. Therefore several other definitions were proposed to indicate tumors 
that are latent and have low probabilities of developing symptoms, based on parameters that 
do not require follow-up in time. The most common definition of indolent disease is an organ 
confined tumor, <=0.5 cm3, with no Gleason grade 4 or 5. This definition requires the removal of 
the prostate for pathological evaluation. In a conservative treatment strategy low-risk tumors are 
therefore defined as tumors with a high probability of being indolent on radical prostatectomy. 
Because the tumor is not removed and progression could thus occur, re-evaluation of its low-risk 
character through time will be necessary. A summary of the different definitions used in the 
context of indolent/low-risk prostate cancer is given in table 1.
Several clinical definitions were proposed to select men with high likelihood of indolent 
prostate cancer on radical prostatectomy. These men are best suitable for a conservative treat-
ment approach. most definitions use a combination of low tumor grade (Gleason <=6), localized 
disease (cT1c-cT2c), low PSA or PSA density (PSA <=10-15, PSA-density <=0.15-0.2), and small 
tumor volume (<= 2 cores positive on prostate biopsy, <=50% tumor involvement per core). Dif-
ferent definitions used for the selection of men on active surveillance studies are shown in table 
2. Although commonly used in clinical practice, these rule-based definitions have some obvious 
disadvantages. The most important limitation of these criteria is that much of the predictive 
value of individual prognostic factors is lost. For example a men with a PSA of 2ng/ml and a men 
with a PSA of 10ng/ml would both meet the same definition if the criterion is: PSA <= 10ng/ml. 
Using the definition would assume these men are similar in risk of having indolent disease, while 
clearly the men with the lower PSA will have a higher probability of indolent disease. moreover, 
Table 1. Definitions used in the context of indolent/low-risk prostate cancer.
Indolent disease over 
time
Indolent disease at radical 
prostatectomy
Low-risk disease
Definition A tumor that will not result 
in symptoms or death 
during a man’s lifetime if 
left untreated
Organ confined, no Gleason 
grade 4 or 5, and a tumor volume 
<=0.5cm3
A tumor with a high probability 
of being indolent at radical 
prostatectomy and/or over 
time, based on its clinical 
characteristics.
Advantage most optimal definition of 
indolent disease
Does not require follow-up Does not require surgical 
excision
Disadvantage •	 	Can	only	be	determined	
in retrospect
•	 Requires	long	follow-up
•	 	Dependent	on	a	man’s	
life expectancy
•	 	Requires	pathological	
examination
•	 	Could	potentially,	even	with	
radical treatment, still progress 
and give rise to symptoms
•	 	Definition	might	be	too	
restrictive for men with a short 
life expectancy
•	 	A	tumor	volume	
<=0.5cm3might be too 
restrictive[43]
•	 	Uncertainty	of	prediction,	
caused by underestimation 
of Gleason score, tumor 
volume or T-stage
•	 	Tumor	is	not	removed	and	
could progress over time, 
reevaluation is therefore 
necessary
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using a rule-based definition of indolent disease exerts equal value to all individual risk factors. 
Both a man with a Gleason score of 7 and a man with a PSA of 10.5ng/ml would not fit the rule 
based definition. The first might have a truly higher chance of having aggressive disease and 
therefore not be suitable for conservative management, while the second may only marginally 
differ in risk of being indolent and could therefore still consider a non-radical approach. Combin-
ing risk factors into an individual risk estimation (risk-based), instead of “eligible” or “non-eligible” 
(rule-based), may better inform the patient and his physician and help to make a more conscious 
decision on treatment choice.
INDIvIDUALIZED PREDICTIONS
Individual risk estimation using a risk-calculator, or nomogram, is frequently applied to other 
areas of prostate cancer care. For instance in the decision to perform a prostate biopsy. mul-
tiple risk-calculators were developed by several study groups to predict the chance of having 
a positive prostate biopsy, as it was realized that performing a prostate biopsy only based on a 
single PSA cut-off was suboptimal.[9] These risk-calculators use different risk factors such as the 
age, PSA value, digital rectal examination, transrectal ultrasound findings, prostate volume, and 
prior biopsy status to calculate an individual risk of having a positive prostate biopsy.[10] It was 
estimated that using these risk-calculators to guide biopsy decision could potentially reduce the 
number of unnecessary biopsy with 30% without missing important prostate cancers (defined 
as Gleason grade >3, PSA >20ng/ml, T-stage 3 or 4, >50% positive cores, >20mm cancer in all 
cores, or <40mm benign tissue in all cores) as compared to a single PSA cut-off approach.[11] 
Risk-calculators could even be used to calculate the risk of having a positive biopsy up to eight 
years in the future.[12] After been validated in other cohorts,[13-17] the effect of using risk-
Table 2. Inclusion criteria for different active surveillance studies.
Active surveillance study Criteria for inclusion
Royal Marsden[44] Gleason <=3+4 (primary Gleason grade <=3); PSA <=15 ng/ml; 
cT1c-2a; <=50% of cores positive
University of Miami[45] Gleason <=6; PSA <=15 ng/ml; cT1c-2c; <= two cores positive; 
<=20% of any core positive
Johns Hopkins[46] Gleason <=3+3; PSA density <= 0,15 ng/ml/ml; cT1c; <= two cores 
positive; <=50% of any core positive
University of California San Francisco[47] Gleason <=3+3; PSA <=10 ng/ml; cT1c-2c; <= 33% of cores positive; 
<=20% of any core positive
University of Toronto[48] Gleason <=6; PSA <=10 ng/ml (until January 2000, for men age >70 
years: Gleason <=3+4; PSA <= 15 ng/ml)
Prostate cancer Research International 
Active Surveillance (PRIAS)[49]
Gleason <=3+3; PSA <=10 ng/ml; PSAD <= 0,2 ng/ml/ml; cT1c-2c; 
<= two cores positive (age >70 years: Gleason <=3+4, maximum 
10% tumor per cores)
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calculators in clinical practice has been assessed.[18] In total 83% of patients complied with the 
recommendation provided by the risk-calculator. If a biopsy was recommended 96% complied 
with the recommendation versus 64% of men with a recommendation against prostate biopsy. 
Of men not complying with a negative biopsy recommendation only 3% were found to have 
a relevant tumor (Gleason >6).[19] The main reason for not complying with a negative biopsy 
recommendation were a PSA >= 3ng/ml for urologists or wanting certainty for patients.[18] In 
the decision to perform a prostate biopsy risk-calculators seem easy tools (most risk-calculators 
today can be found and used online as a web based tool, e.g. www.prostatecancer-riskcalculator.
com, or even downloaded as an app for your mobile phone, e.g. Rotterdam prostate cancer risk 
calculator (Google play store and Apple app store)) to increase patient participation and reduce 
unnecessary examinations.
Several risk-calculators were developed to predict the risk of having an indolent prostate cancer 
as defined by radical prostatectomy characteristics (table 3). Kattan et al. developed a prediction 
model based on a clinical cohort of 409 men with cT1c or cT2a Gleason <=6 prostate cancer who 
received radical prostatectomy.[20] In total 20% of men had indolent disease (defined as organ 
confined, Gleason score<=6, prostate cancer with a tumor volume <=0.5). The model, including 
PSA, primary and secondary Gleason grade, clinical stage, ultrasound prostate volume, and mm 
cancer and mm noncancerous tissue, could reasonably predict indolent disease with a receiver 
operating characteristics (ROC) area under the curve (AUC) of 0.79. As already noted by the 
authors of this nomogram the percentage of men with indolent disease increased over time in 
their population. As the percentage of indolent prostate cancers in the population increases the 
nomogram predictions might underestimate the chance of having a indolent prostate cancer. In 
2007, the nomogram was therefore updated on their website (www.nomograms.org) to better fit 
a more contemporary population.
Because the underlying prevalence of indolent disease in the population the model is de-
veloped on makes a substantial difference in predicted risks, a model was developed to better 
apply to a more intensively PSA screened population.[21] Steyerberg et al. adapted the model 
developed by Kattan et al. based on 278 men detected in the screening arm of the European 
Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam. At radical prostatectomy 
49% of men had indolent disease. The new model uses the same predictors as the previous 
model (PSA, primary and secondary Gleason grade, clinical stage, ultrasound prostate volume, 
and mm cancer and mm noncancerous tissue) and is again able to predict indolent disease 
moderately well with an AUC of 0.76 (online available at www.prostatecancer-riskcalculator.com).
[21]Based on this nomogram it was estimated that in a PSA screening setting 30% of men would 
have indolent disease and could be suitable for conservative management.[22] Because the 
model was developed based on men diagnosed with sextant prostate biopsy, length of prostate 
cancer and length of noncancerous tissue might not be accurate for men diagnosed with more 
contemporary extended biopsy core schemes. Correction factors were therefore calculated to be 
able to accurately predict the risk of men diagnosed with 12- or 18- core biopsies (mm cancer 
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should be divided by 2.03 or 2.72 and mm non-cancerous tissue by 2 or 3 for 12- or 18 core 
biopsies respectively when applying the nomogram).[23]
Additional nomograms to predict indolent disease at radical prostatectomy (again defined as 
organ confined, Gleason score <=6, prostate cancer with a tumor volume <=0.5) were developed 
by Nakanishi et al., Chun et al., and O’Brien et al.[24-26] The first was developed on a cohort of 258 
men with only 1 positive biopsy core on an extended biopsy scheme (10 to 13 cores).[24] Because 
of this strict selection, the percentage of men with indolent disease at radical prostatectomy in 
the study by Nakanishi et al. was higher than previous studies at 52%. Using age, PSA-density, 
and mm cancer tissue the model could moderately well predict indolent disease with an AUC 
of 0.73. Chun et al. developed a nomogram on a European cohort of men of all Gleason scores 
that were most likely not extensively PSA screened.[25] This was underlined by the very low rate 
of indolent disease at radical prostatectomy of only 6%. A model including PSA, biopsy Gleason 
sum score, length of cancer tissue, and % of positive biopsy cores was developed which had a 
AUC of 0.90. In the same analysis the Kattan et al. nomogram was validated which had an AUC of 
0.81 in this cohort.[25] The nomogram developed by O’Brien et al. was developed in an Australian 
cohort of men with all Gleason scores and again a very low rate of indolent disease of 6%.[26] 
AUC was again high at 0.93. In addition, the nomogram slightly outperformed two rule-based 
inclusion criteria for active surveillance programs. Although both the Chun et al. and the O’Brien 
et al. nomogram may have very high predictive capabilities, results need to be interpreted with 
caution. Both cohorts used for model development included a substantial part of men with 
biopsy Gleason scores>6 (41% and 68% for Chun et al. and O’Brien et al. respectively). These 
men almost per definition do not have indolent disease at radical prostatectomy (in the study 
of O’Brien et al 0.5% of men with Gleason score >6 on prostate biopsy had indolent disease due 
to Gleason score downgrading at radical prostatectomy[26]). Inclusion of these men for model 
development tends to inflate the predictive capability of the model as indicated by the AUC. In 
addition, adding these men might alter the estimated prognostic effect of individual parameters 
for men with Gleason scores of 6.
All previously described nomograms are designed to predict the presence of indolent disease 
at immediate radical prostatectomy. However, as previously described this is used as a surrogate 
for a tumor that would not cause any symptoms or death during a man’s life. The last nomogram 
that will be discussed takes a different approach and aims to predict prostate cancer specific 
survival after 10 years if conservative treatment is opted for (i.e. watchful waiting, which differs 
from active surveillance in that it does not attempt to offer curative treatment, but only pal-
liative treatment if symptoms occur).[27] The model was based on 1310 men diagnosed with 
prostate cancer either by biopsy or transurethral resection of the prostate between 1990 and 
1996. Cox regression analysis was used to predict 10 year prostate cancer mortality rates using 
clinical stage, method of diagnosis, % cancer tissue, PSA, age, Gleason sum score, and the use of 
early hormonal treatment (within 6 months).The concordance index (similar to the AUC, but for 
censored data) was moderate (0.73).[27] Low 10 year disease specific mortality rates obtained 
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from this model, combined with a short to intermediate life expectancy, could be used to select 
men for watchful waiting.
WHICH PREDICTION mODEL TO USE?
Clinicians and patient thus have several different nomograms at their disposal to help differenti-
ate between indolent disease, most likely suitable for conservative management, or less indolent 
disease, which might require more aggressive treatment. But which of these nomograms should 
be used and which one is most suitable? Several aspects need to be addressed. First, a nomogram 
developed on a specific cohort might perform well on that cohort, but have limited predictive 
capabilities outside this setting.[28] External validation of a model is therefore essential.[29, 30]
Both the Kattan et al. nomogram and the Steyerberget al. nomogram were validated in an 
external population of 296 men with Gleason score 6, localized disease.[31] At radical prosta-
tectomy 27% had indolent prostate cancer. Both models performed equally well in predicting 
indolent disease with an AUC of 0.77, which is similar to the predictive accuracy of the develop-
ment cohort, indicating good generalizability. A second validation was done of all 5 nomograms 
described above in a contemporary cohort of 370 men with Gleason 6 disease on transrectal 
prostate biopsy.[32] In 38% of patients indolent disease was present on radical prostatectomy. 
Result indicated both the Kattan et al. and the Steyerberg et al. nomograms significantly outper-
formed the Nakanishi et al. nomogram, which in its turn outperformed both the Chun et al. and 
the O’Brien et al. nomograms. Predictive capabilities were again moderately well for the Kattan 
et al. and the Steyerberg et al. nomogram with an AUC of 0.77.[32] These two nomograms also 
showed good calibration and the highest net benefit.[32] It was noted that all models were most 
accurate at low predictive capabilities, indicating that these models are best at excluding indo-
lent disease rather than accurately identifying it. One of the reasons for the lower performance at 
higher predictive values was the presence of anterior and apical tumors.[32] Both located at areas 
not frequently sampled with standard transrectal biopsy schemes. The nomogram predicting 10 
year disease free survival has not yet been externally validated.[27]
As is shown the specific population at external validation may affect results. This is illustrated 
in an example of predicted probabilities of indolent disease (table 3). If the chance of having 
indolent disease for a 65-year-old men with 5 mm prostate cancer in 1 biopsy core is calculated 
with all nomograms, predictions range from 1-79%. Ten year disease free survival is calculated 
at 90-96%. Predicted probabilities seem very dependent on the percentage of men with indo-
lent disease in the development cohort. Both the Chun et al. and the O’Brien et al. nomogram, 
which were developed in a group of men with often Gleason scores >6, seem not well able to 
identify indolent disease in men with lower Gleason scores. Other important differences include 
the development in a clinical cohort or a screening cohort. The latter having more men with 
indolent disease. Furthermore, most cohorts were developed in white European or American 
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men. Applicability to Asian or African men might be limited. Clinicians should be aware of these 
differences and try to select a nomogram best suitable for their patient. Overall, the Kattan et al. 
and Steyerberg et al. nomograms seem to be the most widely applicable, and outperform other 
nomograms.[31, 32] In addition, both nomograms can be easily applied, using an online tool 
(www.prostatecancer-riskcalculator.com and www.nomograms.org) which simply calculates the 
predicted probability after provide parameter data, greatly enhancing clinical usability.
CLINICAL APPLICABILITY
Although many nomograms are developed to help clinicians and patients in treatment decisions, 
very few make it into clinical practice. Physicians may be reluctant to trust nomogram predictions 
and rather choose to follow well established preconceptions. An example is provided by a study 
on the implementation of a risk-calculator to aid in the decision of prostate biopsy.[18] Although 
the risk-calculator (i.e. the ERSPC risk-calculator[10, 11]) was proven superior over a single PSA 
cut-off, 36% of men were biopsied against a negative biopsy recommendation provided by the 
risk-calculator. When asked for the reason of ignoring the advice, 78% of times a PSA >=3.0ng/
ml was replied. Of men ignoring the negative biopsy recommendation only 3% showed ag-
gressive prostate cancer on biopsy.[19] The remaining 97% received an unnecessary biopsies 
because of the prejudice that a PSA-value >=3.0ng/ml should trigger further investigation. That 
said, it seems vital to not only conduct studies on how to improve selection, but also to better 
implement successful tools in clinical practice. This can be done by simple presenting the risk 
provided by a nomogram, but can also be more elaborate e.g. by combine individual risk scores 
Table 3. Overview of risk prediction tools for indolent prostate cancer.
Indolent prostate cancer (organ confined, 
Gleason score 6, tumor volume <= 0.5 cm3) at 
radical prostatectomy
10 year 
disease 
free 
survival
Kattan 
et 
al.[20]
Steyerberg 
et al.[21]
Nakanishi 
et al.[24]
Chun 
et 
al.[25]
O’Brien 
et 
al.[26]
Kattan
et al.[27]
Cohort origin Clinical Screening Clinical Clinical Clinical Clinical
Number of men used for nomogram 
development
409 247 254 1132 2525 1310
Percentage with indolent disease 20% 49% 52% 6% 6% -
Example of risk prediction (Man, age 65 
year, PSA 5ng/ml, prostate volume 50cm3, 
cT1c, Gleason 3+3, 1 of 12 cores positive, 
5mm cancerous tissue, 200mm benign 
tissue, no early hormonal therapy)
48% 79% 37% 4-10%* 1-5%* 96-90%*
*Risk predictions were based on graphical devices and therefore presented as an interval.
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with information on its meaning, prognosis, and the advantages and disadvantages of different 
treatment options into a (personalized) decision aid.
One study aimed to investigated the impact of using a nomogram to advise men on active 
treatment or active surveillance.[33] The Steyerberg et al. nomogram was used to predict the 
presence of indolent disease in 240 men diagnosed with prostate cancer in five Dutch hospi-
tals. As a rule of thumb, a probability cut-off of >=70% was choose to advice men on active 
surveillance. With this cut-off 82% of patients adhered to the recommendation to choose active 
surveillance. Surprisingly 29% of men with a probability <70% of indolent disease also choose 
an initial active surveillance strategy. The main reason being the patients preference to delay 
physical side effect of active treatment.[33] measurements of the decisional conflict scale were 
low in this study, indicating that patients felt well informed by the nomogram and certain in 
their choice of treatment. Two other randomized trials have shown that using decision aids (not 
including individual risk assessments) for treatment choice in localized prostate cancer not only 
helped patients to make more informed decisions on treatment, but also increase satisfaction 
with the decision made.[34, 35] In addition, the better information provided and higher patient 
participation might have an effect on the treatment that is selected.[35, 36] Decision aids, includ-
ing personalized risk assessments, seem good tools not only to improve the selection of men 
with indolent disease, but will also increase patient understanding, participation and satisfaction 
in the treatment chosen for the management of their prostate cancer.
FUTURE PERSPECTIvE
Although the use of nomograms to help treatment decision in the increasing number of men 
diagnosed with low-risk localized prostate cancer seems preferable over rule-based decision sup-
ports to reduce overtreatment, there are some limitations. As with all rule-based criteria, none 
of the presented nomograms is able to perfectly predict the presents of indolent disease. In 
fact the nomograms seem more suitable to exclude the presence of significant disease. most 
likely the restrictions of currently used blind biopsy sampling, often missing anterior and apical 
tumors, contribute to this. Improvement of current nomograms is therefore essential. Promising 
and most likely to be quickly incorporated is the use of mRI. mRI seems especially useful in visual-
izing higher grade prostate cancers.[37, 38] mRI visualized lesions could trigger targeted biopsies 
which might better represent tumor grade and volume. Nomogram predictions are therefore 
likely to improve if data on targeted biopsies could be added. In addition to the information 
provided by targeted biopsies, the mR images itself could provide new parameters on tumor 
characteristics. These not only include tumor volume as can be measured on mRI, but also water 
diffusion coefficients which seen to correlate with tumor aggressiveness.[39]mRI, using spec-
troscopic imaging, could also be used to obtain information on a molecular level, which again 
might help to predict tumor aggressiveness.[40, 41] Next to imaging, genomic and histological 
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information could potentially provide better information on tumor behavior and help to decide 
on the most appropriate treatment strategy. A recent study genotyped 242,221 single nucleotide 
polymorphisms (SNPs) in blood DNA of men with Gleason 6 prostate cancer.[42] Fifteen SNPs 
were found to be able to predict Gleason score upgrading on radical prostatectomy, however 
only one SNP remained predictive if other clinical information was added. The addition of the 
SNP to a clinical model significantly improved the predictive accuracy.[42] Future studies should 
validate if these findings remain significant and could improve the prediction of indolent disease.
CONCLUSION
Several nomograms may aid men in assessing their risk of having an indolent tumor, which 
maybe most suitable for conservative management. These decision aids, although not perfect 
in their prediction of indolent disease, are preferable over commonly used rule-based selection 
criteria for active surveillance, because they provide a more individual risk-assessment, which 
helps to better inform men facing treatment decision. For clinicians it is important to choose a 
nomogram that is most accurate, externally validated and best fits the patients characteristics. 
Well validated nomograms with reasonable accuracy can be found online for a clinical population 
(www.nomograms.org) or for a more intensive PSA screened population (www.prostatecancer-
riskcalculator.com). Future developments, as mRI and new genetic markers, will likely improve 
current nomograms. Implementation into clinical practice is however already shown valuable. 
The time has therefore arrived to start using these prediction tools in clinical practice to provide 
the best of care for the large number of men diagnosed with low-risk prostate cancer today.
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ABSTRACT
Background: men with prostate cancer on active surveillance are advised to follow strict 
follow-up schedules and switch to definitive treatment if risk reclassification occurs. However, 
some men might not adhere to these strict protocols.
Objective: To determine the number of non-compliers and disease reclassification rates in 
men not complying with the follow-up protocol of the Prostate cancer Research International: 
Active Surveillance (PRIAS) study.
Design, setting, and participants: 4547 men with low-risk prostate cancer were included 
and prospectively followed on active surveillance. men were regularly examined using PSA, 
DRE, and repeat biopsies and advised to switch to definitive treatment if disease reclassifica-
tion occurred (>cT2c, Gleason score >3+3, >2 cores positive, or PSA-doubling time (PSA-DT) 
0-3 year).
Outcome measurements and statistical analysis: Rates of men not complying with the 
follow-up visits or recommendation to discontinue active surveillance were reported. Biopsy 
outcome (Gleason score >=7 or > 2 cores positive) between compliers and non-compliers was 
compared using cox proportional hazard analysis.
Results and limitations: The compliance rate with PSA visits was 91%. In contrast compliance 
rates with standard repeat biopsies decreased over time (81%, 60%, 53%, and 33% for 1, 4, 
7, and 10 years after diagnosis respectively). Yearly repeat biopsies in men with faster rising 
PSA (PSA-DT 3-10 year) was low at less than 30%, although these men had higher upgrad-
ing rates at repeat biopsy (25-30% versus 16%). A PSA-DT of 0-3 year was the most common 
recommendation to discontinue, nevertheless 71% continued active surveillance. men with 
PSADT 0-3 year were at higher risk of upgrading on repeat biopsy (HR 2.02; 95% CI 1.36-3.00) as 
compared to men without fast rising PSA.
Conclusion: Some men and their physician do not comply with an active surveillance follow-
up protocol. Especially yearly repeat biopsies in men with fast rising PSA, are often ignored, 
as is the recommendation to discontinue active surveillance due to a very fast rising PSA. 
Although these men are at increased risk of having higher Gleason scores on repeat biopsy, the 
majority still presents favorable tumor characteristics. A fast rising PSA should therefore not be 
a recommendation to advice active treatment, but should rather serve as a criterion for stricter 
follow-up. In addition, we should aim to find ways of safely reducing the amount of biopsies to 
increase adherence to active surveillance protocols.
Patient summary: In this report we looked at the compliance with a large active surveillance 
protocol for low risk prostate cancer. We observed reluctance with yearly biopsies due to a 
fast rising PSA, despite a higher risk of disease progression. Further research should aim to 
safely reduce the amount of repeat biopsies in men on active surveillance, to increase protocol 
adherence.
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INTRODUCTION
Active surveillance for prostate cancer is a treatment option aimed at reducing the negative side 
effects of radical treatment, while at the same time preserving the option for curative treatment. 
It does so by strictly following men and only offering curative treatment to those that show signs 
of disease progression / reclassification. However, optimal criteria for follow-up, inclusion and 
exclusion are currently still being investigated. most common protocols include criteria based on 
a combination of PSA tests, digital rectal examinations (DRE), and repeated prostate biopsies to 
both include patients and define disease reclassification [1-6].
Some men and their physicians might however choose to deviate from these strict protocols, 
ignoring either the follow-up schedule or the advice to switch to curative treatment.
The aim of the current analysis is to determine the number of men who do not comply with 
the protocol of the Prostate cancer Research International: Active Surveillance (PRIAS) study. The 
PRIAS study is currently the largest prospective study on active surveillance, including over 100 
centers in 17 countries aimed to represent a real world situation [1]. Furthermore, follow-up of 
men not complying with the approved protocol allows us to evaluate the protocol by investigat-
ing their intermediate term outcomes (i.e. Gleason score upgrading at repeat biopsy).
mETHODS
In the PRIAS study men with low risk prostate cancer are prospectively followed on active 
surveillance [7]. All centers enter data on inclusion and follow-up trough an online tool (www.
prias-project.org), which automatically provides all recommendations for follow-up based on the 
protocol [7]. Criteria for inclusion are: Gleason score <=3+3, <=cT2c, PSA <=10ng/ml, <= two 
cores positive for prostate cancer, PSA density <=0.2ng/ml/ml, and fitness for curative treatment. 
A minimum number of biopsy cores taken is advised based on prostate volume (prostate volume 
<40cm3: 8 cores, 40-60cm3: 10 cores, >60cm3: 12 cores), but is not a strict inclusion criterion. As 
of 2012 men with minimal Gleason score 3+4 disease (<=10% core involvement) can be included 
if aged >=70 year (n=24)(for follow-up all regular criteria apply except for Gleason score, which 
can be 3+4 on repeat biopsy).
men are followed using PSA testing every 3 months the first 2 years and every 6 months 
thereafter. Digital rectal examination is advised every 6 months the first 2 years and every year 
thereafter. Repeat biopsies are done 1,4,7,10, and subsequent every 5 years after diagnosis. Yearly 
repeat biopsies are only advised if PSA doubling time (PSA-DT) is between 3 and 10 years. PSA-DT 
is calculated using all available PSA values since diagnosis by plotting the base 2 logarithm of 
the PSA values against the time since diagnosis. The PSA-DT is then calculated as the reciprocal 
value of the slope of the regression line through these points. PSA-DT is only used if at least 
4 PSA values are available. A bone scan is recommended if PSA >=20ng/ml. Criteria used to 
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recommend a switch to defi nitive treatment are: Gleason score >3+3, >2 biopsy cores positive 
for prostate cancer, >cT2c, and a PSA-DT of 0-3 year (if at least 4 PSA values are available) on any 
of the follow-up visits (fi gure 1). Follow-up for the current analysis ended 31 December 2014.
Compliance with the follow-up schedule was studied per year of being on active surveillance. 
men were defi ned as being compliant with the PSA visits if in the fi rst 2 years at least 3 PSA tests 
were done per year and at least 1 PSA test in the years thereafter. A biopsy 6 months before 
or after the designated time for the biopsy was classifi ed as being compliant with that biopsy. 
Standard biopsies should have been done in year 1, 4, 7, and 10 in men with >1.5, >4.5, >7.5, 
and >10.5 years of follow-up respectively to classify as being compliant. men with a PSA-DT of 
3-10 years within the years with no scheduled standard repeat biopsy (years 2, 3, 5, 6, 8, 9 after 
inclusion, see fi gure 1) should have had a biopsy in that year. Two defi nitions were used for non-
compliance with a protocol based reason to discontinue active surveillance: at least 1 PSA visit or 
at least 1 biopsy after the protocol recommendation to discontinue.
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Figure 1. Follow-up schedule and criteria for follow-up (left flowchart) of the PRIAS study. As of 2015 the follow-up criteria were 
changed (flow chart to the right).  
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Figure 1. Follow-up schedule and criteria for follow-up (left fl owchart) of the PRIAS study. As of 2015 the follow-
up criteria were changed (fl ow chart to the right).
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STATISTICAL ANALYSIS
Upgrading in men not complying with a recommendation to biopsy
The number of men with upgrading (Gleason score >6 or >2 cores positive) on the second stan-
dard repeat biopsy (year 4) was compared for men without a PSA-DT between 3 and 10 in the 
second and third year and men with a PSA-DT between 3 and 10 during that period, but who did 
not receive an early repeat biopsy, using the Chi-square test. In addition, a comparison was made 
with the number of men with upgrading on repeat biopsy in year 2 or 3 triggered by a PSA-DT 
between 3 and 10. For equal comparison all men had the first scheduled repeat biopsy in year 1.
Upgrading in men not complying with a recommendation to discontinue
As the number of previous biopsies during follow-up could influence upgrading rates we only 
reported upgrading rates on the second repeat biopsy during follow-up for men who ignored a 
recommendation to discontinue active surveillance on the first repeat biopsy during follow-up 
(either Gleason score >6 or > 2 cores positive) or ignored a recommendation to discontinue 
in-between the first and second repeat biopsy (due to a PSA-DT of 0-3 year). As comparison, 
upgrading rates on the second repeat biopsy during follow-up for men without a previous 
recommendation to discontinue were reported. As time between the first two biopsies could 
differ between these groups we conducted a cox proportional hazard analysis with correction for 
age, PSA and number of positive cores at the first repeat biopsy and PSA density at diagnosis to 
predict upgrading on the second repeat biopsy. For this analysis PSA-DT 0-3 was assumed to be 
at the time of the first repeat biopsy, as most PSA-DT 0-3 occurred within 1 year of the first repeat 
biopsy [8]. For all analysis SPSS for windows (version 21.0. Armonk, NY: IBm Corp.) was used.
RESULTS
Until the end of follow-up 4547 men were included and followed on active surveillance in the 
PRIAS study. As inclusion and follow-up is still ongoing, the median time on active surveillance 
for all men was only 1.5 years, but 750 men were followed for more than 4 years and 94 men for 
more than 7 years.
Compliance with PSA and biopsy visits
During follow-up 91% of patients complied with all PSA visits. After year 7 a slight decrease in 
compliance with the scheduled PSA visits was seen (figure 2). The rate of compliance with all 
advised biopsy visits was lower at 70%. Compliance rates with the standard biopsies (year 1, 4, 7, 
and 10) decreased over the years with 1867/2306 men (81%) complying with the 1 year repeat 
biopsy, 333/559 (60%) with the 4 year repeat biopsy, 27/51 (53%) with the 7 year repeat biopsy, 
and 1/3 men (33%) with the 10 year repeat biopsy. Overall compliance rates with the yearly 
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repeat biopsies due to a PSA-DT of 3-10 years was low ranging from 226/702 men (24%) in year 2 
to 1/11 men (9%) in year 8 (figure 2). Of 750 men with more than 4 years of follow-up, 222 (30%) 
complied with all advised biopsies.
men with a biopsy advise in year 2 or 3 (due to a PSA-DT of 3-10 years) who did not comply, 
more often had upgrading (Gleason >6 and/or >2 cores positive) on repeat biopsy at year 4, as 
compared to men without a PSA-DT of 3-10 years in year 2 or 3 (25% versus 16% respectively, 
p=0.028). men with a PSA-DT of 3-10 in year 2 and 3 who did have a biopsy in year 2 or 3, were 
upgraded in 27% and 30% of cases respectively (table 1). In year 7 50 men had a repeat biopsy. Of 
the 22 men that fully complied with the biopsy protocol 1 (5%) had a Gleason score >=7. Of the 
28 that did not fully comply, 5 (18%) had a Gleason score >=7 (p=0.15).
Compliance with recommendation to discontinue active surveillance
During follow-up 10 men had clinical stage >=T3 of which 2 continued AS (20%), 535 men had 
a Gleason score >6 at any repeat biopsy of which 96 continued AS (18%), 734 men had >2 cores 
positive for prostate cancer at any repeat biopsy of which 175 continued AS (24%), and 915 men 
had a PSA-DT of 0-3 year of which 651 continued AS (71%). The percentage of men continu-
ing active surveillance were lower if a stricter definition was used (figure 3). Of all men who 
continued active surveillance despite a recommendation to discontinue 329 out of 839 (varying 
from 245/651 for PSA-DT of 0-3 year to 1/2 for clinical stage >=T3) eventually switched of active 
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Figure 2. Percentage of men complying with PSA testing and prostate biopsies in men on active 
surveillance per year. (standard repeat biopsies are highlighted) 
  Figure 2. Percentage of men complying with PSA testing and prostate biopsies in men on active surveillance 
per year. (standard repeat biopsies are highlighted)
103
6
surveillance after a median follow-up of 1.0 year after their recommendation to discontinue, and 
510 out of 839 are still on active surveillance for a median of 1.7 year.
men who continued active surveillance, and subsequently had a second repeat biopsy, despite 
>2 cores positive for prostate cancer or a PSA-DT of 0-3 year more often had a Gleason score >6 
(15% and 16% respectively), as compared to men without a recommendation to discontinue 
(11%, table 2). After correction for other variables and time between biopsies, both a PSA-DT 
between 0-3 and >2 cores positive on first repeat biopsy were significant predictors of upgrading 
on the second repeat biopsy (table 3).
Table 1. Outcome in men complying and not complying with advised prostate biopsies.
Biopsies during follow-up
group1* group2* group3* group4*
PSA-DT 
3-10
Bx
PSA-DT 
3-10
Bx
PSA-DT 
3-10
Bx
PSA-DT 
3-10
Bx
Year 1 Yes Yes Yes Yes
Year 2 Yes No No - Yes Yes No -
Year 3 Yes No No - Yes Yes
Year 4 Yes Yes
Age at diagnosis, median 
(IqR)
64.9 (61.3-69.9) 65.9 (60.2-70.7) 64.4 (60.3-69) 64.5 (59.4-70.3)
PSA at diagnosis, median 
(IqR)
5.1 (3.6-6.4) 5.7 (4.4-7.5) 5.4 (4.4-6.6) 5.5 (4.4-6.9)
Outcome prostate biopsy 
in:
Year 4 Year 4 Year 2 Year 3
no prostate cancer 58 (43%) 101 (47%) 61 (33%) 44 (37%)
Gleason <=6 56 (42%) 97 (45%) 100 (54%) 57 (48%)
Gleason 3+4 15 (11%) 10 (5%) 18 (10%) 12 (10%)
Gleason 4+3 3 (2%) 5 (2%) 3 (2%) 2 (2%)
Gleason >=8 2 (1%) 2 (1%) 4 (2%) 5 (4%)
>2 cores positive 23 (17%) 25 (12%) 42 (23%) 28 (23%)
Gleason >6 or >2 cores 
positive
34 (25%)a 34 (16%) 51 (27%) 36 (30%)
Total 134 (100%) 215 (100%) 186 (100%) 120 (100%)
*For comparison all men had a biopsy in year 1 and:
Group 1: Non-compliers: no biopsy in year 2 or 3 despite PSA-DT of 3-10 year in year 2 or 3
Group 2: Compliers: no recommendation for biopsy in year 2 or 3
Group 3: Compliers: PSA-DT of 3-10 year in year 2 and a biopsy in year 2
Group 4: Compliers: PSA-DT of 3-10 year in year 3 and a biopsy in year 3
a: p-value as compared to group 2: 0.028.
IqR: interquartile range
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DISCUSSION
The PRIAS study is currently the largest active surveillance study worldwide. It was aimed to 
provide a real world representation of active surveillance outside the more strictly controlled 
academic centers, by including both academic, non-academic and private practices across 17 
countries and 4 continents. We observed a substantial proportion of men who did not comply 
with the repeat biopsies schedule. Especially the yearly biopsies due to a faster rising PSA were of-
ten ignored. PSA kinetics were in addition regularly put aside as recommendation to discontinue 
active surveillance. Both men ignoring the follow-up schedule and criteria for discontinuation of 
active surveillance were at increased risk of disease upgrading. Although a substantial number 
still presented with favorable disease characteristics on repeat biopsy.
We observed a clear decrease over time in the percentage of men receiving the standard 
repeat biopsies, from 81% in the first year, 60% and 53% in the fourth and seventh year, to 33% 
in the tenth year of follow-up. Although not recorded as standard, several common reasons for 
not complying with these standard repeat biopsies were recorded. Some examples included 
“patient does not want biopsy”, “PSA stable”, “no signs of disease progression on previous biopsy” 
or “complications on last biopsy”. This seems to indicate that the repeat biopsies might put a 
substantial strain on men. As compared to PSA testing, which was most often strictly complied 
with, biopsies are considered uncomfortable. In addition, several complications are recorded 
such as pain, hematuria, or even sepsis [9]. These complications will result in some men declining 
repeat biopsies [10]. Furthermore, increasing age (median age at diagnosis, 4, 7, and 10 year was 
65.8, 69.5, 72.2, and 76.0 respectively) or previous negative biopsies combined with unchang-
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Figure 3. Percentage of men not complying with protocol based reasons to discontinue active 
surveillance. 
Figure 3. Percentage of men not complying with protocol based reasons to discontinue active surveillance.
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ing PSA values, might reassure both physicians and patients of stable disease which might not 
become clinically significant. This assumptions seems to be confirmed by biopsy results in men 
with a negative PSA-DT or a PSA-DT >10 years. In these men a biopsy 4 years after diagnosis 
showed Gleason score >6 in only 8% (group 2, table 1). This questions whether yearly biopsies 
for everyone, as used in some active surveillance studies [2, 11, 12], are justified. As active surveil-
lance is primarily aimed at reducing the side effects of aggressive treatment to improve quality of 
Table 2. Outcome of second repeat biopsy in men continuing active surveillance despite protocol advice to 
switch to active treatment either at the first repeat biopsy (Gleason >6, >2 cores positive) or between first and 
second repeat biopsy (PSA-DT <=3 year), compared with men adhering to the protocol (no protocol based 
reason to discontinue).
Continuation despite protocol advice
No protocol advice 
to discontinue
PSA-DT 0-3 year
>2 cores 
positive with 
PCa
Gleason score >6
Biopsies during follow-
up
Bx
PSA-DT 
0-3
Bx
>2 
cores
Bx
Gleason 
>6
Bx
 Year 1 1st Bx 1st Bx Yes 1st Bx Yes 1st Bx
Yes
 Year 2, 3, or 4 2nd Bx 2nd Bx 2nd Bx 2nd Bx
Age at diagnosis, median 
(IQR)
64.7 (59.8-69.5) 64.5 (60.6-69.9) 65.9 (59.9-70.3) 68.4 (62.1-71.5)
PSA at diagnosis, median 
(IQR)
5.6 (4.3-7) 5.1 (3.6-6.4) 4.9 (3.5-6.6) 5.6 (5-7.3)
Time from first to second 
repeat biopsy, median 
(IQR)
2.2 (1.1-3.0) 1.5 (1.0-2.9) 1.3 (1.0-2.9) 0.5 (0.5-1.9)
Time between PSA-DT 
0-3 and second repeat 
biopsy, median (IQR)
- 1.4 (1.0-2.6) - -
Outcome second repeat 
biopsy
 no PCa 267 (43%) 81 (37%) 4 (12%) 1 (8%)
 Gleason <=6 283 (46%) 103 (47%) 24 (73%) 4 (33%)
 Gleason 3+4 45 (7%) 21 (10%) 2 (6%) 6 (50%)
 Gleason 4+3 10 (2%) 6 (3%) 1 (3%) 0 (0%)
 Gleason >=8 11 (2%) 8 (4%) 2 (6%) 1 (8%)
 >2 cores positive 83 (13%) 12 (5%) 15 (45%) 5 (42%)
 Gleason >6 or >2 cores 
positive
120 (19%) 64 (29%) 18 (55%) 7 (58%)
Total 616 (100%) 219 (100%) 33 (100%) 12 (100%)
PSA-DT: PSA doubling time
IqR: interquartile range
PCa: prostate cancer
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life, one might argue that the small portion of men that might benefit from yearly biopsies does 
not outweigh the additional burden and its possible reduction of quality of life. Especially in men 
with a slow rising PSA (PSA-DT negative of >10 years) the risk of upgrading was low, which could 
trigger some patients and their physicians to switch to a watchful waiting strategy, avoiding 
further biopsies.
men with a PSA-DT of 3-10 year do seem to have a higher risk of having higher grade and 
extent of disease. In year 2 and 3 approximately 30% of men with a biopsy due to a PSA-DT of 
3-10 year were upgraded (Gleason >6 or >2 cores positive). men who ignored the biopsy advise 
in year 2 or 3 seemed to have a similar rate of upgrading if biopsied in year 4. This indicates that 
for 10-15% of men ignoring the recommendation to have a repeat biopsy based on PSA kinetics, 
upgrading is delayed by 1-2 year. Despite the increased risk, which was published before [1, 13], 
many men do not have yearly biopsies. It seems important that during theoretical design of 
active surveillance follow-up schedules, practical adoption and compliance should not be disre-
garded. Instead we need to develop follow-up schedules that are acceptable to those who follow 
it. Less harmful ways of monitoring tumor progression, such as mRI [14], might be incorporated 
in the protocol design to improve compliance. In the PRIAS study we initiated a side study to 
investigate if replacing yearly biopsies in men with fast rising PSA by mRI with targeted biopsies 
in case of visible tumor progression could substantially reduce the amount of biopsies (protocol 
Table 3. multivariable cox proportional hazard model predicting upgrading (Gleason >6 and/or >2 cores posi-
tive) on the second repeat biopsy during follow-up.
HR (95% CI) p-value
Age first repeat biopsy 1.00 (0.98 - 1.02) 0.9
PSA first repeat biopsy 1.00 (0.93 - 1.07) >0.9
PSA second repeat biopsy 1.05 (0.99 - 1.11) 0.078
PSA density at diagnosis (0.1 increase) 1.26 (0.88 - 1.82) 0.2
Gleason >6 first repeat biopsy (but continued active surveillance) 3.59 (1.62 - 7.98) 0.002
Number of positive cores first repeat biopsy <0.001
0 ref
1 2.12 (1.48 - 3.03) <0.001
2 3.19 (2.22 - 4.59) <0.001
>=3 (but continued active surveillance) 4.32 (2.43 - 7.66) <0.001
PSA-DT between first and second repeat biopsy 0.002
Always >10 years or negative ref
At least once from 10-3 years 1.45 (1.02 - 2.08) 0.039
At least once from 3-0 years (but continued active surveillance) 2.02 (1.36 – 3.00) <0.001
PSA-DT: PSA doubling time
CI: confidence interval
HR: hazard ratio
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available on www.prias-project.org). Even if such an approach will delay active treatment for 
some, the reduced strains of follow-up might outweigh the harms.
Of the 4 protocol based recommendations to discontinue active surveillance, a PSA-DT for 
0-3 year occurred most frequently. At the same time this was the recommendation most often 
ignored. more than 70% of men (or perhaps more likely their physicians) did not comply with 
the recommendation to discontinue active surveillance. more men presented with a Gleason 
score >6 in this group as compare to men not having a PSA-DT of 0-3 years. The higher risk of 
upgrading remained after correction for other variables. This correlation between PSA-DT and 
biopsy outcome was reported before in the PRIAS study [1, 13], but not in another study [15]. Dif-
ferences could be due to variances in study population or to the relatively small numbers in the 
later study [15]. If looked at the outcome on radical prostatectomy of men who did discontinue 
active surveillance, 29% of men who discontinued due to a low PSA-DT only had unfavorable 
outcomes (defined as Gleason >=4+3 or cT3-4 disease)[16]. Low PSA-DT was also found to be 
a strong predictor of biochemical recurrence after radical treatment [6]. However, despite these 
higher risks, a substantial part of men still had favorable disease characteristics. As many men 
might thus be excluded from active surveillance without having true unfavorable disease, and 
many men and their physicians did not follow the advice to discontinue, the recommendation to 
discontinue active surveillance if PSA-DT is 0-3 years was removed from the PRIAS protocol as of 
2015 (see figure 1 for new follow-up schedule). Instead more frequent (yearly) repeated biopsies, 
preferably sampling the anterior transition zone, are advised as with a PSA-DT of 3-10 years. If 
available and mRI with targeted biopsies could be done to rule out large anterior tumors in men 
with fast rising PSA.
Another recommendation to discontinue active surveillance that occurred frequently and was 
sometimes ignored was >2 cores positive for prostate cancer. These men had higher rates of 
Gleason score >6 at repeat biopsy than men with only 1 or 2 cores positive. However, a previous 
analysis indicated that a substantial part of men had Gleason 6 prostate cancer if subsequently 
treated with radical prostatectomy [16]. As metastasis in men with true Gleason 6 disease, ir-
respective of tumor volume, seems very rare [17, 18], the number of cores positive for prostate 
cancer might currently only function as a surrogate for higher grade disease. If targeted biopsies 
could (partially) eliminate this undergrading problem, determining the extent of the tumor might 
become obsolete in the future. In the PRIAS mRI side study the number of cores is therefore omit-
ted as a criterion to recommend active treatment (protocol available on www.prias-project.org).
Outcome in the current analysis was defined as the outcome on repeat biopsy. Although this 
allows for a comparison of compliers and non-compliers the effect on more definitive outcomes 
(e.g. prostate specific death) could currently not be assessed, as no such events were reported 
yet. Longer follow-up is warranted to assess the effect of non-compliance on definitive outcomes.
108
CONCLUSION
Some men with low risk prostate cancer on active surveillance do not comply with the schedule 
for follow-up and recommendations to switch to active treatment. Repeat biopsies, especially 
yearly biopsies in men with fast rising PSA, are often ignored, as is the recommendation to dis-
continue active surveillance due to a very fast rising PSA. Although these men are at increased 
risk of having higher Gleason scores on repeat biopsy, the majority still presents favorable tumor 
characteristics. A fast rising PSA should therefore not be a recommendation to advice active 
treatment, but should rather serve as a criterion for stricter follow-up. In addition, reducing the 
amount of yearly biopsies might increase the amount of men complying with the active surveil-
lance protocol.
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ABSTRACT
Objective: To study the risk of serial prostate biopsies on complications in men on active 
surveillance and determine the effect of complications on receiving further biopsies.
Materials and methods: In the global Prostate cancer Research International: Active Surveil-
lance (PRIAS) study men are prospectively followed on active surveillance and repeat prostate 
biopsies are scheduled 1, 4, and 7 years after the diagnostic biopsy, or once yearly if PSA-
doubling time (PSA-DT) is <10 years. Data on complications after biopsy, including infection, 
hematuria, hematospermia, and pain, were retrospectively collected for all biopsies done 
during follow-up in men from several large participating centers. Generalized estimating 
equations were used to test predictors of infection after biopsy. Competing risk analysis was 
used to compare the rates of men receiving further biopsies between men with and without 
previous complications.
Results: In total 2184 biopsies were done in 1164 men. Infection was reported after 55 biop-
sies (2.5%), and one in five men reported any form of complication. At multivariable analysis 
the number of previous biopsies was not a significant predictor of infection (OR 1.04, 95% CI 
0.76-1.43). The only significant predictor for infection was the type of prophylaxis used. Of all 
men with a complication at the diagnostic or first repeat biopsy 21% did not have a repeat 
biopsy at the time a repeat biopsy was scheduled according to protocol, versus 12% for men 
without a previous biopsy complication.
Conclusion: In our cohort of men on active surveillance we found no evidence that repeated 
prostate biopsies in itself pose a risk of infection. Complications after biopsy were however not 
uncommon and after a complication men were less likely to have further biopsies. We should 
aim to safely reduce the amount of repeat biopsies in men on active surveillance.
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INTRODUCTION
Active surveillance aims to reduce overtreatment, and its side effects, by initially monitoring men 
with low-risk prostate cancer instead of immediate invasive treatment (e.g. radical prostatectomy). 
If signs of more aggressive disease appear, men on active surveillance are offered treatment with 
curative intent. monitoring usually consists of regular PSA tests, digital rectal examinations, and 
repeated prostate biopsies.
We recently showed that some men on active surveillance are reluctant to undergo repeat bi-
opsies [1]. Some of the reasons stated were previous complications of the prostate biopsies. With 
every prostate biopsy men are at risk of harboring complications such as an infection, hematuria, 
or pain. It was suggested that the risk of some complications, such as infection, increases with the 
number of previous biopsies taken in men on active surveillance [2, 3].
We therefore set out to study the risk of complications after serial prostate biopsies in men on 
active surveillance in the Prostate cancer Research International: Active Surveillance (PRIAS) study 
and the effect of a previous complication on receiving subsequent biopsies.
mATERIALS AND mETHODS
The study protocol of the PRIAS study has been described in detail previously [4, 5]. In brief, 
men with low risk prostate cancer (Gleason score <=3+3, <=cT2c, PSA <=10ng/ml, <= two cores 
positive for prostate cancer, PSA density <=0.2ng/ml/ml, and fitness for curative treatment) can 
be included and prospectively followed on active surveillance. All centers collect data through an 
online tool (www.prias-project.org). During follow-up regular PSA tests and digital rectal exami-
nations are advised. Repeat biopsies are planned 1, 4, 7, 10, and subsequent every 5 years, after 
diagnosis. Yearly repeat biopsies are only indicated if PSA doubling time (PSA-DT) is between 
0 and 10 years. A minimum number of biopsy cores is advised according to prostate volume 
(prostate volume <40cm3, 8 cores; 40-60cm3, 10 cores; >60cm3, 12 cores). Until the end of march 
2015, 4749 men were included by more than 100 centers in 17 different countries.
For this analysis several large participating centers from different countries (including approxi-
mately 25% of all men included in PRIAS) retrospectively collected data through chart review 
on complications after biopsy for all participants in their center. This included data on infection 
(defined as temperature >38°C/100.4°F within 3 days after biopsy), hematuria (> 3 days), hemato-
spermia, and pain. To minimize the risk of reporting bias due to selective reporting of men with 
infections, only men were included for whom data on infectious complications on all biopsies 
during follow-up were entered. Complication rates were reported per subsequent biopsy during 
follow-up. Generalized estimating equations (GEE) were used to study the effect of number of 
previous biopsies on infection rates. In GEE all biopsies are used for prediction, while at the same 
time accounting for possible correlations among multiple biopsies in the same man. Results were 
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presented before and after correction for age at biopsy, year of biopsy, biopsy route (perineal 
versus rectal), type of prophylaxis, and an infection on last biopsy. Competing risk analysis was 
used to compare the percentage of men without a subsequent biopsy between men with and 
without any previous biopsy complication at the time a repeat biopsy is indicated by the study 
protocol (competing risk being men who discontinued before their next biopsy). For the analysis 
SPSS for windows (version 21.0. Armonk, NY: IBm Corp.) and the survival package of R (R Founda-
tion for Statistical Computing, vienna, Austria.) were used.
RESULTS
For 1164 men complication data were entered for all biopsies during follow-up and were used 
for analysis. In total, 2184 biopsies were done in these men during follow-up, 465 men only had 
1 biopsy, 464 men had two biopsies, 149 had 3 biopsies, and 86 men had 4 or more biopsies.
Table 1. Characteristics for men with and without an infection after biopsy.
No infection Infection Total
Age at biopsy
<50 21 (100%) 0 (0%) 21 (100%)
50-59 327 (97%) 10 (3%) 337 (100%)
60-69 1092 (97.3%) 30 (2.7%) 1122 (100%)
70-79 666 (98.1%) 13 (1.9%) 679 (100%)
>=80 23 (92%) 2 (8%) 25 (100%)
Prophylaxis used
Fluorquinolones 1830 (97.3%) 51 (2.7%) 1881 (100%)
TMP SMX 15 (100%) 0 (0%) 15 (100%)
Other 234 (99.6%) 1 (0.4%) 235 (100%)
Not used 16 (84.2%) 3 (15.8%) 19 (100%)
Missing 34 (100%) 0 (0%) 34 (100%)
Biopsy route
Rectal 1789 (97.3%) 49 (2.7%) 1838 (100%)
Perineal 228 (97.9%) 5 (2.1%) 233 (100%)
Missing 112 (99.1%) 1 (0.9%) 113 (100%)
Country
European 1327 (97.4%) 36 (2.6%) 1363 (100%)
Japan 592 (97.9%) 13 (2.1%) 605 (100%)
Australia/New Zealand 39 (95.1%) 2 (4.9%) 41 (100%)
Canada 171 (97.7%) 4 (2.3%) 175 (100%)
Total 2129 (97.5%) 55 (2.5%) 2184 (100%)
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In total there were 55 infections after biopsy (2.5%) in 54 men. The majority of biopsies were 
rectal biopsies (84%) and Fluorquinolones were the most common prophylaxis used (86%). 
Infection rates were 2.7% for rectal biopsies and 2.1% for perineal biopsies. Nineteen men did 
not receive prophylaxis, 3 of whom had an infection (16%). There were no large differences in 
infection rates between countries or the age at which the biopsy was taken (table 1).
Infection rates slightly increased after the diagnostic biopsy (2.3%), to 2.6% and 3.8% at the first 
and second repeat biopsy respectively, after which it decreased to 1.2% for >=3 repeat biopsies 
(table 2). Infection rates increase over the course of time from 0% in and before 2006 to 4.8% in 
2015 (figure 1). Data on hematuria, hematospermia, and pain after biopsy were missing in many 
cases (not often reported in the medical records). In men for which the data was available only 
pain after biopsy seemed to increase with subsequent biopsies from 10% at diagnostic biopsy, to 
27% at >=3 repeat biopsies (table 2).
In total 273 out of 1164 men (23%) had at least one complication (infection, pain, hematuria, or 
hematospermia) on the diagnostic biopsy. After 1.5 years of follow-up (standard repeat biopsy is 
planned 1 year after diagnosis) 17% of men with a complication at the diagnostic biopsy did not 
have a repeat biopsy yet versus only 10% for men without a biopsy complication. After the first 
repeat biopsy 21% of men with any complication on the diagnostic or first repeat biopsy did not 
go on to have a biopsy after 3.5 years of follow-up (second standard repeat biopsy is planned 3 
years after first repeat biopsy) versus 12% of men without a biopsy complication. A sub analysis 
comparing only men with an previous infection (instead of any biopsy complication) did not 
show a higher percentage of men without a subsequent biopsy (9% did not receive a biopsy after 
1.5 years of follow-up versus 11% of men without an infection).
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Figure 1. Infection rates per year the biopsy was taken.  
<=2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
No 78 114 156 171 220 274 288 334 414 80
Yes 0 1 4 3 4 11 9 7 12 4
0%
1%
2%
3%
4%
5%
Figure 1. Infection rates per year the biopsy was taken.
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On univariable analysis a small, non-significant, increase in the odds of infection was seen for 
every additional previous biopsy (odds ratio (OR) 1.08, 95% confidence interval (CI) 0.79-1.48). On 
multivariable analysis the effect of the number of previous biopsies on infection diminished (OR 
1.04, 95% CI 0.76-1.43). The only significant predictor for infection after biopsy was the type of 
prophylaxis used (table 3).
DISCUSSION
In the current analysis we assessed complication rates after repeated prostate biopsies in men 
on active surveillance. We found no evidence that repeated prostate biopsies in itself pose an 
increased risk of infection. However, approximately one in five men report some sort of complica-
Table 2. Complications per subsequent biopsy on active surveillance.
Diagnostic 
biopsy
Repeat biopsy 
1
Repeat biopsy 
2
Repeat biopsy 
>=3
Total
Infection
Yes 27 (2.3%) 18 (2.6%) 9 (3.8%) 1 (1.2%) 55 (2.5%)
% of men with filled 
data (yes/no)
2.3% 2.6% 3.8% 1.2% 2.5%
No 1137 (97.7%) 681 (97.4%) 226 (96.2%) 85 (98.8%) 2129 (97.5%)
Missing 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Hematuria
Yes 148 (12.7%) 66 (9.4%) 14 (6%) 8 (9.3%) 236 (10.8%)
% of men with filled 
data (yes/no)
21.0% 20.3% 22.6% 42.1% 21.3%
No 556 (47.8%) 259 (37.1%) 48 (20.4%) 11 (12.8%) 874 (40%)
Missing 460 (39.5%) 374 (53.5%) 173 (73.6%) 67 (77.9%) 1074 (49.2%)
Hematospermia
Yes 152 (13.1%) 50 (7.2%) 13 (5.5%) 3 (3.5%) 218 (10%)
% of men with filled 
data (yes/no)
22.6% 15.9% 22.4% 18.8% 20.5%
No 521 (44.8%) 264 (37.8%) 45 (19.1%) 13 (15.1%) 843 (38.6%)
Missing 491 (42.2%) 385 (55.1%) 177 (75.3%) 70 (81.4%) 1123 (51.4%)
Pain
Yes 70 (6%) 39 (5.6%) 11 (4.7%) 3 (3.5%) 123 (5.6%)
% of men with filled 
data (yes/no)
10.1% 13.0% 20.0% 27.3% 11.6%
No 620 (53.3%) 262 (37.5%) 44 (18.7%) 8 (9.3%) 934 (42.8%)
Missing 474 (40.7%) 398 (56.9%) 180 (76.6%) 75 (87.2%) 1127 (51.6%)
Total 1164 (100%) 699 (100%) 235 (100%) 86 (100%) 2184 (100%)
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tion after biopsy, with only pain seeming to increase with subsequent biopsies. men with a previ-
ous complication were less likely to undergo a repeated biopsies while under active surveillance 
for prostate cancer.
In total infection was reported after 2.5% of biopsies in this cohort of men on active surveil-
lance for prostate cancer. This reported percentage is somewhat lower than previous reports on 
infectious complications after prostate biopsy [6-9]. As with previous reports there was however 
an increase, although not statistically significant, in the rate of infection with increasing year of 
biopsy [6, 9, 10]. Increasing bacterial resistance to Fluorquinolones is seen as the most important 
reason for this increase in infection rates. In our cohort Fluorquinolones were the most com-
mon prophylaxis (86%) used. The rate of infection was higher in these men as compared to men 
receiving other antibiotic prophylaxis. As fluorquinolones are one of the standard recommended 
prophylaxis in for instance the EAU guideline [11], it could be that the other prophylaxis used 
were targeted based on a rectal swab. This could explain the lower infection rates, in addition to 
differences in resistance patterns. In men on active surveillance, who receive repeated biopsies 
and are therefore at increased risk of an infection, rectal swabs might be a method to reduce the 
risk of infection [8, 12].
Another method sometimes proposed to reduce the amount of infections after biopsy is 
perineal biopsies instead of rectal biopsies [13]. Although initially the infection rate for perineal 
biopsies were lower in our study, after correction for the type of prophylaxis used the protective 
effect disappeared. A recent review and meta-analysis was also not able to find a difference in 
complication rates between the rectal and perineal approach [14]. The lower infection rates in 
men receiving perineal biopsy thus seem to be a result of different antibiotic prophylaxis used 
instead of a different biopsy route. This suggests that there might be another pathway for 
prostatic infection after (perineal) biopsy, other than an infection because of pathogens passing 
directly through the rectal wall as result of the biopsy needle passing. Instead prostatic infec-
tions after biopsy might be caused by direct inoculation from within the urinary tract. It was 
Table 3. Predictors of infection after prostate biopsy.
Univariable Multivariable
OR (95% CI) p-value OR (95% CI) p-value
Age at biopsy (1 year increase) 0.99 (0.95-1.03) .713 0.99 (0.95-1.03) .663
Year of biopsy (1 year increase) 1.11 (1.00-1.24) .053 1.12 (1.00-1.26) .051
Number of previous biopsies 1.08 (0.81-1.46) .589 1.04 (0.77-1.4) .819
Perineal biopsy route (vs rectal) 0.83 (0.28-2.44) .740 1.02 (0.36-2.91) .975
Infection on last biopsy 2.17 (0.32-14.86) .429 2.06 (0.24-17.65) .511
Antibiotic prophylaxis used
Fluorquinolones 1 1
TMP SMX/Other 0.13 (0.02-0.88) .037 0.12 (0.02-0.70) .018
No prophylaxis used 6.73 (1.86-24.35) .004 5.59 (1.40-22.23) .015
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recently discovered that, opposite of what was commonly thought, urine is not sterile [15-17]. 
The prostate is in direct contact with urine, and consists of multiple ducts that might provide a 
sheltered environment for bacteria. Prostatic biopsies may then facilitate tissue infection from 
bacteria that are already present in the prostate at the time of the biopsy. An indirect observation 
supporting this hypothesis is the very high infection rate (27%) after prostate biopsy seen in 
men with asymptomatic bacteriuria [18]. Further research is needed to investigate the pathways 
causing infections after rectal and perineal prostate biopsies.
As men on active surveillance receive repeated prostate biopsies they are at increased abso-
lute risk of an infection as a result of a biopsy. However, repeated biopsies in itself were not a risk 
factor for infection in our cohort. This was also shown in a large database study [19]. Furthermore, 
a recent study showed no increase in fluorquinolone resistance in rectal swabs before repeated 
biopsy in men on active surveillance [12]. This is in contrast with a previous study which did 
show an increased risk of infection with every subsequent biopsy in men on active surveillance 
[2]. This difference might be due to the low number of events in that study or because no cor-
rections were made for confounding factors. Also, lack of data on the number of prediagnostic 
biopsy sessions (with benign histology) may confound the analysis. Additionally, it was shown 
that although previous fluorquinolones use was a risk factor for infection after biopsy it was only 
so if used within the previous 3 months [20]. As in the PRIAS study repeat biopsies are done 1, 4, 
7 and 10 year after diagnosis the effect of previous prophylaxis might be passed.
Despite the lack of increase in infectious complications with subsequent biopsies, there was an 
increase in pain reported after repeated biopsies. Furthermore, men with any previous complica-
tion after biopsy (either infection, hematuria, hematospermia, or pain) were less likely to have a 
repeat biopsy at the time it is normally scheduled. As there was no difference in the percentage 
of men discontinuing active surveillance (both for protocol based reasons and other reasons) 
between these groups (data not shown), men with a previous complication were simply more 
likely to continue active surveillance without having a repeat biopsy at the designated time. We 
observed that the percentage of men not receiving further biopsies was even higher in a sub-
group of men who apart from a previous complication on prostate biopsy presented with a stable 
PSA during follow-up (defined as a PSA doubling time >10 years or negative)(50% of men with a 
previous complication did not have a biopsy at the allocated time in this subgroup versus 14% for 
men without a previous complication, data not shown). This is in line with a previous report in the 
PRIAS study that showed that men were becoming less likely to have a repeated biopsies over 
time during active surveillance [1]. However, as also shown in this analysis [1], upgrading rates on 
biopsies later during follow-up, especially in men with stable PSA, were relatively low. It could be 
questioned if the risk of missing these biopsies might balance against the discomfort and risk of 
complications. We must therefore find ways to safely reduce the amount of biopsies (e.g. by bet-
ter risk-stratifying men at increased risk of disease progression/ reclassification) or even replace 
the biopsies for instance with mRI [21]. Reducing the amount of biopsies at times it is relatively 
safe might increase the compliance at times when there is a truly higher risk of upgrading.
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This analysis has some limitations. First, as this was a retrospective analysis there might be an 
underreporting of complications. It was noted that especially data on hematuria, hematospermia 
and pain were often missing from the medical records. In addition, very few data on hospitaliza-
tion and resistance patterns in men with an infection were available and this was therefore not 
reported. Despite the possibility of underreporting there was no reason to believe that there 
was selective underreporting for one of the biopsy session, making an effect on the conclusions 
drawn highly unlikely. Second, data on comorbidity (Charlson score) was only available at the 
time of the diagnostic biopsy and could therefore not be added to the main analysis. When 
only looking at the diagnostic biopsy there was a small, statistically non-significant (p=0.48), 
lower infection rate in men with any comorbidity (1.8% had an infection) versus men without 
any comorbidity (2.5% had an infection)(data not shown). Third, although the overall number of 
events was low for the multivariable analysis, most statistically non-significant OR’s were close 
to one indication little predictive effect. Last, no correction could be made for the number of 
biopsies before the start of active surveillance.
In conclusion, we did not find evidence in this analysis that repeated biopsies in itself increase 
the risk of infection in men on active surveillance for prostate cancer. However, in one in five men 
some sort of complication was reported after biopsy. men with a previous complication were 
less likely to undergo a subsequent repeat prostate biopsy as indicated by the active surveillance 
protocol. We should therefore aim to safely reduce the amount of biopsies in men on active 
surveillance to reduce the absolute risk of complications and increase compliance with active 
surveillance protocols.
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ABSTRACT
Background: Discordance between biopsy and radical prostatectomy tumor grade are not 
uncommon, but are unwanted in men on active surveillance for prostate cancer.
Objective: To investigate if pathologic biopsy reevaluation and implementation of immuno-
histochemical biomarkers could improve prediction of radical prostatectomy outcome in men 
initially on active surveillance.
Methods: Biopsy specimens from diagnosis until switching to radical prostatectomy in men 
initially on active surveillance in the Dutch part of the Prostate cancer Research International 
Active Surveillance (PRIAS) study were collected and revised by a single pathologist. Original 
and revised biopsy Gleason score were compared and correlated with radical prostatectomy 
Gleason score. Biopsy specimens were immunohistochemically stained for Ki67 and ERG. 
Predictive ability of clinical characteristics and biomarkers on Gleason >=7 or >=pT3 on radical 
prostatectomy was tested using logistic regression and ROC curve analysis.
Results: A total of 150 biopsies in 95 men were revised. In 13% of diagnostic or second-to-last 
biopsies and 20% of the last biopsies on active surveillance revision of Gleason score resulted 
in change of recommendation (i.e. active treatment or active surveillance). Concordance 
with Gleason on radical prostatectomy was however similar for both the revised and original 
Gleason on biopsy. Ki67 and ERG were not statistically significant predictors of Gleason >=7 or 
>=pT3 on radical prostatectomy.
Conclusions: Although interobserver differences in pathology reporting on biopsy could result 
in a change of management strategy in approximately 13-20% of men on active surveillance, 
both pathological revision and tested biomarkers (Ki67 and ERG) did not improve prediction 
of outcome on radical prostatectomy. Undersampling of most aggressive tumor remains the 
main focus in order to increase accurate grading at time of treatment decision making.
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INTRODUCTION
Discrepancies in prostate cancer grade at biopsy and radical prostatectomy specimen are not 
uncommon (1, 2). This is especially an issue in the context of active surveillance, as underestima-
tion of true tumor characteristics might lead to an unwanted delay, and overestimation to an 
unnecessary switch to active treatment.
While sampling error is considered the most important cause for grading discrepancy, inter-
observer variability and guideline differences for grading at biopsy and prostatectomy might also 
play a role (3). Pathologic biopsy reevaluation might change outcome and increase grading con-
cordance. Secondly, immunohistochemical staining of biopsy specimens with markers known to 
correlate with more aggressive characteristics could help better to define the true tumor state (4).
The objective of this study is to investigate the effect of pathologic biopsy reevaluation and 
implementation of immunohistochemical biomarkers on predicting radical prostatectomy out-
come in men initially on active surveillance for prostate cancer.
mETHODS
For this study we selected all Dutch men initially on active surveillance in the Prostate cancer 
Research International Active Surveillance (PRIAS) study who switched to radical prostatectomy 
before July 2014. The PRIAS study was initiated in 2006 and includes men with low risk prostate 
cancer (Gleason score <=3+3, <=cT2c, PSA <=10ng/ml, <= 2 cores positive for prostate cancer, 
PSA density <=0.2ng/ml/cm3, and fitness for curative treatment) on active surveillance (5). Crite-
ria used to recommend a switch to active treatment were Gleason score >6, >2 positive biopsy 
cores, a PSA-doubling time of 0-3 years, and >cT2.
We retrieved all available biopsy specimens from diagnosis until end of active surveillance 
as well as pathology reports from all biopsy and radical prostatectomy specimens from the 
participating hospitals. All biopsy specimens were re-evaluated for Gleason score (ISUP 2014 (6)), 
number of positive biopsies cores, and mm and percentage tumor per core, by a single patholo-
gist (GvL) blinded for the initial biopsy report.
Immunohistochemical staining
Per biopsy session (both diagnostic biopsy and all repeat biopsies) one core, with either the 
highest Gleason score or the largest tumor size in mm, was selected for immunostaining with 
ERG and Ki67.
Sections were cut (4µm) and deparaffinized in xylene and dehydrated in ethanol. Endogenous 
peroxidase was blocked by 0.3% hydrogen peroxide/phosphate buffered saline (PBS) for 20 min-
utes. Slides were placed in a microwave in pH9 Tris (hydroxymethyl)aminomethane-EDTA buffer 
for 15 minutes and incubated with primary antibody overnight at 4 degrees Celsius. Secondary 
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antibody (antimouse, Envision kit) was applied, followed by chromogenic visualization (Envision, 
DAKO kit), and counterstaining with hematoxylin. ERG was scored as either positive of negative, 
representative for ERG-gen fusion (7). Ki67 was scored for the percentage of positive tumor cells.
Statistical analysis
Concordance between initial and revised number of positive biopsy cores and the Gleason score 
were analyzed, and compared to the Gleason score on radical prostatectomy. Univariable logistic 
regression analysis was used to assess the predictive value of immunohistochemical biomarker 
and other tumor characteristics (PSA at the time of the biopsy, biopsy Gleason (<=6 or >=7), 
number of positive biopsy cores (<=2 or >2), and >50% single core involvement (yes or no)) 
on unfavorable outcome (Gleason score >=7 or >=pT3) on radical prostatectomy. multivariable 
analysis was not conducted due to the low number of events. ROC curves were used to test clini-
cal performance. All analysis were done separately for the diagnostic or second-to-last biopsy, 
and for the last biopsy before switching to radical prostatectomy. Analysis were done using SPSS 
for windows (version 23.0. Armonk, NY: IBm Corp.).
RESULTS
Patients characteristics
A total of 150 biopsy sessions of 95 participants who switched to radical prostatectomy after 
initial active surveillance were received and available for analysis. Of these, 71 biopsies were 
diagnostic biopsies, 11 biopsies were repeat biopsies not being the last biopsy, and 89 biopsies 
were last biopsy before switching to radical prostatectomy (21 men only had 1 biopsy during 
active surveillance, in these men the diagnostic and last biopsy are the same). The reason for 
discontinuation of active surveillance was protocol based progression of disease in 63 (66%) men 
and non-protocol based in 32 (34%) men (i.e. anxiety, patient request, or other). At diagnosis 
median age was 64 years (IqR 60-67, median PSA 6.1 ng/ml (IqR 5.0-7.4), and all men had Gleason 
6 on biopsy.
Pathologic review
Six out of the 82 diagnostic or second-to-last biopsies, and 4 out of the 89 last biopsies could 
not be revised as not all representative slides were received, leaving a total of 76 and 85 biopsy 
sessions for review, respectively.
On diagnostic or second-to-last biopsy the original Gleason score was <=6 in all men while the 
revised score was >=7 in 10 men (13%) (table 1a), and in 8 men (11%) originally <=2 cores were 
scored positive while revision reported >2 cores to be positive (table 2a). Based on pathologic revi-
sion of Gleason score and number of positive biopsy cores, a total of 17 men (22%) would either not 
fulfill the criteria for inclusion or should have switched off active surveillance at an earlier time-point.
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On the last biopsy before switching to radical prostatectomy, 10 men (12%) had an original 
Gleason score <=6 while the revised score was >=7, and 8 men (9%) had an original Gleason 
score =7 with a revised Gleason score <=6 (table 1b). The number of positive cores on last biopsy 
was initially reported <=2 in 6 men (7%) while revision reported >2 cores positive and in 6 men 
was initially reported >2 cores positive while revision reported <=2 cores to be positive (table 
2b). Based on pathologic revision of Gleason score and number of positive biopsy cores, 6 (7%) 
men would still be eligible for active surveillance at last biopsy. The number of positive biopsy 
cores was initially not reported or could not accurately be determined due to tissue fragmenta-
tion, on diagnostic or second-to-last biopsy, or last biopsy in 6 and 7 men, respectively (table 2a 
and 2b). Overall in only 13% of cases all biopsy cores were put in separate containers ensuring 
accurate determination of total number of positive biopsies.
Table 1a. Original versus revised Gleason score of diagnostic and second-to-last biopsy on active surveillance 
before switching to radical prostatectomy.
Revised Gleason score
No PCa 3+3 3+4 4+3 4+4 Total
O
ri
gi
na
l G
le
as
on
 s
co
re
No PCa 4 1 - - - 5
2+2 - 1 - - - 1
2+3 1 3 - - - 4
3+2 - 1 - - - 1
3+3 2 51 8 1 1 63
Not reported - 1 1 - - 2
Total 7 58 9 1 1 76
* Of the 82 diagnostic of second-to-last biopsies: 6 could not be assessed due to too little remaining biopsy tis-
sue for analysis, 21 were also the last biopsy.
Table 1b. Original versus revised Gleason score of last biopsy on active surveillance before switching to radical 
prostatectomy.
Revised Gleason score
No PCa 3+3 3+4 4+3 4+4 5+3 5+5 Total
O
ri
gi
na
l G
le
as
on
 s
co
re
No PCa 3 - - - - - - 3
2+3 - 1 - - - - - 1
3+3 2 46 9 1 - - - 58
3+4 - 8 9 - - - - 17
4+3 - - 2 - - - 1 3
4+4 - - - 1 1 - - 2
5+4 - - - - - 1 - 1
Total 5 55 20 2 1 1 1 85
* Of the 89 last biopsies: 4 could not be assessed due to too little remaining biopsy tissue for analysis, 21 were 
also the diagnostic biopsy.
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The clinico-pathologic characteristics of radical prostatectomy specimens is given in table 3. 
On the diagnostic or second-to-last biopsy on active surveillance (original Gleason <=6 for all 
men), 11 men (14%) were revised as Gleason >=7, 5 of whom had a Gleason >=7 on radical 
prostatectomy (table 4a). On last biopsy upgrading from a Gleason <=6 to a Gleason >=7 on 
radical prostatectomy occurred in 40% of men based on the original score and in 45% of men 
based on the revised score. Downgrading from a Gleason >=7 to <=6 occurred in 13% and 28% 
for the original and revised score respectively (table 4b).
Table 2a. Original versus revised number of cores positive on diagnostic and second-to-last biopsy on active 
surveillance before switching to radical prostatectomy.
Revised number of cores positive
0 1 2 3 4
Cannot be 
determined*
Total
O
ri
gi
na
l n
um
be
r o
f c
or
es
 
po
si
tiv
e
0 4 1 - - - - 5
1 2 33 4 2 1 - 42
2 - - 16 5 - 1 22
3 - - - 1 - 1 2
4 - - - - 1 - 1
Not in report - 1 - 1 - 2 4
Total 6 35 20 9 2 4 76
* Cannot be determined accurately due to multiple biopsies on one slide.
** Of the 82 diagnostic of second-to-last biopsies: 6 could not be assessed due to too little remaining biopsy 
tissue for analysis, 21 were also the last biopsy.
Table 2b. Original versus revised number of cores positive on last biopsy on active surveillance before switching 
to radical prostatectomy.
Revised number of cores positive
0 1 2 3 4 >4
Cannot be 
determined*
Total
O
ri
gi
na
l n
um
be
r o
f c
or
es
 
po
si
tiv
e
0 3 - - - - - - 3
1 - 19 - - - - - 19
2 1 - 12 4 2 - 1 20
3 - - 6 7 5 1 - 19
4 - - - 3 7 1 - 11
>4 - - - - - 7 1 8
Not in report - 3 1 1 - - - 5
Total 4 22 19 15 14 9 2 85
* Cannot be determined accurately due to multiple biopsies on one slide.
** Of the 89 last biopsies: 4 could not be assessed due to too little remaining biopsy tissue for analysis, 21 were 
also the diagnostic biopsy.
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Table 3. Characteristics on radical prostatectomy
n (%)
T-stage
pT2 71 (75%)
pT3a 14 (15%)
pT3b 0 (0%)
pT4 2 (2%)
Missing 8 (8%)
Gleason score*
<=6 36 (38%)
3+4 36 (38%)
4+3 5 (5%)
>=8 10 (11%)
Missing 8 (8%)
Surgical margin
Negative 68 (72%)
Positive 16 (17%)
Missing 11 (12%)
Total 95 (100%)
* Gleason score on radical prostatectomy was not revised. Original Gleason score is reported here.
Table 4a. Comparison of the original and revised Gleason score of the diagnostic and second-to-last biopsy on 
active surveillance with the Gleason score on radical prostatectomy.
Gleason score radical prostatectomy
G
le
as
on
 s
co
re
 o
n 
bi
op
sy
Original (O) versus Revised (R) <=6 >=7 Unknown* Total
O and R equal: <=6 24 36 4 64
O <=6, R >=7 5 5 - 10
O not reported, R <=6 - 1 - 1
O not reported, R >=7 1 - - 1
Total 30 42 4 76
* Radical prostatectomy data were not available.
Table 4b. Comparison of the original and revised Gleason score of the last biopsy on active surveillance with the 
Gleason score on radical prostatectomy.
Gleason score radical prostatectomy
G
le
as
on
 s
co
re
 o
n 
bi
op
sy
Original (O) versus Revised (R) <=6 >=7 Unknown* Total
O and R equal: <=6 25 20 7 52
O and R equal: >=7 2 13 - 15
O <=6, R >=7 5 5 - 10
O >=7, R <=6 1 7 - 8
Total 33 45 7 85
* Radical prostatectomy data were not available.
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Immunohistochemical analysis
For 48 out of the 87 diagnostic or second-to-last biopsies and 58 out of the 85 last biopsies 
enough tissue was remaining for immunohistochemical analysis. For all biopsies the median 
percentage of Ki67 positive tumor cells was 2% (IqR 2-4%), while ERG was scored positive in 67% 
of men. On univariable analysis percentage of tumor cells positive for Ki67 and ERG positivity 
were not statistically significant predictors of Gleason >=7 or >=pT3 on radical prostatectomy on 
both diagnostic or second-to-last biopsy, and on last biopsy (table 5a and 5b). Gleason score on 
last biopsy and >50% tumor in a single core were the only significant predictors of Gleason >=7 
or >=pT3 on radical prostatectomy (table 5b). The area under the ROC curve for Gleason >=7 or 
>=pT3 on radical prostatectomy was 0.66 for Gleason score on last biopsy, 0.75 with the inclusion 
of >50% tumor involvement in a single core, and 0.79 if Ki67 and ERG were added to Gleason on 
last biopsy and >50% tumor in a single core. On diagnostic or second-to-last biopsy only ERG 
expression showed some discriminative ability with an area under the ROC curve of 0.58.
Table 5a. Correlation between biopsy characteristics on diagnostic and second-to-last biopsy and unfavorable 
outcome (pT3 or Gleason score >=7) on radical prostatectomy.
Univariable
OR (95% CI) p-value
Original biopsy Gleason* - -
>50% involvement in a single core 1.4 (0.4-4.5) .621
>2 cores positive* - -
PSA, ng/ml 1.0 (0.8-1.3) .896
Ki67 1.0 (0.8-1.3) .670
ERG 0.3 (0.1-1.5) .149
* All Gleason <=6 and <=2 cores positive on biopsy
Table 5b. Correlation between biopsy characteristics on last biopsy and unfavorable outcome (pT3 or Gleason 
score >=7) on radical prostatectomy.
Univariable
OR (95% CI) p-value
Original biopsy Gleason 6.5 (1.8-24.3) .005
>50% involvement in a single core 4.3 (1.5-12.5) .007
>2 cores positive 1.8 (0.7-4.7) .226
PSA, ng/ml 1.1 (0.8-1.4) .597
Ki67 1 (0.9-1.2) .960
ERG 0.7 (0.2-2.3) .541
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DISCUSSION
Discordance between tumor characteristics at biopsy and subsequent radical prostatectomy is 
a well-known caveat in prostate cancer management. In men with Gleason score 6 on biopsy 
upgrading on radical prostatectomy occurs in approximately 40% of men (8). In this analysis we 
studied the effect of pathologic biopsy reevaluation and implementation of immunohistochemi-
cal biomarkers on predicting radical prostatectomy outcome in men initially on active surveillance 
for prostate cancer. Although we found differences in Gleason score or number of positive cores 
leading to a change in management in approximately 20% of cases, there was no improvement 
in correlation with final pathology. Suggesting that only by reducing undersampling on biopsy 
better predictions can be made on radical prostatectomy outcome.
Although revision by a dedicated uro-pathologist did thus not improve the correlation with 
pathology on radical prostatectomy, clinical implications can still be large. In the current analysis 
revision resulted in a change of management (either active treatment or active surveillance) in 
13% and 20% of men at diagnosis or on last available biopsy. This was even higher than a previous 
analysis which reported changes in treatment strategy in 10% of men on active surveillance (9). 
Inter-observer variability in Gleason grading is most prominent in distinguishing Gleason score 
6 from 7 (6). Gleason grade 4 encompasses a heterogeneous group of tumor growth pattern, of 
which ill-formed and fused glands are particularly sensitive for interpretation difficulties. Current 
grading guide-lines state that any amount of higher Gleason grade should be incorporated in 
the biopsy Gleason score, implying that even one single atypical glandular structure interpreted 
as Gleason grade 4 would lead to a Gleason score of 7 at biopsy.
As revision did not improve correlation with final pathology, undersampling of most aggressive 
tumor parts remains as main explanation for the discordance between biopsy and final pathol-
ogy. For correct determination of tumor characteristics the focus should thus be on improving 
accurate tumor sampling. Simply increasing the number of biopsy cores taken or the frequency 
with which they are taken might not be the best method, as even with saturation biopsies there 
is substantial undergrading and it does not selectively targets the tumor (10-12). Alternatively, 
methods of targeting biopsies to areas suspicious for higher grade cancer could be a way to 
decrease under sampling. Currently, mRI seems the best option to direct biopsies in men on 
active surveillance (13). At inclusion, men with negative mRI have a very low probability of having 
higher grade tumor (13). Once the absence of higher grade tumor is established, progression 
rates to a higher Gleason while being on active surveillance are estimated to be low (14). The fre-
quency at which men on active surveillance are tested could thus be reduced if initial sampling 
is more accurate. This might help to increase the acceptance and follow-up of men on active 
surveillance as biopsies are considered the most important drawbacks of active surveillance (15).
Secondly we studied if biomarker staining on biopsy tumor tissue could help in improving 
predictions of final pathology. The tested markers were selected as they previously have shown 
to correlate with Gleason score in radical prostatectomy specimens (16, 17). The lack of correla-
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tion of these markers on biopsy with final pathology found in the current study could be related 
to again undersampling. Other than with Gleason grading it could however be theorized that 
biomarkers might still hold their predictive value in the presence of undersampling. Two main 
pathways in which a higher grade tumor is expected to develop are that of an independent ori-
gin (e.g. a Gleason 3+4 tumor develops independent of an already existing Gleason 3+3 tumor) 
or shared origin and progression (e.g. a Gleason 3+4 develops from the already existing Gleason 
3+3 tumor). In the latter case genetic and biochemical changes could occur throughout the 
entire tumor (both Gleason 3 and 4 parts) or in Gleason grade 3 tumor cells that are in the process 
of progression towards a Gleason grade 4 (16). If this is the case, tissue biomarkers might help in 
distinguishing true low grade tumors and tumors with a higher grade. In the current analysis no 
such predictive marker was identified, similar to (18), (only ERG had some discriminative ability, 
albeit not statistically significant and primarily on initial biopsy). Although there are genetic dif-
ferences between Gleason grades most studies studying these differences report an accuracy in 
differentiating Gleason grade 3 from Gleason grade 4 less or equal to 70%, or do not discuss the 
discriminative power (19-22). It seems better markers should still be discovered before they can 
be used to select and follow men on active surveillance.
In the current analysis apart from biopsy Gleason the only statistically (and clinically) significant 
variable predictive for Gleason grade >=7 or >=pT3 on radical prostatectomy was the presence 
of >50% tumor involvement in a single core. This variable is used as an inclusion criteria in some 
active surveillance studies (23). Although it proved to increase predictive capability in our study, 
the discriminative value was not very high (a lot of men with >50% tumor involvement still have 
favorable disease and vice versa). Hence, we feel that % tumor involvement on biopsy is not 
of value in selecting or excluding men for active surveillance. It could however be used to risk 
stratify men for stricter or less strict follow-up during AS.
The current analysis has some limitations. Not all biopsy specimens were available for revision 
and if they were available for revision the remaining biopsy tissue was in some cases too small for 
biomarker analysis. There was however no indication of selective missing of cases. Furthermore, 
radical prostatectomy specimens were not revised. It is likely that concordance between biopsy 
and radical prostatectomy Gleason is higher if scored by a single pathologist, irrespective of the 
fact whether this is the ‘correct’ Gleason score for both.
CONCLUSION
Interobserver differences in both scoring of tumor grade and extend on biopsy could result in a 
change of management strategy in approximately 13-20% of men on active surveillance for pros-
tate cancer. Despite differences when re-grading biopsy specimens there was no improvement 
in correlation with final pathology on radical prostatectomy. This suggests that interobserver 
differences are not an important determinant of discordant tumor characteristics on biopsy and 
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radical prostatectomy specimen. Undersampling of most aggressive tumor remains the main 
focus in order to increase accurate grading at time of treatment decision. Tested tissue biomark-
ers (Ki67, and ERG) were not able to improve prediction of final pathology.
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ABSTRACT
Background: The Prostate cancer Research International Active surveillance (PRIAS) study was 
initiated a decade ago to study the most optimal selection and follow-up of men on active 
surveillance.
Objective: We report on 10 years of follow-up of men on active surveillance in the PRIAS 
study and evaluate if criteria used to recommend a switch to active treatment truly predict 
unfavorable outcome on subsequent radical prostatectomy (RP).
Design, setting, and participants: men with low-risk prostate cancer were included and 
prospectively followed on active surveillance. Follow-up consisted of regular PSA tests, digital 
rectal examinations (DRE) and biopsies. men with Gleason >3+3, >2 biopsy cores positive, or 
>cT2 were advised to switch to active treatment (until 2014 a PSA-doubling time (PSA-DT) of 
0-3 years was used as well).
Outcome measurements and statistical analysis: Reclassification rates, treatment after 
discontinuation, and outcome on RP after discontinuing active surveillance were reported. 
Regression analysis on the outcome of RP was used to evaluate the predictive value of criteria 
currently used to recommend a switch to active treatment. Kaplan meier and competing risk 
analysis were used to report discontinuation rates over time, and long term oncological end-
points.
Results and limitations: A total of 5302 men were included in PRIAS across 18 countries. 
Reclassification rates remained stable on all subsequent biopsies, with 22-33% of men having 
either Gleason >3+3 or >2 cores positive on any repeat biopsy. At 5 and 10 years of follow-up 
52% and 73% of men had discontinued active surveillance, the majority because of protocol 
based reclassification. One third of men undergoing subsequent RP had favorable pathologi-
cal tumor features (Gleason 3+3 and pT2). Of the criteria used to recommend a switch to active 
treatment >2 cores positive and a PSA-DT of 0-3 years were not predictive of unfavorable 
pathological outcome on RP.
Conclusions: A substantial group of men discontinued active surveillance without subse-
quent unfavorable tumor features on RP. We therefore propose Gleason upgrading and cT3 as 
only indicators of an immediate switch to active treatment. Surrogate indicators (such as >2 
cores positive and a fast rising PSA) should not trigger immediate active treatment, but further 
investigation to confirm the suspicion of higher risk disease.
Patient summary: In the current study we confirm the safety of active surveillance as treat-
ment option for men with low-risk prostate cancer. However some changes could be made to 
the follow-up protocol to safely increase the number of men that remain on active surveillance.
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INTRODUCTION
The Prostate cancer Research International Active surveillance (PRIAS) study was initiated a 
decade ago (2006) with the aim of providing evidence-based recommendations on how to 
select and follow men with low risk prostate cancer on active surveillance (1). Other than most 
single (academic) center active surveillance studies, the PRIAS study aims to represent a more 
‘real world’ situation with inclusions from academic, non-academic, and private practices across 
the world greatly increasing the generalizability of the results. Since its introduction the PRIAS 
study developed into the largest prospective active surveillance study worldwide, with at present 
more than 150 participating centers in 18 countries. Data on the first 500 study participants were 
reported in 2010 (2), with an update on 2500 men in 2012 (3).
In this paper we report on more than 5000 men followed on active surveillance in the PRIAS 
study to date, and we specifically evaluate the criteria used to recommend a switch to active 
treatment by assessing their ability to predict outcome on radical prostatectomy (RP) in men 
discontinuing active surveillance.
mETHODS
All centers prospectively enter data on inclusion and follow-up through the PRIAS website (www.
prias-project.org) which automatically provides recommendations on follow-up (1). The original 
criteria for inclusion are Gleason score <=3+3, <=cT2c, PSA <=10ng/ml, <= 2 cores positive 
for prostate cancer, PSA density <=0.2ng/ml/cm3, and fitness for curative treatment. In 2012 
and 2015 inclusion criteria were adapted to include minimal Gleason 3+4, and accommodate 
changes in the number of positive cores caused by mRI targeted biopsies or saturation biopsies 
(all changes made to the study protocol are summarized in table 1). No minimum number of 
biopsy cores is required, but based on prostate volume the following is advised: <40cm3: 8 cores, 
40-60cm3: 10 cores, >60cm3: 12 cores.
In the first two years of follow-up a PSA test is scheduled every 3 months and Digital Rectal 
Examination (DRE) every six months. Thereafter PSA is measured every six months and DRE is 
performed once yearly. Standard repeat biopsy are scheduled 1,4,7, and 10 years after diagnosis, 
and subsequently every 5 years. Yearly biopsies are only recommended if PSA doubling time 
(PSA-DT) is between 0 to 10 years. A bone scan is recommended if PSA >=20 ng/ml.
Criteria used to recommend a switch to active treatment are Gleason >3+3, >2 cores positive, 
and >cT2. A PSA-DT between 0 and 3 years (if at least four PSA values are available) was used to 
recommend immediate active treatment until the end of 2014, but was dropped afterwards due 
to the low number of men complying with this recommendation and the high percentage of 
men receiving unnecessary treatment, as described in a recent publication (4). Criteria used to 
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recommend a switch to active treatment were adapted for those included with Gleason 3+4 and 
>2 cores based on mRI or saturation biopsies (table 1).
more information on the follow-up schedule and a flowchart of the current follow-up protocol 
can be found online (www.prias-project.org). Follow-up for the current analysis ended November 
2015.
STATISTICAL ANALYSIS
Descriptive statistics were used to report baseline characteristics, reclassification rates on 
subsequent biopsies, treatment after discontinuation, and outcome on RP after discontinuing 
active surveillance. Pathological outcome on RP was divided in three categories: favorable pa-
thology (Gleason 3+3 and pT2), intermediate pathology (Gleason 3+4 and pT2), and unfavorable 
pathology (Gleason >= 4+3 or >=pT3), based on a previous analysis and recent reports on low 
metastatic potential of men with Gleason 3+3 organ confined disease on RP (5-7).
Table 1. Changes made and proposed to the PRIAS study protocol.
Year 2012 2015 2015
2016 (Proposed 
in current 
manuscript)
2016 (Proposed 
in current 
manuscript)
Change to Inclusion criteria Inclusion criteria Follow-up criteria Follow-up criteria
Follow-up 
schedule
Change
Gleason 3+4 
(<=10% tumor 
involvement 
per biopsy core, 
maximum 2 cores 
positive) can be 
included if aged 
>=70 years.
(Upgrading 
during follow-up 
is defined as 
Gleason 4+3, all 
other criteria still 
apply)
>2 cores can 
be positive (no 
maximum) if an 
mRI, including 
targeted biopsies 
on positive 
lesions, is done at 
inclusion.
AND
If saturation 
biopsies are done 
(>=20 cores), 15% 
of cores can be 
positive with a 
maximum of 4.
(Upgrading based 
on the positive 
number of 
cores is adapted 
accordingly, all 
other criteria still 
apply)
A PSA-doubling 
time (PSA-DT) 
of 0-3 years is 
removed as 
recommendation 
to switch to active 
treatment. Instead 
yearly biopsy are 
advised as with 
a PSA-DT of 3-10 
years. If mRI is 
available an mRI 
can be performed 
to rule out 
anterior tumors.
>2 cores positive 
should trigger an 
mRI with targeted 
biopsy instead 
of an immediate 
switch to active 
treatment.
PSA testing can 
be reduced to 
once yearly after 4 
years of follow-up
AND
A digital rectal 
examination can 
be performed 
at the time of a 
biopsy only
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multinomial logistic regression analysis was used to evaluate the predictive value of criteria 
used to recommend a switch to active treatment (Gleason >3+3, >2 cores positive, PSA-DT 
between 0 and 3 years) on pathological RP outcome. The predictive value of cT3 could not be as-
sessed due to the low number of men with this characteristic. Corrections were made for clinical 
characteristics at the time of switching to active treatment (age and PSA).
Kaplan meier and competing risk analysis were used to report discontinuation rates over time, 
(prostate cancer) mortality, and a combined endpoint of biochemical recurrence (BCR, defined 
as a PSA >=0.2ng/ml after RP or a PSA level 2.0ng/ml above the nadir after radiotherapy (RT)) or 
local recurrence after active treatment (either RP or RT), metastasis, and prostate cancer death, 
whichever occurred first for all men included.
Analysis were done for all men included and for men fulfilling the original inclusion criteria, 
except for the multinomial analysis which was only done in men fulfilling the original inclusion 
criteria. For analysis SPSS for Windows (version 21.0. Armonk, NY: IBm Corp.) and the survival 
package of R (R Foundation for Statistical Computing, vienna, Austria.) were used.
RESULTS
In total 5302 men were included and prospectively followed on active surveillance in the PRIAS 
study across 18 countries (figure 1, supplements). Out of these men 622 were followed on active 
surveillance for more than 5 years, and 107 for more than 7.5 years. At diagnosis median age was 210 
 
210 
 
Figure 1 (Supplements). Number of inclusion in the PRIAS study per country. 
 
 
  
Figure 1 (Supplements). Number of inclusion in the PRIAS study per country.
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65.9 years, median PSA 5.7 ng/ml, most men had 1 biopsy core positive (69%) with Gleason 3+3 
(99%), and a clinical stage T1c (88%) (table 2). A total of 216 men (4%) did not fully comply with 
the original inclusion criteria (due to the changes in protocol or because the PRIAS website cur-
rently allows ‘off protocol’ inclusions). Sub analyses in men fulfilling the original inclusion criteria 
yielded identical results and are therefore not presented.
During follow-up 3379 men received at least one repeat biopsy, 1077 men two biopsies, 282 
men three biopsies, 68 men four biopsies, and 15 men five biopsies. Reclassification rates remain 
stable on all subsequent biopsies, with 13-16% of men having a Gleason >3+3, 16-27% of men 
having >2 cores positive for prostate cancer, and 22-33% of men having either Gleason >3+3 or 
>2 cores positive (figure 2).
A total of 1768 out of the 5302 men discontinued active surveillance until the end of follow-up. 
The majority (n=1102) because of protocol based reclassification. Treatment after discontinuation 
Table 2. Characteristics at diagnosis of all men included in the PRIAS study.
Median (IQR)/N (%)
Age, years 65.9 (61.0-70.4)
PSA, ng/ml 5.7 (4.5-7.1)
Prostate volume, cm3 45 (35-59)
PSA density, ng/ml/ cm3 0.13 (0.09-0.16)
Number of biopsy cores 12 (10-12)
Number of cores positive
1 3643 (69%)
2 1615 (30%)
>=3 44 (1%)
Gleason
3+3 5271 (99%)
3+4 31 (1%)
T-stage
cT1c 4649 (88%)
cT2a 579 (11%)
cT2b 54 (1%)
cT2c 20 (<1%)
Charlson score
0 3745 (71%)
1 264 (5%)
2 734 (14%)
>=3 559 (11%)
Total 5302 (100%)
IqR = interquartile range
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was RP or RT in 67% of men and only 3% received hormonal therapy (HT) as primary treatment 
(table 3). There were no differences in tumor characteristics (PSA, PSA-DT, Gleason, and number 
of positive cores on last biopsy) between men switching to RP or RT, but the latter had a 2 year 
higher median age at the time of discontinuation (67 vs 69 years, respectively, p <0.001).
211 
 
211 
 
Figure 2. Reclassification rates on subsequent repeat biopsies (Pbx) during follow-up. 
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Figure 2. Reclassification rates on subsequent repeat biopsies (Pbx) during follow-up.
Table 3. Discontinuation and treatment after discontinuation.
RP RT HT WW Other Unknown Died/Lost 
to FU
Total
Non-protocol based
Anxiety/Patient request 52
(29%)
32
(18%)
2
(1%)
- 2
(1%)
89
(50%)
- 177
(100%)
Other/Unknown 108
(45%)
78
(32%)
2
(1%)
- 27
(11%)
27
(11%)
- 242
(100%)
Switch to WW - - - 134
(100%)
- - - 134
(100%)
Died - - - - - - 57
(100%)
57
(100%)
Lost to FU - - - - - - 56
(100%)
56
(100%)
Protocol based* 496
(45%)
419
(38%)
29
(3%)
30
(3%)
30
(3%)
98
(9%)
- 1102
(100%)
Total 656
(37%)
529
(30%)
33
(2%)
164
(9%)
59
(3%)
214
(12%)
113
(6%)
1768
(100%)
* Gleason >3+3, >2 cores positive, >cT2, or PSA-DT 0-3 years. RP = radical prostatectomy, RT = radiotherapy, HT 
= hormonal therapy, WW = watchful waiting, FU = follow-up.
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After 5 and 10 years of follow-up 48% and 27% of men were still on active surveillance, 34% and 
41% discontinued because of protocol based reclassification, 5% and 5% discontinued due to 
anxiety/patient request (without having reclassification, anxiety and patient request were equally 
distributed), 5% and 15% switched to watchful waiting (WW) or died of other cause (without 
having reclassification), and 8% and 12% discontinued due to other reasons (without having 
reclassification) (figure 3).
Pathology data for 360 men receiving RP after discontinuing active surveillance were available 
for analysis. For men who switched to RP due to anxiety, 13 (57%) had a favorable pathological 
outcome, 6 (26%) had an intermediate pathological outcome, and 4 (17%) had an unfavorable 
pathological outcome. For men who switched to RP because of protocol based reclassification, 
82 (30%) had favorable pathological outcome, 85 (34%) intermediate pathological outcome, 
and 100 (36%) unfavorable pathological outcome. pT3a, pT3b, pT4, Gleason >=8, and N1 was 
found in 61,13,2,14, and 1 men (out of 119 men receiving a lymph node dissection) respectively. 
Large differences in distribution of outcomes were observed between different protocol based 
reasons to discontinue active surveillance (table 4). On regression analysis only Gleason score >6 
on last biopsy was a statistically significant predictor of intermediate or unfavorable pathological 
outcome on RP (table 5).
Table 4. Outcome on radical prostatectomy after discontinuing active surveillance.
Favorable
(Gleason 3+3 
and pT2)
Intermediate
(Gleason 3+4 and 
pT2)
Unfavorable
(Gleason >=4+3 
or >=pT3)
Total
Non-protocol based
Anxiety/Patient request 13 (57%) 6 (26%) 4 (17%) 23 (100%)
Other/Unknown 28 (47%) 12 (20%) 20 (33%) 60 (100%)
Protocol based
(1) Only Gleason >3+3
Gleason 3+4 7 (27%) 15 (58%) 4 (15%) 26 (100%)
Gleason >=4+3 1 (7%) 3 (21%) 10 (71%) 14 (100%)
(2) Only >2 cores positive 28 (41%) 22 (32%) 18 (26%) 68 (100%)
(3) Only PSA-DT 0-3 years 24 (46%) 9 (17%) 19 (37%) 52 (100%)
(4) Only cT3 1 (50%) - 1 (50%) 2 (100%)
Combination 1+2 1 (2%) 28 (55%) 22 (43%) 51 (100%)
Combination 1+3 2 (18%) 3 (27%) 6 (55%) 11 (100%)
Combination 2+3 16 (50%) 6 (19%) 10 (31%) 32 (100%)
Combination 1+2+3 2 (10%) 9 (43%) 10 (48%) 21 (100%)
Total 123 (34%) 113 (31%) 124 (34%) 360 (100%)
PSA-DT = PSA doubling time
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Until the end of follow-up out of all men included 30 men had biochemical recurrence (BCR) 
after active treatment (either RP or RT), 10 men had local recurrence, 8 developed metastasis, and 
1 died of prostate cancer, resulting in 98% and 94% of all men included to be free of BCR, local 
recurrence, metastasis, and prostate cancer death 5 and 10 years after diagnosis (figure 4, supple-
ments). Other cause mortality and disease specific mortality for all men included were 3% and 
<1% 5 years after diagnosis, and 11% and <1% 10 years after diagnosis (figure 5, supplements).
Table 5. Predictors of intermediate (Gleason 3+4 and pT2) and unfavorable outcome (Gleason >=4+3 or >=pT3) 
on radical prostatectomy (only men fulfilling the original inclusion criteria were included, n=347)
Intermediate Unfavorable
OR (95% CI) p-value OR (95% CI) p-value
Age at discontinuation, years 1.04 (0.99-1.09) .136 1.04 (0.99-1.09) .101
Last PSA, ng/ml 0.93 (0.85-1.03) .146 1.00 (0.91-1.09) .925
PSA-DT 0-3 years 0.71 (0.37-1.38) .312 1.44 (0.79-2.63) .230
Number of positive cores >2 on last 
biopsy 1.50 (0.83-2.70) .183 1.37 (0.78-2.43) .274
Gleason >6 on last biopsy 7.44 (3.68-15.06) <0.001 6.12 (3.04-12.32) <0.001
OR= odds ratio; CI= confidence interval; PSA-DT = PSA doubling time
OR as compared to favorable RP outcome213 
 
213 
 
Figure 4 (Supplements). Time since diagnosis free of biochemical recurrence (BCR), local recurrence, metastasis, or prostate cancer 
death for all men included in PRIAS.  
  
Figure 4 (Supplements). Time since diagnosis free of biochemical recurrence (BCR), local recurrence, metasta-
sis, or prostate cancer death for all men included in PRIAS.
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DISCUSSION
Active surveillance aims to reduce overtreatment of tumors that are very unlikely to cause 
symptoms if left untreated. Nevertheless, the possibility remains that tumors with initial low-risk 
features will turn out not to be indolent and develop into lethal disease. Active surveillance is 
supposed to selectively filter out these men as soon as possible while avoiding invasive treat-
ment in the majority that prove to be truly indolent. The first part of the aim of active surveillance 
seems partially fulfilled. In the Toronto and Johns Hopkins cohort of men on active surveillance 
very low prostate cancer mortality and metastasis rates were observed, comparable to those 
after more invasive treatment (RP and RT) (8, 9). Although only few men were followed for more 
than 10 years in the current analysis, results support the safety of active surveillance. Prostate 
cancer mortality was <1% and a combined end-point of adverse outcome (BCR, local recurrence, 
metastasis, or prostate cancer death) was observed in only 6% of men 10 years from diagnosis.
However, in the current analysis we found only 50% of men to still be on active surveillance 
after 5 years of follow-up and approximately only 25% after 10 years of follow-up, lower than re-
ported by other active surveillance studies (8-10). Some of these differences could be explained 
by the setup of the PRIAS study which is not a strictly controlled single academic center study, 
but instead tries to represent a real world situation (e.g. resulting in more men switching to active 
treatment without a clear protocol based reason or more men switching to WW). However even 
if accounting for the 15% of men stopping active surveillance because of a switch to WW or other 
cause mortality, a substantial part of men (60% of the initial cohort) received a form of active 
treatment after 10 years of follow-up. This, together with the observation that one third of men 
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Figure 5 (Supplements). Overall and prostate cancer specific mortality since diagnosis for all men included in the PRIAS study. 
 
  Figure 5 (Supplements). Overall and prostate cancer specific mortality since diagnosis for all men included in 
the PRIAS study.
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still had a favorable pathological outcome on RP, indicates that the criteria used to recommend 
a switch to active treatment are far from optimal. On regression analysis the only statistically 
significant predictor of intermediate or unfavorable pathological outcome on RP was a Gleason 
score >6 on last biopsy. In men who switched to RP due to > 2 cores positive on last biopsy and 
in men with a PSA-DT of 0-3 years the rates having favorable pathological outcome were close 
to 50%, although the rates of unfavorable pathological outcome were higher than in men who 
switched to active treatment without a protocol based recommendation. Both these protocol 
based indications thus seem to increase the risk of unfavorable pathological outcome, but are 
not specific enough to trigger an immediate switch to active treatment. Importantly, PSA-DT 
0-3 and >2 cores positive with prostate cancer together are responsible for more than 50% of all 
recommendations to switch to active treatment.
To achieve a higher rate of men who continue active surveillance while selectively identifying 
those with unfavorable disease, we propose a change of protocol for the PRIAS study. Instead 
of an immediate switch to active treatment if >2 cores are positive, men should receive further 
investigation to confirm higher risk disease. As mRI is shown to have a negative predictive value 
for Gleason upgrading very close to 100% in men on active surveillance (11-13), it currently 
seems the best method to exclude the presence of a higher Gleason score. If the mRI is negative 
active surveillance can thus be continued, if a lesion is present targeted biopsies should confirm 
Gleason upgrading before a switch to active treatment is advised. mRI with targeted biopsies in 
men with increased risk is expected to detect the majority of men with truly unfavorable tumor 
characteristics (11, 14). This modification is in line with the recently changed recommendation in 
men with a PSA-DT of 0-3 years and with the changed inclusion criteria which allow inclusion of 
any number of positive cores if an mRI with targeted biopsies is done (4). Gleason >6 and cT3 will 
thus remain the only indicators for an immediate switch to active treatment. It is estimated, based 
on the data in this article, that because of the suggested protocol change instead of 43/100 men, 
64/100 men could have stayed on active surveillance after 3 repeat biopsies.
In the (near) future mRI might even be able to replace systematic repeat biopsies altogether. 
Systematic biopsies currently appears one of the largest burdens for men on active surveillance 
(4, 15, 16), and in fact are redundant in three quarters of men as they do not show reclassification 
(figure 2). But, before we can definitively adopt such a change we must collect enough data on 
men with a negative mRI who simultaneously received systematic biopsies. We therefore plea 
for increased inclusion of men in e.g. the PRIAS mRI side study (www.prias-project.org) to further 
establish the negative predictive value of mRI in men on active surveillance. If confirmed, many 
systematic biopsies can be replaced by less invasive imaging.
Some changes to the number and frequency of follow-up visits remain to be discussed. PSA 
testing is done regularly and used to calculate PSA-DT (used to recommend more frequent 
biopsies) and a bone scan (if PSA >20ng/ml). We previously showed data from the PRIAS study 
indicating that after 4 years of follow-up both a change in PSA-DT triggering a biopsy and an 
absolute PSA >20 occurred very infrequently (17). Furthermore, clinical utility was low (all bone 
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scans were negative and biopsies were only advanced by six months). It was concluded that PSA 
testing can be reduced to once yearly after 4 years of follow-up.
It is sometimes suggested to use an absolute PSA value (e.g. >20ng/ml) to recommend a 
switch to active treatment. The PRIAS study did not include such a recommendation as it was felt 
that once included with a PSA <=10ng/ml the PSA value could only rise slowly (in which case 
BPH might be a more likely cause) or fast but then PSA-DT would trigger further investigation 
with biopsies to exclude rapid tumor development as its cause. The analysis presented in table 
5 confirms that this initial assumption is now justified as the absolute PSA value does not show 
a positive correlation with RP outcome within the current follow-up protocol which includes 
regular repeat biopsies and additional biopsies in the case of fast rising PSA. We therefore do not 
recommend an absolute PSA cut-off to discontinue active surveillance.
As reclassification on DRE only occurred in 10 men (<1% of all reclassifications) one could 
argue to reduce the number of DRE’s as well, e.g. only perform a DRE at the time of a biopsy, 
although the potential benefit of reducing this relative inexpensive and easy to perform test 
could be questioned. The largest benefit should come from individualizing the frequency of 
repeat biopsies (or in the future possibly mRI’s). Currently we individualize the biopsy frequency 
only based on the PSA-DT. Several other predictors of reclassification were however specified 
(e.g. PSA density, the number of positive biopsy cores, and time since last biopsy) (3, 4, 18, 19). 
Risk prediction models were already developed and should be validated and updated in several 
cohorts to prolong the time to next biopsy in men with low risk of reclassification and increase 
the frequency in men with high risk (19). In the future these models can be supplemented by 
newly validated marker predictive of outcome (20).
Such models can also be used to assist in the timing of when to stop active surveillance and 
switch to WW. Simultaneous predictions on life expectancy and time until symptoms from a low-
risk tumor left untreated are needed. This is one of the topics of the movember-GAP3 project (21), 
which combines the majority of the worldwide available active surveillance cohorts, including 
the PRIAS study.
Criticisms of the current analysis are that follow-up data of men who discontinued active 
surveillance, including outcome of RP, was missing in several cases. Although limiting the power 
of some of the analyses, there was no indication of selective reporting, which could have affected 
the results (men with and without RP data available did not differ in terms of age, PSA, PSA-DT, 
Gleason, and number of positive cores on last biopsy).
CONCLUSION
After a decade of active surveillance in the PRIAS study criteria used to recommend a switch to 
active treatment seem not selective enough to avoid unnecessary switches to active treatment. 
A substantial proportion of men abandoning active surveillance based on a protocol advice do 
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not have unfavorable features after RP. We therefore propose Gleason score upgrading or cT3 on 
rectal examination as the only reasons for a direct switch to active treatment. Other factors, such 
as >2 biopsy cores positive and fast rising PSA, should first trigger further investigation to confirm 
the suspicion of higher risk disease.
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This thesis set out to provide further in-depth information on prostate cancer screening and 
active surveillance by addressing two main questions: “What are the mechanisms that lead to 
the observed reduction in prostate cancer mortality?” (part 1, screening) and “Are we able to 
selectively identify men with aggressive disease?” (part 2, active surveillance). To address these 
two main questions several sub-questions were studied.
PART 1, SCREENING
- What type of prostate cancers are detected and at what time during the screening process? (Chap-
ter 1)
Cancer detection rates remained stable in men without a previous biopsy throughout the course 
of the screening program, but the majority of high risk cancers were detected in the first screen-
ing round. Underlying the stable cancer detection rate was the detection of cancers in men who 
at the previous screening had PSA values below the biopsy cut-off. men with a previous negative 
biopsy only accounted for a small proportion of the cancers detected at repeat screenings, which, 
supported by an on average larger prostate volume, suggests that the prolonged elevation of the 
PSA level in these men is most likely not caused by prostate cancer.
- What is the effect of contamination and noncompliance on the observed prostate cancer 
mortality reduction? (Chapter 2)
Especially contamination (unwanted screening) in the control arm of the European screening 
study had a large diluting effect on the mortality reduction observed. This indicates that the ef-
fect of screening on an individual’s risk of dying from prostate cancer is (substantially) larger than 
recorded for the entire study population. As non-compliance was low its effect on the observed 
mortality reduction was small.
- What is the effect of treatment on the observed prostate cancer mortality reduction in the 
European screening study? (Chapter 3 and 4)
Due to later detection in time, tumors in the control arm were able to benefit from progressing 
insight in how best to treat prostate cancer (chapter 3). The overall effect of treatment differences 
on the observed prostate cancer mortality reduction outcome was however small (chapter 4).
- Where does the benefit of prostate cancer screening originate from? (Chapter 1 to 4)
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The benefit, in terms of prostate cancer mortality reduction, seemed to originate from all screen-
ing rounds (chapter 1), by an absolute reduction of metastatic disease at diagnosis (i.e. a stage 
shift: chapter 4). Treatment differences had little effect on the observed benefit (chapter 3 and 4), 
but to better estimate the mortality reduction for an individual a correction should be made for 
contamination and noncompliance, as both dilute the overall effect observed (chapter 2).
In conclusion from part 1 we can say that screening works through early detection (stage shift) 
and subsequent adequate treatment.
PART 2, ACTIvE SURvEILLANCE
- Are we able to selectively identify men with aggressive disease using risk based selection at inclu-
sion? (Chapter 5)
Risk based selection of potential candidates for active surveillance, as opposed to rule based 
selection, helps them to make a more conscious and personal treatment choice by providing 
individualized risk estimates. However, as with rule based selection, distinction between aggres-
sive and non-aggressive disease is not perfect yet. Advances should be made to improve the 
information available for risk-based selection, including forthcoming biomarkers and imaging 
procedures.
- Are we able to selectively identify men with aggressive disease using information coming from 
pathology and biomarkers? (Chapter 8)
The immunohistochemical biomarkers that were tested (Ki67, ERG, and P27), and reevaluation of 
biopsy pathology report, were not able to improve the initial evaluation of disease aggressive-
ness based on standard used parameters. Undersampling of most aggressive tumor fragments 
seems the limiting factor that should be focused on first.
- Is prostate biopsy the best method to detect aggressive disease, i.e. what are its drawbacks? (Chap-
ter 6 and 7)
Prostate biopsies result in complications in a substantial part of men (chapter 7) and form a 
substantial burden in men on active surveillance. This might very well be the reason that many 
recommended biopsies during follow-up are ignored (chapter 6). Furthermore, many currently 
indicated biopsies do not lead to disease reclassification and might thus be avoidable.
- Should we change the current follow-up protocol for men on active surveillance? (Chapter 9)
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After a decade of active surveillance the results of the PRIAS study underline its safety. However, a 
substantial number of men switch to active treatment without subsequently showing aggressive 
disease on final pathology. The follow-up protocol should thus be adapted to reduce the number 
of men that unnecessarily switch to active treatment.
In conclusion, it is possible currently to selectively identify men without aggressive disease 
for active surveillance. This results in very low rates of disease-specific mortality. However, cur-
rent protocols are not selective enough. Especially during follow-up they result in a substantial 
number of men still being overtreated. Some improvements to more (and better) individualized 
protocols can already be made, but further research is definitively needed.
The findings of all previous chapters will be discussed in more detail in the following section.
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SCREENING (HOW DOES SCREENING RESULT IN A mORTALITY REDUCTION?)
Screening for prostate cancer results in a reduction of prostate cancer specific mortality [1]. 
However, the underlying mechanism is not completely clear. Furthermore, although PSA based 
screening for prostate cancer is effective, it is far from optimal. mortality reduction is in the order 
of 20% (i.e. 80% of prostate cancer deaths are not avoided) and there are substantial side effects. 
Thus, optimizing screening is key, both for men who already choose to be screened and those 
who want screening but at the moment opt out due to the suboptimal balance between harms 
and benefits. So, it is crucial to understand what factors influence the way screening works and 
how can we use this information to optimize screening.
EXTERNAL FACTORS THAT AFFECT HOW SCREENING WORKS
External factors do not result from the working of the screening algorithm itself, but originate e.g. 
from issues in its practical implementation or from other factors that could influence the course 
of the tumor. In order to provide clear information on the results of screening if performed under 
optimal conditions these external factors should be corrected for.
Noncompliance
The first external factor studied in this thesis is noncompliance to the screening protocol (chapter 
2). In a randomized screening study (with a intervention and control arm) there can be two types 
of noncompliance. The first (contamination) is if men in the control arm receive the intervention 
under study (in this case screening), which will dilute the observed effects (both positive and 
negative) of the trial. As discussed in chapter 2 correction for contamination had a substantial 
effect on the measured outcome of screening (from a 32% mortality reduction as calculated by 
the intention to treat analysis up to 47% after correction for contamination). This information 
is relevant for an individual deciding on screening. Although the negative effects of screening 
(namely overdiagnosis) are diluted as well, the relative effect of the correction on prostate cancer 
mortality is slightly larger than the relative effect on overdiagnosis (calculated from table 4 and 
figure 2, chapter 2), meaning that there is no decrease in the harms to benefits ratio. Other than 
providing more accurate information on the effect of screening for an individual, contamination 
does not need to be addressed in daily practice as there is no control arm to consider.
The second form of noncompliance is nonattendance in the screening arm. Nonattendance 
as defined in chapter 2 (nonattendance to all screening rounds) was relatively small, as was its 
effect on mortality (from a 32% mortality reduction to 33%). The low nonattendance observed in 
chapter 2 might be a result of the study setup as only men providing upfront consent (and thus 
willing to undergo screening) were randomized. Nonattendance in the general population is 
likely higher. However, for those willing to undergo screening the observed, low, nonattendance 
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has some implications. First, it implies that the screening algorithm itself is not too demanding 
on the participant (i.e. if nobody attended one could question if the screening algorithm itself 
might be the cause). Secondly as nonattendance seems limited to a specific group of men with 
above average comorbidity it might not be a large problem in daily practice as the effect on 
mortality for men with short life expectancy (generally <10 years) is considered to be limited [2]. 
The impact of nonattendance in an organized screening program selected by an individual is 
thus low and predicted effects will closely resemble the effects in real life.
These properties of an organized screening program might not be transferable to an unorga-
nized screening program (opportunistic screening), thus making predictions on its effect far more 
difficult. There is evidence that suggests that in an unorganized screening setting the benefits 
(reduced mortality) are smaller while the harms (overdiagnosis) are larger [3]. In a sense this is 
logical. Evidence on how best to screen can merely come from scientific studies. Per definition 
the only means of performing better than the best available evidence is by pure coincidence 
(there might be a system behind the ‘coincidence’ in which case new evidence can be synthe-
sized, but this can only be proven better after a process of empirical validation). As unorganized 
screening is often not strictly according to best protocol as provided by the evidence [3-6], it can 
at best be equally good. This pleas for an organized screening program once screening is elected 
by an individual, to maximize the benefits and minimize the harms.
Treatment
Treatment is essential for screening to be effective. After all if screening would not subsequently 
be followed by treatment it would simply advance diagnosis but not delay death. Screening is 
based on the principle that treatment is more effective if the tumor is diagnosed at an earlier 
stage. Taken to the extreme, if there is a treatment for metastasized prostate cancer that would 
cure in 100% of cases, the screening algorithm itself would not necessarily be ineffective, but it 
would be rather abundant as, compared to no screening, there would be no additional benefit. 
Subsequently, if improvements are made in the treatment of earlier stage prostate cancer, the 
observed effect of screening would also become larger.
In chapter 3 and 4 of this thesis we questioned whether there were differences in treatment 
between the two arms of the screening study and whether this affected the outcome of screen-
ing as observed in the screening trial. Two key observations were made. First, there was an 
improvement in treatment in the control arm of the study (chapter 3), most likely resulting from 
progressive insight in how best to treat prostate cancer over time. Second, despite these differ-
ences and differences in the treatment modality itself between the screening and control arm, 
the effect of treatment on the observed benefit of screening was estimated to be very low (<10% 
of changes in prostate cancer mortality)(chapter 4). Thus, changes in treatment which occurred 
during the course of the screening study (and are reflected by differences in treatment between 
the arms) are currently not a major determinant for the positive effect of screening in real life.
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Interestingly the studies in chapter 3 and 4 also provided us with information on how the 
actual screening process affects disease specific mortality. This obviously warrants further discus-
sion, but before doing so some other internal factors that underlie the mechanisms of mortality 
reduction through screening will be discussed.
INTERNAL FACTORS THAT DETERmINE HOW SCREENING WORKS
Internal factors control the effect of the screening algorithm itself. By determining which factors 
are most influential, efforts could be focused on improving these factors to maximize the return 
on resource and energy spent.
Screening is based on the assumption that treatment is more effective if applied at an earlier 
stage. This makes the effect of screening not only dependent on treatment but also on the natural 
development of prostate cancer (i.e. the ‘stages’ it runs through, and at which it can be detected). 
Three models of the natural history of cancer are commonly considered [7, 8]. The first describes 
the natural history as a stepwise process with the cancer originating from one point within the 
organ, always progressing through distinct steps before distant systemic spread (A). The second 
assumes the disease not to go through distinct steps but to be systemic directly (or at least 
at the time it is detectable with currently available diagnostic tools)(B). The last considers the 
likelihood of systemic spread (i.e. metastasis) as a direct function of tumor size, with a constant 
tumor growth rate (C). Although these models seem to be very distinct representations of how a 
tumor matures, they can all be considered variances of a continuous spectrum describing tumor 
development an progression, and describing the effect of intervening (detection and treatment) 
in this process. This is illustrated in figure 1a. On the x-axis the time from tumor development until 
death is plotted, on the y-axis the average time (or probability) death can be delayed by interven-
tion (diagnosis and treatment). In the graph the last model is represented by line C (systematic 
spread as continues function of time), the second to last by line B (immediate systematic spread), 
and the first model by line A (in this case with two distinct steps through which the tumor pro-
gresses). But essentially any line connecting the beginning and the end is a possible representa-
tion of how tumor development interacts with intervention. As described above treatment will 
affect these lines, so for further discussion on internal factors we assume it to be a constant (as 
the effect of treatment differences was small this is at the moment a reasonable representation 
of real life). Two internal parameters of screening determine where screening interacts in this 
figure of tumor development; timing of screening (starting time and frequency), and the method 
used for early detection. The latter limits how close to the point of tumor origin screening can 
interact, starting time and frequency where screening is likely to interact between this limit and 
prostate cancer death (figure 1b). As any line, or combination of lines, (representing a different 
tumor model) can be considered possible, we first need to estimate which percentage of all 
tumors are likely to have progressed to a state where little benefit of diagnosis and treatment 
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can be expected before they can be picked up with current detection methods. This group of 
tumors will only benefit from screening if we change the method of detection to pick them out 
at an even earlier stage. (In the following section this group will be named group B (figure 1c)).
Method of detection
As screening is proven to reduce mortality we can say that men in whom prostate cancer death 
is avoided by screening do not belong to group B. Taken the most intensive screening program 
tested (ERSPC Sweden [3, 9]), and maximum correction for noncompliance (chapter 2), this 
percentage can be estimated at 35%-51% of all prostate cancer deaths in absence of screening. 
question is then which percentage of men remaining (49%-61%) do belong to group B? The cur-
rent detection method of screening is based on identification by PSA (>3 ng/ml) and subsequent 
diagnosis by biopsy. Starting with PSA, every men who died of prostate cancer while diagnosed 
and treated with a PSA <3 ng/ml can be considered part of group B. In the screening arm of the 
ERSPC Rotterdam this were 4 men (data not shown), 2% of expected prostate cancer deaths in 
absence of screening at the time. (Even if men with a PSA of up to 6 ng/ml were considered 
(these men might still be ‘incurable’ if detected with half their PSA) the percentage would still 
be 10%.) Based on these data and having used PSA as method of detection, group B can be 
estimated to be relatively small. It must be noted that this is a rough estimation, based on strong 
assumptions. A study to directly test this estimate would however be very difficult to conduct. 
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Figure 1a. The effect of detection and treatment on prostate cancer specific survival during the 
natural development of prostate cancer. Three examples (lines A through C) are given of 
possible tumor pro ression. 
 
*On the y-axis ‘average time prostate cancer death is delayed’ is interchangeable with 
‘probability prostate cancer death is delayed’/’percentage of men in which prostate cancer is 
delayed’.    
Figure 1a. The effect of detection and treatment on prostate cancer specific survival during the natural devel-
opment of prostate cancer. Three examples (lines A through C) are given of possible tumor progression.
*On the y-axis ‘average time prostate cancer death is delayed’ is interchangeable with ‘probability prostate can-
cer death is delayed’/’percentage of men in which prostate cancer is delayed’.
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GOne could frequently test PSA from a very young age and remove every prostate if PSA rose above 3 ng/ml: the remaining prostate cancer deaths are group B.
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Figure 1b. Two parameters of screening (method of detection and timing of screening) that 
determine where screening is likely to interact during tumor development.  
  
Figure 1b. Two parameters of screening (method of detection and timing of screening) that determine where 
screening is likely to interact during tumor development.
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Figure 1c. Group B is defined as the percentage of men that do not benefit any more once they 
are detectable.  
  
Figure 1c. Group B is defined as the percentage of men that do not benefit any more once they are detectable.
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The second part of early prostate cancer detection is diagnosis by systematic biopsy, which is 
known to miss cancer in some cases [10]. In chapter 1 we observed however that only a small 
proportion of cancers were detected after a previous negative biopsy (12% of high grade can-
cers). The majority of men were diagnosed on first biopsy. This was either in the first screening 
round in men with often higher PSA values, or in men with PSA rising above the biopsy threshold 
for the first time in subsequent screening rounds. A previous study concluded that <10% of 
observed prostate cancer deaths in the screening arm of the ERSPC Rotterdam at the time were 
in men with a previous negative biopsy and were thus potentially missed on first biopsy [11]. 
Taken together with the percentage of men missed by a PSA cut-off of 3 ng/ml, up to 12% of men 
can be considered to belong to group B. These men can potentially only benefit from screening if 
changes are made to the method of detection. The benefit of simply lowering the PSA threshold 
or increasing the biopsy intensity will however likely be disproportional to the additional harms. 
Focusing on group B will thus only be worthwhile if substantial improvements are made to the 
methods of detection.
The remaining men not belonging to group B (37%-49%) will benefit from changes in starting 
time and frequency of screening as this increases the likelihood of earlier intervention. So what is 
the most optimal timing of screening?
Timing of screening
A substantial part of men with cancer were diagnosed in the first screening round (chapter 1). If 
specifically looked at those men that have died of prostate cancer within the available follow-up 
time, >50% were diagnosed in the first screening round [12]. This suggests that for some men 
screening simply started too late. In the ERSPC Rotterdam the age that screening started was 
between 55 and 74 years [13]. To test whether the starting age should be even younger than 55 
we analyze data of the 55-59 year age group at the start of the screening trial and estimated the 
percentage of men (out of all prostate cancer deaths) that were already ‘beyond cure’ at that time 
[14]. This percentage turned out to be relatively low (<10%-20%), implying 55-59 is a reasonable 
starting age in order to maximize benefit (the percentage of men ‘beyond cure’ for the age group 
60-64, 65-69, and 70-74 are estimated using the same method at 16%-29%, 31%-64%, and 49%-
70% respectively (data not shown)). Obviously the age limit at time of inclusion in ERSPC limits 
further analyses but one could argue that of the <10%-20% with potential benefit of starting 
before the age of 55 a relatively large part will belong to group B (aggressive growing tumors 
with quick systemic spread), the effect of starting earlier will then become increasingly smaller. 
Given a starting age we can focus on what the subsequent ideal frequency of testing should be.
The frequency chosen for PSA testing and biopsy in the ERSPC Rotterdam was 4 years ending 
if aged 75 or above. As the frequency of testing in the Swedish part of the ERSPC was 2 years, 
both algorithms could be directly compared [15]. Based on these data it was concluded that 
doubling the testing frequency indeed resulted in a stage shift with less advance (40% reduc-
tion) and more early cancers detected. Unfortunately this cannot directly be translated into the 
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proportion of prostate cancer deaths averted. A rough estimation based simply on the difference 
in mortality reduction indicates approximately up to 10% of all prostate cancer deaths benefit 
from a doubling in testing frequency from 4 to 2 years [13, 16]. Whether a further reduction of 
time between screens would result in a similar reduction of prostate cancer deaths is dependent 
on the average natural course. If the average course tends more towards line C (linear model) in 
figure 1 an equal reduction in mortality can be expected for every equal reduction in screening 
interval. If the average course tends more towards line A (stepwise model) in figure 1 with similar 
times to sharp decreases in benefit, there might be an optimal screening interval. So can we 
make a better estimation on the average natural course of the cancers detected by screening?
The natural course of prostate cancers detected by screening
In chapter 3, figure 1 (reprinted here as figure 2), we illustrated a model of how screening could 
result in mortality reduction. The figure is in fact similar to figure 1, but only depicts a stepwise 
tumor model with the most important steps being represented by distinct clinical characteristics 
(defined as low-risk, intermediate-risk, high-risk, and metastatic disease). A comparison was made 
in disease free survival (defined as no evidence of recurrent disease after treatment with cura-
tive intent) between these groups (arrow 1, figure 2), but also within the groups themselves by 
comparing the control arm and screening arm (arrow 2, figure 2). Where in the latter comparison 
the difference between arms represent a difference in time of detection within a specific group. 
Based on the data it could be concluded that there was indeed an indication for a more stepwise 
model (instead of a linear model), as the difference in disease free survival between groups was 
much larger than that within groups but with earlier detection. This is supported by the results 
of the study described in chapter 4. Here we specifically looked at the effect on prostate cancer 
mortality of changes in stage of detection. It was concluded that changes in the stage of detec-
tion almost completely (94%) account for the changes seen in prostate cancer mortality. most 
prostate cancer deaths avoided by the current screening algorithm thus seem to tend towards a 
stepwise development (if this also accounts for the men that were not saved by screening cannot 
be inferred directly).
If screening works by shifting the stage at which the cancer is detected it would be interesting 
to known if every shift in stage is equally important in terms of the benefit on survival. If e.g. a 
shift from the metastatic group to the high risk group provides the largest improvement we 
could focus on detecting cancers in the high risk stage. If every step contributes equally then 
the most benefit is obtained by detecting the cancer in the earliest stage (in this case as low risk) 
and focusing on detection in higher stages would result in an subsequent decrease in benefit. 
It is unfortunately not possible to directly observe which prostate cancer deaths are prevented 
by screening and at which stage they are diagnosed and would have been diagnosed if not 
screened. But, there are indirect signs that provide some information on their origin, some of 
which can be found in figure 3A, chapter 4 (reprinted here as figure 3).
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To explain the origin of this evidence consider the following example (depicted in figure 4a-c): 
Suppose there are two distinct stages in which cancers can be diagnosed, called m- and m+, with 
cancers always progressing from the first to the last. In the absence of screening 200 men would 
be diagnosed with cancer, 100 as m- and 100 as m+, and 60 would die as a result, 10 diagnosed 
as m- and 50 diagnosed as m+ (figure 4a). Now we introduce an early detection program, but do 
not subsequently treat the men that are detected earlier (the absolute number of prostate cancer 
deaths thus remains similar). As a result 50 men (25 of which died of prostate cancer) previously 
diagnosed as m+ are now diagnosed as m- (figure 4b). Finally we also decide to immediately treat 
men who were diagnosed at an earlier stage and as a result 20 of the 25 men who previously died 
of prostate cancer (but shifted from the m+ group to the m- group) do not so any more (figure 
4c). Suppose we were only in the possession of the data in figure 4a and 4c of the example, can 
we then still work out that exactly 20 men were ‘saved’ by early detection in the m- instead of m+ 
group? The answer is yes, if we assume that stage shift with subsequent early treatment is the 
only method to do so (notice that the increase in deaths in the m- group is an indirect indication 
of deaths being prevented by shifting to that group). This is off course a simplified example. 
Directly applying its principles to real life (figure 3) is not as straight forward. (Additional factors 
should be accounted for and further assumptions should be made to make a realistic estimation 
on the risk group in which men ‘saved’ by prostate cancer screening were diagnosed.) But looking 
at figure 3 it can already be seen that the largest increase in mortality in the screening arm was 
in the low risk group, indicating that at least some of the prostate cancer deaths prevented were 
diagnosed at this stage.
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Figure 2. Model on how screening could result in better outcome (adapted from figure 1, 
chapter 3) 
 
1: Screening could result in a stage shift, resulting in better prognosis. 
2: If screening did not result in a clinical apparent stage shift, earlier diagnosis and treatment in 
time could still have resulted in a better prognosis, for instance because of less time for the 
tumor to develop outside the prostate.   
 
 
  
Figure 2. model n how scree ing could result in be ter outcom  (adapted from figure 1, chapter 3)
1: Screening could result in a stage shift, resulting in better prognosis.
2: If screening did not result in a clinical apparent stage shift, earlier diagnosis and treatment in time could 
s ll have resulted in a better prognosis, for instance because of less time for the tumor to develop outside the 
prostate.
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HOW TO USE THIS INFORmATION TO OPTImIZE SCREENING ALGORITHmS IN 
THE FUTURE?
One of the biggest challenges in prostate cancer screening today is to decrease its harms. The 
most important harms being overdiagnosis and subsequent overtreatment of very early stage 
prostate cancers. However, as set out above, due to the natural tumor development increasingly 
earlier detection will also expand the benefit (prostate cancer mortality reduction) of screening. 
more benefit thus seems to equal more harm. This implies that we either should find a way 
to distinguish overdiagnosed cancers from those that are not, accept some loss of benefit at 
the expense of reduced harm (preferable in an uneven ratio, as otherwise there is no overall 
gain), or deal with the effect of overdiagnosis in another matter. The latter could be achieved by 
e.g. reducing the side effects of detection and treatment, or reducing overtreatment altogether, 
although then the initial paradox might remain.
So, can we distinguish cancers that are overdiagnosed from those who are not? The answer 
is likely no, at least not upfront. We might be able to identify cancers that are definitively not 
overdiagnosed (i.e. as symptoms occur and we are thus too late), but the remaining men can 
still be both. The reason being that we can never definitively know how the cancer would have 
behaved or will behave in the future if it was not diagnosed. Furthermore, overdiagnosis is not 
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Figure 3. Distribution of prostate cancer mortality in the screening and control arm per risk 
group. For comparison data were indexed on the total prostate cancer mortality in the control 
arm. (reprinted from figure 3a, chapter 4) 
 
  
Total metastatic high-risk intermediate-risk low-risk missing
Control arm 100 50 43.6 5.3 0.5 0.5
Sreening arm 80.2 18.6 46.2 7.4 8 0
0
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Figure 3. Distribution of prostate cancer mortality in the screening and control arm per risk group. For com-
parison data were indexed on the total prostate cancer mortality in the control arm. (reprinted from figure 3a, 
chapter 4)
172
245
Figure 4. Example of effect of stage shift and treatment on distribution of prostate cancer and 
mortality 
  
10 
50 
90 
50 
M -  M +  
A: NO SCREENING 
Prostate cancer death No prostate cancer death
35 25 
115 
25 
M -  M +  
B: EARLY DETECTION, BUT 
NOT EARLY  TREATMENT 
Prostate cancer death No prostate cancer death
15 25 
135 
25 
M -  M +  
C: EARLY DETECTION, AND 
EARLY TREATMENT 
Prostate cancer death No prostate cancer death
Figure 4. Example of effect of stage shift and treatment on distribution of prostate cancer and mortality
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only dependent on the natural course of the tumor but also on life expectancy of its host, again 
a factor that cannot be ascertained upfront.
What we can do is strive to make the most accurate prediction on the likelihood of the cancer 
not causing symptoms if directly diagnosed and treated and weigh this against the chance of 
loss in benefit if not detected and treated directly. Those with high probability of being over-
diagnosed might be good candidates to be monitored (either before or after diagnosis (after 
diagnosis is discussed below)). This will ideally result in maximization of harm reduction, at the 
cost of minimal loss to profit (lower mortality). One of the best currently available predictors of 
a cancer being overdiagnosed is the (modified) Gleason score. It has been shown that men with 
Gleason scores of 6, if radically treated, have a probability of close to zero to still giving rise to 
symptoms [17-19]. While the tumor remains at this stage diagnosis and treatment might thus not 
be necessary. In fact, reevaluation of biopsy Gleason score showed upgrading close to 50% in 
those men that died of prostate cancer, but were diagnosed in the lowest risk group in the ERSPC 
Rotterdam (20% in men who did not die) [20]. Predicting the presence of Gleason scores above 6 
can already be done with fairly good accuracy based on currently available clinical characteristics 
[21-23]. Improvements should come from more accurate prostate sampling, e.g. by targeting 
biopsies using mRI [24]. As the negative predictive value of current risk prediction tools seem 
already quite good [25], the added value of mRI might mainly be in men with increased risk 
according to these risk prediction tools. The Gleason 6 group could potentially be extended 
with Gleason 3+4 that possess certain favorable characteristics (e.g. certain growth patterns). 
The second focus should then be on the optimal monitoring frequency in men based on their 
predicted risk (e.g. as shown in [26]). Development, validation, but above all implementation of 
tools to stratify men depending on risk for more or less frequent screening programs cannot 
only potentially reduce overdiagnosis, but also reduce unnecessary biopsies (close to 90% of 
secondary biopsies are negative (chapter 1)). Evaluation should be according to the change in 
the balance of harms to benefits.
New predictors, once found and validated, can then with relative ease be combined with 
existing predictors to improve stratification for monitoring frequency. Although one should be 
cautious to have too high expectations on any new predictor. An example of this is the, com-
monly referred to, ‘golden marker’. This marker is said to selectively identify those tumors that will 
result in prostate cancer death, or at least systemic spread. But how valuable will such a marker 
be? Consider the following: Imagine different human cells all have specific properties, which are 
determined by DNA. The cells divide to produce new cells. Normally this goes well, but some-
times alterations in the DNA occur (e.g. by deletions, mutations, activations, rearrangements, 
etc.) which change the properties of the new cell. At some point there might occur an alteration 
that provides the new cell with the property of systemic spread (likely a combination of several 
other properties). From this point forward this property can be measured in the form of a marker 
(i.e. the ‘golden marker’). But what is the value of knowing this property at this point? Wouldn’t 
the cell with the property of systemic spread immediately spread systemically? There is after all 
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nothing any more that holds it back. The measurement and intervention should thus be at the 
moment it occurs to have any effect. Before the systemic spread property is present, we can by 
internal observation at best say something about the probability of it occurring based on the cur-
rent properties of the cells involved (e.g. a larger tumor volume equals more division and thus a 
higher chance of this specific property occurring). In this view the presence of the ‘golden marker’ 
will thus not be very useful as it will only tell us that we are already too late for curative treatment, 
while its absence will merely tell us it might or might not be present sometime in the future. 
(Knowing systemic spread has occurred could possibly prevent organ specific treatment with 
its side effects, although the alternative treatment (systematic treatment) is often not with less 
harm. Furthermore there is evidence that suggests that treating the primary cancer source might 
still cause slowing of overall cancer growth [27].) Instead of searching for the ‘golden marker’ it 
might be better to focus on markers that can improve risk stratification at an earlier stage.
This section discussed monitoring before a diagnosis is made, but monitoring after diagnosis 
might also be a viable option to reduce the harms of detection. This monitoring is commonly 
referred to as active surveillance.
ACTIvE SURvEILLANCE (ARE WE ABLE TO SELECTIvELY FILTER OUT mEN WITH 
AGGRESSIvE DISEASE?)
Active surveillance might aid in addressing the paradox discussed above that by early prostate 
cancer detection we will reduce the chance of prostate cancer death, but simultaneously in-
crease the risk of detecting cancers that are no threat to a man’s health. In a sense this section is 
therefore a direct continuation of that discussed above. As we are likely not able to immediately 
distinguish those cancers that are overdiagnosed and those that are not, some form of monitor-
ing should be in place to selectively filter out those that tend towards more aggressive growth. 
But first we should make a selection who should be monitored and for whom this is too risky and 
would thus be better served with direct invasive treatment.
SELECTION OF mEN FOR ACTIvE SURvEILLANCE
As discussed above Gleason score 6 tumors, if directly treated, have almost zero chance of still 
causing symptoms. This indicated that while the tumor remains at this grade treatment can 
safely be postponed. Gleason 6 thus seems a good starting point for selection of men for active 
surveillance, as with every increase in Gleason there might be a potentially loss of benefits from 
early detection. Unfortunately, the presence of solely Gleason 6 tumor can currently only be 
firmly established after the prostate is removed (the primary reason being under sampling on 
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diagnostic biopsy). We thus have to make the best possible estimation on the probability that 
there is indeed only Gleason 6 tumor present.
At the start of active surveillance (one to two decades ago) several predictors were selected 
for this aim, PSA (density), tumor extent on biopsy (either number of biopsy cores positive or a 
quantification of involve of a single core), and tumor stage. Often they are combined in a crude 
risk estimation using rule based selection criteria (chapter 5). A better solution seems however 
the use of risk prediction tools that provide a man’ s individual risk. These risk prediction tools are 
not necessarily better in terms of selecting men (although certainly not worse) [28], but provide 
more accurate information for an individual to make a decision (chapter 5). Preferably this infor-
mation should be combined in a decision aid incorporating personal weights attached to the 
risks of harm and benefit. This is however easier said than done. Research shows that humans 
are poor in prediction their reaction and feelings to events they have not yet experienced (e.g. 
how badly a side effect will influence their daily quality of life) [29]. There thus seems a place for 
increasing research in how patients could be aided to make more accurate predictions on actual 
reactions to future events. Examples of methods that could be used are narratives of people that 
already have experience with such events [30], or the use of tests that determine e.g. how ‘risk 
avoiding’ patients in general are and correlate this to reactions on certain outcomes. Although 
there is currently little evidence to support its use, it can be theorized that new technologies such 
as virtual reality might be of help as they offer patients the opportunity of ‘virtually’ experiencing 
future events, increasing their ability to estimate its influence on personal wellbeing [31].
To correctly inform men we need to know how well the initially selected active surveillance 
entry criteria predict the presence of Gleason 6 on radical prostatectomy. The best way of testing 
this is to immediately operate men who fulfill the active surveillance criteria and correlate this 
with the radical prostatectomy outcome. If all men with Gleason 6 on biopsy would be selected 
for active surveillance 35%-50% will turn out to have Gleason >6 [28, 32]. If men fulfilled the 
PRIAS criteria this dropped to 25%-38% [28, 32]. However, this also meant that a substantial part 
of men were not selected by the criteria, and that the majority still had Gleason 6 on radical 
prostatectomy. The area under the ROC curve was therefore moderate for the PRIAS criteria at 0.6 
(other active surveillance selection criteria had similar results) [28]. Of the individual parameters 
of the inclusion criteria only PSA, PSA density and T-stage had some predictive ability [32]. It 
might therefore be reasonable to expand the selection criteria and search for methods of better 
predicting the presence of Gleason score >6 on radical prostatectomy. In chapter 6 we proposed 
the use of mRI with targeted biopsies instead of <=2 cores positive for prostate cancer to safely 
increase the number of men that can select active surveillance. The reason being that mRI with 
targeted biopsies has a high negative predictive value for the presence of more aggressive 
disease [33]. A small radical prostatectomy series of men with diagnostic mRI indeed showed 
a lower rate of upgrading in men with negative mRI, although still not perfect [34]. Prediction 
models incorporating mRI results with classic predictors might offer the best result in near future. 
New markers could be added if proven to increase accuracy. Currently especially blood/urine/
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prostate fluid biomarkers seem the best candidates as tissue biomarkers are likely still hampered 
by under sampling (chapter 8), although the initially results of currently available markers offer 
only moderate additional value [35].
FOLLOW-UP OF mEN ON ACTIvE SURvEILLANCE
In theory follow-up should selectively filter out those that progress to a more aggressive disease 
state (e.g. Gleason >6). Preferably this should be done just before the tumor truly reaches such a 
state, and thus there must be a prediction made on the chance of it occurring in the short term 
to adapt the follow-up frequency accordingly. Currently follow-up seems mostly in place to find 
those tumors that were not adequately picked out at inclusion. Although further improvement 
in selection criteria might change this, there likely remains a place for confirmation of the results 
found at entrance. Timing of this confirmation test could be discussed, but might be primarily 
dependent on personal patient preference (i.e. some might want direct confirmation, others 
might prefer to postpone). Research indicates that postponing radical treatment up to one year 
in men selected for active surveillance does not change outcome [36], and hence men can safely 
choose any time for confirmatory testing within this period.
So, if after confirmation only men with favorable tumor features are selected, what is then the 
subsequent rate of progression over time? Two modeling studies addressed grade progression in 
prostate cancer, one before detection (in a screening setting) [37], and one during active surveil-
lance [38]. Both concluded that there is grade progression over time, but only the latter also 
estimated the rate of progression (12%-24% over a 10 year time period) [38]. It can immediately 
be appreciated that for the majority of men (>75%) follow-up should thus not result in a change 
of treatment and preferably be kept to a minimum. In chapter 9 we studied a switch to active 
treatment in the first 10 years of active surveillance in the PRIAS study. Although one should 
also consider the imperfect selection (with 25%-38% under grading), the percentage of men 
that switched to active treatment in 10 years (60%) was somewhat higher than can be expected 
based on the estimated progression rates. Especially considering the fact that of these men 35% 
still presented with Gleason 6 on radical prostatectomy specimen (chapter 9), and more men 
were advised to discontinue active surveillance, but did not adhere to this recommendation 
(chapter 6). I.e., the recommendations used to advise a switch to active treatment are too strin-
gent, while on the other hand potentially missing aggressive cancers (34% of men presented 
with unfavorable outcome on radical prostatectomy), urging the need for improvements. Two of 
the initial criteria used to recommend active treatment that were most frequent in occurrence, 
but simultaneously had the highest rate of men with Gleason 6 on radical prostatectomy, were 
>2 cores positive and a PSA-doubling time (PSA-DT) between 0-3 years (chapter 9 and 6). Instead 
of a direct switch to active treatment we therefore proposed stricter follow-up (in the form of an 
mRI with targeted biopsies), as there was an increased risk the presence of higher risk disease. 
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This change could reduce the number of men that directly switch to active treatment by up to 
30% to 50% (chapter 9 and 6), lessened with the number of men that are subsequently upgraded 
after mRI. Some other refinements were proposed, and it can be theorized that in the future 
even more will change. The reason that the number of positive core was used as selection tool 
is that it represents tumor volume (which in itself can be used to predict tumor aggressiveness). 
Unfortunately, the number of positive cores seems more dependent on variations in biopsy plac-
ing between biopsies sessions than actual changes in tumor volume (the same could be said on 
tumor involvement in a single non-targeted biopsy core). Lesion size on mRI could potentially 
correlate better with actual tumor volume and might thus replace the number of positive cores 
as surrogate for tumor extend and growth. But mRI offers other possibilities. Not only does it pro-
duce rough anatomical maps, it can also be used to get more in-depth knowledge on functional 
aspects of cellular structure (e.g. diffusion weighted [39] and contrast enhanced imaging [40]), or 
even information on a cellular level (e.g. oxygenation status, and chemical composition [41, 42]). 
much of these aspects are currently understudied in prostate cancer and active surveillance [33]. 
mRI might be supplemented by other imaging modalities that provide information on chemical 
composition and potentially behavior (e.g. nuclear imaging). If more firmly established, biopsies 
might then only serve as tool to confirm what was seen on the images.
more noninvasive testing in general seem to be the main focus for improving how patients 
experience active surveillance. Currently follow-up in men on active surveillance is for a substan-
tial part based on repeat biopsies. They are however not without side effects, such as infection, 
hematuria, and discomfort (chapter 7). In fact, this resulted in men not receiving the biopsies 
recommended by the protocol (chapter 7), with overall compliance dropping substantially dur-
ing active surveillance (chapter 6). As active surveillance is meant to reduce the side effect of 
prostate cancer treatment as much as possible, some trade off in the form of loss in immediate 
detection of higher grade cancer could be acceptable for men. Active surveillance protocols 
might even evolve into truly personalized management strategies in which the choice, timing, 
and even intensity (e.g. systematic yes or no) of the biopsy (to confirm presence of absence 
of higher grade disease) is up to the patient based on his weighing of risks (discussed above 
are some caveats that should be considered in such an approach). Research should thus aim at 
providing the most accurate dynamic risk predictions to base decisions on. This can already be 
done using available clinical characteristics, soon supplemented by mRI, and in the future with 
every new marker detected that provides additional predictive value.
EPILOGUE
This thesis set out to gain better insight in our understanding of early detection of prostate can-
cer in reducing disease specific mortality, while preventing related harms as much as possible. 
Information that in combination with existing knowledge, can be used to well-inform every men 
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deciding on what is best for this health now and in the future. As with all scientific information it 
is however part of an ongoing process of providing the best possible current state of knowledge. 
By design this means that the best state of knowledge today might not necessarily be that of 
tomorrow. Although this seems unfortunate, it is only by showing that our current theories are 
false that we are truly able to learn something new and can provoke ourselves to think of a better 
one.
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Dit proefschrift heeft als doel om verdere informatie te verschaffen over screening op, en een 
actief afwachtend beleid bij, prostaatkanker. Twee hoofdvragen worden behandeld: “Wat zijn de 
mechanismen die leiden tot de waargenomen daling van prostaatkanker sterfte bij screening?” 
(Deel 1, screening) en “Zijn we in staat zijn om bij een actief afwachtend beleid selectief man-
nen met een agressieve ziekte te identificeren?” (deel 2, active surveillance). Om deze twee 
hoofdvragen te beantwoorden worden een aantal sub-vragen behandeld. Hieronder worden de 
belangrijkste bevindingen per sub-vraag besproken:
DEEL 1, SCREENING:
- Wat voor typen prostaatkanker worden opgespoord en op welk moment tijdens de 
screening? (Hoofdstuk 1)
Kanker detectie blijft stabiel gedurende elkaar opvolgende screeningsrondes bij mannen eerder 
biopt. Desondanks werd de meerderheid van de hoog risico kankers detecteert in de eerste 
screeningsronde. De stabiele kanker detectie lijkt ten komen door diagnose van kanker bij man-
nen die bij hun vorige onderzoek een PSA-waarden onder de biopsie afkap hadden. Slechts 
een klein deel van de gedetecteerde kankers is gevonden in mannen met een eerder negatief 
biopt. Dit ondersteund de suggestie dat de langdurige verhoging van het PSA bij deze mannen 
waarschijnlijk niet het gevolg is van prostaatkanker.
- Wat is het effect van het niet naleven van het screeningsprotocol op de waargenomen 
reductie van prostaatkanker sterfte in een screeningsstudie? (Hoofdstuk 2)
vooral ongewenste screening in de controlegroep van de Europese screenings studie had een 
groot verdunnend effect op de waargenomen mortaliteitsreductie. Dit indiceert dat het effect 
van screening op het risico van overlijden aan prostaatkanker voor een individu (aanzienlijk) 
groter is dan wat gevonden wordt in de totale onderzoekspopulatie.
- Wat is het effect van verschillen in behandeling tussen de armen van de Europese screening 
studie op de gevonden mortaliteitsreductie? (Hoofdstuk 3 en 4)
vanwege latere detectie in tijd konden tumoren in de controlegroep profiteren van voortschrij-
dend inzicht in de beste manier prostaatkanker te behandeling (hoofdstuk 3). Het effect van 
verschillen in de behandeling tussen de armen op de waargenomen prostaatkanker specifieke 
sterftereductie was echter klein (hoofdstuk 4).
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- Hoe komt het dat screening op prostaatkanker resulteert in een reductie van sterfte? (Hoofd-
stuk 1-4)
De reductie van prostaatkankersterfte lijkt afkomstig uit alle screeningsrondes (hoofdstuk 1) en 
is het resultaat van verschuiving naar detectie van tumoren in een vroeger stadium (hoofdstuk 
4). verschillen in behandeling tussen de armen had weinig effect op de waargenomen sterftere-
ductie (hoofdstuk 3 en 4).
DEEL 2, ACTIvE SURvEILLANCE:
- Zijn we in staat om selectief mannen met meer agressieve ziekte te identificeren door middel 
van individuele risicostratificatie bij inclusie voor een actief afwachtend beleid? (Hoofdstuk 5)
Selecteren van potentiële kandidaten voor een actief afwachtend beleid op basis van individu-
ele risicostratificatie helpt in tegenstelling tot selectie op basis van vaste criteria om een  meer 
bewuste een persoonlijke behandelkeuze te maken. Individuele risicostratificatie is echter nog 
niet accuraat genoeg om agressieve van niet-agressieve ziekte te onderscheiden. Toekomstig 
onderzoek moet zich richten op het vergrijpen van informatie om een betere risico inschatting 
te kunnen maken.
- Zijn we in staat om selectief mannen met een agressieve ziekte te identificeren op basis van 
informatie afkomstig van pathologie en biomarkers? (hoofdstuk 8)
De immunohistochemische biomarkers die werden getest (Ki67, ERG en P27) en herevaluatie 
van het biopsie pathologieverslag waren niet in staat om een betere inschatting te maken van 
de ziekte agressiviteit. Undersampling van de meest agressieve tumor fragmenten met systema-
tische biopten lijkt daarvoor de belangrijkste reden.
- Is prostaatbiopsie de beste methode om agressieve ziekte op te sporen, d.w.z. wat zijn de 
nadelen? (Hoofdstuk 6 en 7)
Prostaatbiopsieën leiden tot complicaties in een substantieel deel van de mannen (hoofdstuk 
7) en vormen een aanzienlijke last bij mannen op een actief afwachtend beleid. Dit is mogelijk 
een reden dat veel van de aanbevolen biopten tijdens de follow-up niet worden ondergaan 
(hoofdstuk 6). Daarnaast leidt het meerderdeel van de biopten niet tot een verandering van het 
beleid. Het aantal vervolgbiopten in mannen op een actief afwachtend beleid zou dus omlaag 
moeten.
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- moeten we het huidige follow-up protocol voor mannen op een actief afwachtend beleid 
veranderen? (Hoofdstuk 9)
Na tien jaar onderstrepen de resultaten van de PRIAS studie de veiligheid van een actief af-
wachtend beleid. maar een aanzienlijk deel van de mannen dat volgens protocol overstapt naar 
een actieve behandeling blijken op definitieve pathologie geen aanwijzingen te hebben voor 
een agressieve ziekte. De follow-up protocol moet dus worden aangepast om de hoeveelheid 
mannen dat onterecht stopt met een actief afwachtend beleid te verminderen. Op basis van 
de beschikbare gegevens worden in dit proefschrift verschillende voorstellen gedaan om het 
protocol voor een actief afwachtend beleid nu en in de toekomst te verbeteren.

189
A
ABOUT THE AUTHOR
Leonard Pieter Bokhorst was born in Rheden on July 11, 1988. He completed high school at the 
‘Stedelijk Gymnasium Arnhem’, after which he started medical school at the University of Utrecht. 
In 2013 he obtained his medical degree after which he started with PhD research at the depart-
ment of Urology, Erasmus medical Center Rotterdam. His main topics were active surveillance 
and screening for prostate cancer. Currently, he is working as a resident at the department of 
Radiation Oncology, University medical Center Utrecht.

191
L
LIST OF PUBLICATIONS
[1] Bokhorst LP, Zappa m, Carlsson Sv, et al. Correlation between stage shift and differences 
in mortality in the European Randomized study of Screening for Prostate Cancer (ERSPC). BJU 
international. 2016.
[2] Bruinsma Sm, Bangma CH, Carroll PR, et al. Active surveillance for prostate cancer: a narrative 
review of clinical guidelines. Nature reviews Urology. 2016;13(3):151-67.
[3] Bokhorst LP, Lepisto I, Kakehi Y, et al. Complications after prostate biopsies in men on active 
surveillance and its effect on receiving further biopsies in the Prostate cancer Research Interna-
tional: Active Surveillance (PRIAS) study. BJU international. 2016.
[4] Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol mJ. Risk-based 
Patient Selection for magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Tran-
srectal Ultrasound-guided Random Biopsy Avoids Unnecessary magnetic Resonance Imaging 
Scans. European urology. 2015.
[5] Bruinsma Sm, Bokhorst LP, Roobol mJ, Bangma CH. How Often is Biopsy Necessary in Patients 
with Prostate Cancer on Active Surveillance? The Journal of urology. 2016;195(1):11-2.
[6] Bokhorst LP, Roobol mJ. Ethnicity and prostate cancer: the way to solve the screening prob-
lem? BmC med. 2015;13:179.
[7] venderbos LD, Roobol mJ, Bangma CH, van den Bergh RC, Bokhorst LP, Nieboer D, et al. Rule-
based versus probabilistic selection for active surveillance using three definitions of insignificant 
prostate cancer. World J Urol. 2015.
[8] Alberts AR, Bokhorst LP, Roobol mJ. [Guidelines on the early detection of prostate cancer]. Ned 
Tijdschr Geneeskd. 2015;159:A8811.
[9] Bokhorst LP, Alberts AR, Rannikko A, valdagni R, Pickles T, Kakehi Y, et al. Compliance Rates 
with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease 
Reclassification in Noncompliers. Eur Urol. 2015.
[10] Bokhorst LP, venderbos LD, Schroder FH, Bangma CH, Steyerberg EW, Roobol mJ. Do 
Treatment Differences between Arms Affect the main Outcome of ERSPC Rotterdam? J Urol. 
2015;194:336-42.
192
[11] Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, et al. magnetic resonance 
imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015;67:627-36.
[12] Schroder FH, Hugosson J, Roobol mJ, Tammela TL, Zappa m, Nelen v, et al. Screening and 
prostate cancer mortality: results of the European Randomised Study of Screening for Prostate 
Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027-35.
[13] Bokhorst LP, Roobol mJ, Kranse R. Reply from Authors re: Sigrid v. Carlsson, Peter C. Albertsen. 
Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with 
Clinical Diagnosis: A Real Effect or Lead-time Bias? Eur Urol. 2015;68(2):183-4: Better Treatment in 
the Control Arm of the ERSPC Rotterdam: A Point Worth Noting? Eur Urol. 2014;68:184-5.
[14] Bokhorst LP, Kranse R, venderbos LD, Salman JW, van Leenders GJ, Schroder FH, et al. Dif-
ferences in Treatment and Outcome After Treatment with Curative Intent in the Screening and 
Control Arms of the ERSPC Rotterdam. Eur Urol. 2015;68:179-82.
[15] Bokhorst LP, Steyerberg EW, Roobol mJ. Decision support for low-risk prostate cancer. (Chap-
ter 24; Prostate cancer: science and clinical practice, mydlo JH, Godec CJ. 2015.)
[16] Roobol mJ, Bokhorst LP. The ProtecT trial: what can we expect? Lancet Oncol. 2014;15:1046-7.
[17] Bokhorst LP, moss Sm, Roobol mJ. Reply from Authors re: Chris metcalfe. Can the Results of 
the European Randomized Study of Screening for Prostate Cancer Be Decontaminated? Eur Urol. 
2014;65(2):337-8: Yes, by Remaining Conservative in Our Assumptions. Eur Urol. 2013;65:338-39.
[18] Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, moss Sm, Schroder FH, et al. Prostate-
specific Antigen-Based Prostate Cancer Screening: Reduction of Prostate Cancer mortality After 
Correction for Nonattendance and Contamination in the Rotterdam Section of the European 
Randomized Study of Screening for Prostate Cancer. Eur Urol. 2014;65:329-36.
[19] Roobol mJ, Kranse R, Bangma CH, Otto SJ, van der Kwast TH, Bokhorst LP, et al. Reply from 
Authors re: michael Baum. Screening for Prostate Cancer: Can We Learn from the mistakes of the 
Breast Screening Experience? Eur Urol 2013;64:540-1: Screening for Prostate Cancer: We Have 
Learned and Are Still Learning. Eur Urol. 2013;64:541-3.
[20] venderbos LD, Bokhorst LP, Bangma CH, Roobol mJ. Active surveillance: oncologic outcome. 
Curr Opin Urol. 2013;23:268-72.
193
L
[21] Bokhorst LP, Zhu X, Bul m, Bangma CH, Schroder FH, Roobol mJ. Positive predictive value of 
prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends 
over time in a European randomized trial*. BJU Int. 2012;110:1654-60.
[22] Bokhorst LP, Zegers RH. [Couching then and now] Staarsteek vroeger en nu. Ned Tijdschr 
Geneeskd. 2011;155:A3283.

195
D
DANKWOORD
Het dankwoord is waarschijnlijk het meest gelezen deel van een proefschrift, ik vrees soms het 
enige. maar is dat niet zonde? Zonde van alle moeite die het de onderzoeker gekost heeft om de 
resultaten goed en leesbaar op schrift te krijgen, zonde van het papier en zonde van de tijd die 
in de rest is gaan zitten? Is bovendien de weergave van het eigenlijke onderzoek en wetenschap-
pelijke discussie in de andere hoofdstukken niet vele malen interessanter dan een opsomming 
van namen en verdiensten? Ik denk het wel en daarom volsta ik hier met een korte tekst, zodat 
ook de lezer met drukke agenda geen excuus heeft om de overige hoofdstukken terzijde te 
leggen (mijn dank is er niet minder om). Naast mijn promotoren, Chris en Ewout, wil ik vooral 
monique bedanken (echt voor alles) en natuurlijk de overige mensen die het screeningsbureau 
maken tot wat het is: Conja en marlies (voor de gezelligheid), Lionne, Arnout, Jolanda, Elaine 
en Frank-Jan (kamergenoten door de jaren), Prof. Schröder en meneer Knol (“vast meubilair” in 
de goede zin van het woord), Sophie en Lisette (onderzoekers op de 17e verdieping), mathijs, 
Robert, meelan, Xiaoye en Roderick (voorgangers en mede onderzoekers), Ries (voor de gedach-
tenvorming), Arno (voor een kijkje door de microscoop), members of the ERSPC and the PRIAS 
steering committee, patiënten en overige personen die bijdroegen en/of bijdragen aan de PRIAS 
en ERSPC studies, de grote en kleine commissie, Wouter en Woody, nieuwe collega’s en tot slot 
familie, vrienden en natuurlijk Berdine.
Gratias agimus tibi!

197
P
PhD PORTFOLIO
Name   Leonard P. Bokhorst
PhD period  January 2013 – December 2015
Erasmus mC department Urology
Promotors  Prof. dr. C.H. Bangma, Prof. dr. E.W. Steyerberg
Supervisor  Dr. m.J. Roobol
PhD training Year Workload 
(ECTS)
General courses
Biostatistical methods I: Basic Principles 2013 5.7
Biostatistical methods II: Classical Regression models 2013 4.3
Research Integrity 2014 0.3
‘Basiscurcus klinisch onderzoekers (BROK)’ 2014 1
Seminars and workshops
Workshop, targeted prostate biopsies, Paris 2013 0.5
Department of Urology journal club 2013-2015 1
Department of Urology internal course 2013-2015 1
Department of Urology PhD meeting 2013-2015 0.5
Symposium Urological tumors IKNL 2013-2015 0.5
Presentations
Annual meeting EAU, milan 2013 0.5
Andrology and Oncology seminar, Ehrenhausen 2013 1
ERSPC meeting, Göteborg 2013 0.5
Prostatakarzinom, Heidelberg 2014 1
Annual meeting EAU, Stockholm 2014 1
Annual meeting AUA, Orlando 2014 0.5
Annual meeting SIU, Glasgow 2014 0.5
ERSPC meeting, Antwerp 2014 0.5
Pelvic happiness for pelvic cancer patients, Lisbon 2015 1
Externe refereeravond Erasmus mC, Rotterdam 2015 0.5
Annual meeting EAU, madrid 2015 1
Annual meeting AUA, New Orleans 2015 0.5
ERSPC meeting, madrid 2015 0.5
EmUC, Barcelona 2015 1
Symposium ‘Een leven lang screenen’, venlo 2015 0.5
ESO conference active surveillance, milan 2016 1
198
Conferences
Annual meeting EAU 2013-2015 1.5
Annual meeting AUA 2012,2014,2015 1.5
Annual meeting ERSPC 2013-2015 1.5
SIU 2014 0.5
EmUC 2015 0.5
ESO conference active surveillance 2014,2016 1
Global congress on prostate cancer 2012 0.5
NvU meeting 2013-2015 0.5
Teaching
Klinisch chemici in opleiding (PSA kinetiek in active surveillance) 2013,2014 1
Prostaat echografie huisartsen 2014 0.5
Lichamelijk onderzoek co-assistenten 2014,2015 0.5
Total ECTS 35.8


